

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1r_wp297, Report 1

Request ID: cder_mpl1r_wp297_nsdp_v01

Request Description: In this report, we characterized dispensing and administration patterns of 26 New Molecular Entities (NMEs) approved from January 1, 2018, to July 31, 2018, stratified by age and sex in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis module (CIDA), version 14.2.0.

Data Source: We distributed this request to 13 Sentinel Data Partners on June 16, 2025. We included aggregate results from all 13 Data Partners in this report. The study period included data from January 1, 2018, to December 31, 2024. Report 2 includes NMEs approved from August 1, 2018 to December 31, 2018 Please see Appendix A for a list of available data dates for each Data Partner.

Study Design: We identified individuals initiating any of the 26 NMEs of interest. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with the relevant drug. The analyses characterized dispensing patterns by examining cumulative exposure episode duration, first exposure episode duration, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall and stratified by age group and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were NMEs approved between January 1, 2018, and July 31, 2018, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of non-proprietary and proprietary names of medical products, and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

Cohort Eligibility Criteria: We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the study period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24, 25-40, 41-64, 65+ years.

Baseline Characteristics: We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 33 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 26 chronic conditions and seven lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse¹ (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease, Non-Alzheimer's Dementia, atrial fibrillation, diabetes mellitus, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, osteoporosis, and liver disease. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes, and Appendix E for a list of non-proprietary and proprietary names of medical products used to define baseline characteristics in this request.

Please refer to Appendices F, G, and H for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinel-system.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinel-system.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

¹Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. <https://www.ccwdata.org/web/guest/condition-categories>

Table of Contents

Glossary (CIDA)	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
Table 1a	Aggregated Characteristics of Lutetium Lu 177 dotatate in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1b	Aggregated Characteristics of Bictegravir embitcitabine tenofovir alafenamide in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1c	Aggregated Characteristics of Tezacaftor and ivacaftor in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1d	Aggregated Characteristics of Apalutamide in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1e	Aggregated Characteristics of Ibalizumab-uiyk in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1f	Aggregated Characteristics of Tildrakizumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1g	Aggregated Characteristics of Burosumab-twza in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1h	Aggregated Characteristics of Fostamatinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1i	Aggregated Characteristics of Fosnetupitant and palonosetron in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1j	Aggregated Characteristics of Lofexidine hydrochloride in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1k	Aggregated Characteristics of Erenumab-aooe in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1l	Aggregated Characteristics of Sodium zirconium cyclosilicate in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1m	Aggregated Characteristics of Avatrombopag in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1n	Aggregated Characteristics of Pegvaliase-pqpz in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1o	Aggregated Characteristics of Baricitinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1p	Aggregated Characteristics of Moxidectin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1q	Aggregated Characteristics of Cannabidiol in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1r	Aggregated Characteristics of Plazomicin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1s	Aggregated Characteristics of Binimetinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1t	Aggregated Characteristics of Encorafenib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1u	Aggregated Characteristics of Tecovirimat in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1v	Aggregated Characteristics of Ivosidenib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1w	Aggregated Characteristics of Tafenoquine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1x	Aggregated Characteristics of Elagolix sodium in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
Table 1y	Aggregated Characteristics of Fish oil triglycerides in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Table of Contents

<u>Table 1z</u>	Aggregated Characteristics of Lusutrombopag in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 2a</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 2b</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 2c</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 2d</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 2e</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 2f</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 3a</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 3b</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 3c</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 3d</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 3e</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 3f</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 4a</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 4b</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 4c</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 4d</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 4e</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 4f</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 5a</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 5b</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 5c</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 5d</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 5e</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 5f</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

Table of Contents

<u>Table 6a</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 6b</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 6c</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 6d</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 6e</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 6f</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 7a</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 7b</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 7c</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 8a</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 8b</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex
<u>Table 8c</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group
<u>Table 9</u>	Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Table 10</u>	Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1a</u>	Patient Entry into Study by Month for Lutetium Lu 177 dotatate in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1b</u>	Patient Entry into Study by Month for Bictegravir embitcitabine tenofovir alafenamide in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1c</u>	Patient Entry into Study by Month for Tezacaftor and ivacaftor in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1d</u>	Patient Entry into Study by Month for Apalutamide in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1e</u>	Patient Entry into Study by Month for Ibalizumab-uiyk in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1f</u>	Patient Entry into Study by Month for Tildrakizumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1g</u>	Patient Entry into Study by Month for Burosumab-twza in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1h</u>	Patient Entry into Study by Month for Fostamatinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1i</u>	Patient Entry into Study by Month for Fosnetupitant and palonosetron in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1j</u>	Patient Entry into Study by Month for Lofexidine hydrochloride in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1k</u>	Patient Entry into Study by Month for Erenumab-aooe in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Table of Contents

<u>Figure 1i</u>	Patient Entry into Study by Month for Sodium zirconium cyclosilicate in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1m</u>	Patient Entry into Study by Month for Avatrombopag in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1n</u>	Patient Entry into Study by Month for Pegvaliase-pqpz in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1o</u>	Patient Entry into Study by Month for Baricitinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1p</u>	Patient Entry into Study by Month for Moxidectin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1q</u>	Patient Entry into Study by Month for Cannabidiol in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1r</u>	Patient Entry into Study by Month for Plazomicin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1s</u>	Patient Entry into Study by Month for Binimetinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1t</u>	Patient Entry into Study by Month for Encorafenib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1u</u>	Patient Entry into Study by Month for Tecovirimat in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1v</u>	Patient Entry into Study by Month for Ivosidenib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1w</u>	Patient Entry into Study by Month for Tafenoquine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1x</u>	Patient Entry into Study by Month for Elagolix sodium in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1y</u>	Patient Entry into Study by Month for Fish oil triglycerides in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Figure 1z</u>	Patient Entry into Study by Month for Lusutrombopag in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024
<u>Appendix A</u>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (June 16, 2025)
<u>Appendix B</u>	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request
<u>Appendix C</u>	List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), and National Drug Code (NDC) Codes Used to Define Exposures in this Request
<u>Appendix D</u>	List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request
<u>Appendix E</u>	List of Nonproprietary and Brand Proprietary of Medical Products Used to Define Covariates in this Request
<u>Appendix F</u>	Specifications Defining Parameters for this Request
<u>Appendix G</u>	Specifications Defining Parameters for Baseline Characteristics in this Request
<u>Appendix H</u>	Diagram Detailing the Design of the Request

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded.

Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Glossary of Terms for Analyses Using

Cohort Identification and Descriptive Analysis (CIDA) Module*

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Characteristics of Lutetium Lu 177 dotatate in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Lutetium Lu 177 dotatate		
Patient Characteristics	Number	Percent
Unique patients	6,363	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	68.4	9.6
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	136	2.1%
41-64 years	1,553	24.4%
≥ 65 years	4,656	73.2%
Sex		
Female	3,080	48.4%
Male	3,283	51.6%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	80	1.3%
Black or African American	580	9.1%
Multi-racial	33	0.5%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	821	12.9%
White	4,823	75.8%
Hispanic origin		
Yes	125	2.0%
No	5,159	81.1%
Unknown	1,079	17.0%
Year		
2018	541	8.5%
2019	1,082	17.0%
2020	1,068	16.8%
2021	967	15.2%
2022	903	14.2%
2023	1,057	16.6%
2024	745	11.7%
Health Characteristics		
Acute Myocardial Infarction	36	0.6%
Alzheimer's Disease	13	0.2%
Non-Alzheimer's Dementia	76	1.2%
Atrial Fibrillation	494	7.8%

Table 1a. Aggregated Characteristics of Lutetium Lu 177 dotatate in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Lutetium Lu 177 dotatate		
Patient Characteristics	Number	Percent
Diabetes Mellitus	1,888	29.7%
Heart Failure	588	9.2%
Hyperlipidemia	2,133	33.5%
Hypertension	3,374	53.0%
Depression	1,112	17.5%
Ischemic Heart Disease	1,142	17.9%
Rheumatoid Arthritis/Osteoarthritis	795	12.5%
Stroke/TIA ³	106	1.7%
Breast Cancer	270	4.2%
Colorectal Cancer	335	5.3%
Prostate Cancer	379	6.0%
Lung Cancer	223	3.5%
Endometrial Cancer	23	0.4%
Acquired Hypothyroidism	842	13.2%
Anemia	2,159	33.9%
Asthma	234	3.7%
Benign Prostatic Hyperplasia	427	6.7%
Chronic Kidney Disease	828	13.0%
COPD ⁴ and Bronchiectasis	371	5.8%
Glaucoma	501	7.9%
Osteoporosis	296	4.7%
Obesity: diagnosed or identified by weight management procedures	932	14.6%
Obesity: identified by weight management-related dispensings	72	1.1%
Overweight	592	9.3%
Smoking: diagnosed or identified by smoking cessation procedures	1,728	27.2%
Smoking: identified by smoking-related dispensings	22	0.3%
Alcohol Abuse or Dependence	118	1.9%
Drug Abuse or Dependence	196	3.1%
History of Cardiac Arrest	15	0.2%
History of Coronary Angioplasty or Bypass	331	5.2%
Liver Disease Based on CCW ⁵ Definition	1,158	18.2%
Liver Disease Extended Definition (CCW + Additional Codes)	1,163	18.3%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	21.8	10.8
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.3	0.8
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	6.2	9.9

Table 1a. Aggregated Characteristics of Lutetium Lu 177 dotatate in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Lutetium Lu 177 dotatate		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	18.4	14.7
Mean number of generics dispensed	8.4	5.3
Mean number of unique drug classes dispensed	7.8	4.7

¹N/A: Not Applicable

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1b. Aggregated Characteristics of Bictegravir embitcitabine tenofovir alafenamide in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Bictegravir embitcitabine tenofovir alafenamide		
Patient Characteristics	Number	Percent
Unique patients	244,961	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	46.8	12.7
Age	Number	Percent
0-17 years	1,507	0.6%
18-24 years	13,116	5.4%
25-40 years	77,234	31.5%
41-64 years	126,324	51.6%
≥ 65 years	26,780	10.9%
Sex		
Female	63,660	26.0%
Male	181,301	74.0%
Race ²		
American Indian or Alaska Native	2,080	0.8%
Asian	3,402	1.4%
Black or African American	93,092	38.0%
Multi-racial	2,176	0.9%
Native Hawaiian or Other Pacific Islander	436	0.2%
Unknown	76,282	31.1%
White	67,493	27.6%
Hispanic origin		
Yes	27,423	11.2%
No	154,909	63.2%
Unknown	62,629	25.6%
Year		
2018	36,246	14.8%
2019	57,997	23.7%
2020	48,142	19.7%
2021	50,450	20.6%
2022	17,094	7.0%
2023	18,432	7.5%
2024	16,600	6.8%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	1,422	0.6%
Alzheimer's Disease	279	0.1%
Non-Alzheimer's Dementia	3,125	1.3%
Atrial Fibrillation	3,169	1.3%

Table 1b. Aggregated Characteristics of Bictegravir embitcitabine tenofovir alafenamide in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Bictegravir embitcitabine tenofovir alafenamide		
Health Characteristics	Number	Percent
Diabetes Mellitus	23,258	9.5%
Heart Failure	9,829	4.0%
Hyperlipidemia	33,035	13.5%
Hypertension	48,873	20.0%
Depression	54,448	22.2%
Ischemic Heart Disease	13,460	5.5%
Rheumatoid Arthritis/Osteoarthritis	12,280	5.0%
Stroke/TIA ³	3,865	1.6%
Breast Cancer	755	0.3%
Colorectal Cancer	1,273	0.5%
Prostate Cancer	1,700	0.7%
Lung Cancer	757	0.3%
Endometrial Cancer	71	0.0%
Acquired Hypothyroidism	5,031	2.1%
Anemia	27,585	11.3%
Asthma	10,587	4.3%
Benign Prostatic Hyperplasia	4,928	2.0%
Chronic Kidney Disease	12,572	5.1%
COPD ⁴ and Bronchiectasis	12,704	5.2%
Glaucoma	5,842	2.4%
Osteoporosis	1,790	0.7%
Obesity: diagnosed or identified by weight management procedures	23,818	9.7%
Obesity: identified by weight management-related dispensings	2,418	1.0%
Overweight	12,080	4.9%
Smoking: diagnosed or identified by smoking cessation procedures	50,251	20.5%
Smoking: identified by smoking-related dispensings	7,837	3.2%
Alcohol Abuse or Dependence	14,119	5.8%
Drug Abuse or Dependence	33,570	13.7%
History of Cardiac Arrest	404	0.2%
History of Coronary Angioplasty or Bypass	3,917	1.6%
Liver Disease Based on CCW ⁵ Definition	7,645	3.1%
Liver Disease Extended Definition (CCW + Additional Codes)	7,827	3.2%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	8.8	14.9
Mean number of emergency room encounters	0.7	1.9
Mean number of inpatient hospital encounters	0.2	0.7

Table 1b. Aggregated Characteristics of Bictegravir embitcitabine tenofovir alafenamide in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Bictegravir embitcitabine tenofovir alafenamide		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.5	17.8
Mean number of filled prescriptions	19.0	20.4
Mean number of generics dispensed	6.6	5.5
Mean number of unique drug classes dispensed	5.9	4.9

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 1c. Aggregated Characteristics of Tezacaftor and ivacaftor in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Tezacaftor and ivacaftor		
Patient Characteristics	Number	Percent
Unique patients	4,020	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	24.5	11.2
Age	Number	Percent
0-17 years	1,493	37.1%
18-24 years	826	20.5%
25-40 years	1,263	31.4%
41-64 years	378	9.4%
≥ 65 years	60	1.5%
Sex		
Female	1,998	49.7%
Male	2,022	50.3%
Race ²		
American Indian or Alaska Native	26	0.6%
Asian	*****	*****
Black or African American	69	1.7%
Multi-racial	32	0.8%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,218	30.3%
White	2,663	66.2%
Hispanic origin		
Yes	229	5.7%
No	2,671	66.4%
Unknown	1,120	27.9%
Year		
2018	2,203	54.8%
2019	1,288	32.0%
2020	337	8.4%
2021	137	3.4%
2022	16	0.4%
2023	21	0.5%
2024	18	0.4%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	16	0.4%
Diabetes Mellitus	957	23.8%

Table 1c. Aggregated Characteristics of Tezacaftor and ivacaftor in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Tezacaftor and ivacaftor		
Health Characteristics	Number	Percent
Heart Failure	102	2.5%
Hyperlipidemia	54	1.3%
Hypertension	208	5.2%
Depression	819	20.4%
Ischemic Heart Disease	24	0.6%
Rheumatoid Arthritis/Osteoarthritis	78	1.9%
Stroke/TIA ³	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	78	1.9%
Anemia	317	7.9%
Asthma	703	17.5%
Benign Prostatic Hyperplasia	15	0.4%
Chronic Kidney Disease	100	2.5%
COPD ⁴ and Bronchiectasis	1,091	27.1%
Glaucoma	38	0.9%
Osteoporosis	97	2.4%
Obesity: diagnosed or identified by weight management procedures	80	2.0%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	84	2.1%
Smoking: diagnosed or identified by smoking cessation procedures	152	3.8%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	49	1.2%
Drug Abuse or Dependence	143	3.6%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁵ Definition	312	7.8%
Liver Disease Extended Definition (CCW + Additional Codes)	315	7.8%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	9.1	9.9
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.6	1.0
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	14.2	25.8
Mean number of filled prescriptions	32.8	24.5

Table 1c. Aggregated Characteristics of Tezacaftor and ivacaftor in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Tezacaftor and ivacaftor		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	11.0	6.1
Mean number of unique drug classes dispensed	10.4	5.5

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1d. Aggregated Characteristics of Apalutamide in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Apalutamide		
Patient Characteristics	Number	Percent
Unique patients	17,467	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	75.2	8.1
Age	Number	Percent
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	15,599	89.3%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	59	0.3%
Asian	290	1.7%
Black or African American	2,652	15.2%
Multi-racial	49	0.3%
Native Hawaiian or Other Pacific Islander	51	0.3%
Unknown	2,198	12.6%
White	12,168	69.7%
Hispanic origin		
Yes	407	2.3%
No	13,832	79.2%
Unknown	3,228	18.5%
Year		
2018	1,284	7.4%
2019	1,655	9.5%
2020	2,578	14.8%
2021	3,465	19.8%
2022	2,699	15.5%
2023	3,131	17.9%
2024	2,655	15.2%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	149	0.9%
Alzheimer's Disease	179	1.0%
Non-Alzheimer's Dementia	651	3.7%
Atrial Fibrillation	1,938	11.1%
Diabetes Mellitus	4,692	26.9%

Table 1d. Aggregated Characteristics of Apalutamide in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Apalutamide		
Health Characteristics	Number	Percent
Heart Failure	2,201	12.6%
Hyperlipidemia	7,422	42.5%
Hypertension	9,872	56.5%
Depression	2,041	11.7%
Ischemic Heart Disease	4,856	27.8%
Rheumatoid Arthritis/Osteoarthritis	2,658	15.2%
Stroke/TIA ³	473	2.7%
Breast Cancer	1,072	6.1%
Colorectal Cancer	316	1.8%
Prostate Cancer	17,247	98.7%
Lung Cancer	211	1.2%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	1,167	6.7%
Anemia	5,168	29.6%
Asthma	387	2.2%
Benign Prostatic Hyperplasia	3,846	22.0%
Chronic Kidney Disease	2,904	16.6%
COPD ⁴ and Bronchiectasis	1,494	8.6%
Glaucoma	1,856	10.6%
Osteoporosis	658	3.8%
Obesity: diagnosed or identified by weight management procedures	3,202	18.3%
Obesity: identified by weight management-related dispensings	292	1.7%
Overweight	2,116	12.1%
Smoking: diagnosed or identified by smoking cessation procedures	4,788	27.4%
Smoking: identified by smoking-related dispensings	69	0.4%
Alcohol Abuse or Dependence	476	2.7%
Drug Abuse or Dependence	422	2.4%
History of Cardiac Arrest	42	0.2%
History of Coronary Angioplasty or Bypass	1,672	9.6%
Liver Disease Based on CCW ⁵ Definition	648	3.7%
Liver Disease Extended Definition (CCW + Additional Codes)	659	3.8%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	18.2	13.2
Mean number of emergency room encounters	0.4	1.2
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	5.0	8.7
Mean number of filled prescriptions	17.7	14.5

Table 1d. Aggregated Characteristics of Apalutamide in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Apalutamide		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	8.0	4.8
Mean number of unique drug classes dispensed	7.5	4.3

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1e. Aggregated Characteristics of Ibalizumab-uiyk in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Ibalizumab-uiyk		
Patient Characteristics	Number	Percent
Unique patients	365	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	52.3	12.7
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	65	17.8%
41-64 years	242	66.3%
≥ 65 years	*****	*****
Sex		
Female	89	24.4%
Male	276	75.6%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	166	45.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	*****	*****
White	123	33.7%
Hispanic origin		
Yes	28	7.7%
No	268	73.4%
Unknown	69	18.9%
Year		
2018	85	23.3%
2019	98	26.8%
2020	73	20.0%
2021	43	11.8%
2022	23	6.3%
2023	31	8.5%
2024	12	3.3%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	61	16.7%

Table 1e. Aggregated Characteristics of Ibalizumab-uiyk in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Ibalizumab-uiyk		
Health Characteristics	Number	Percent
Heart Failure	30	8.2%
Hyperlipidemia	87	23.8%
Hypertension	135	37.0%
Depression	116	31.8%
Ischemic Heart Disease	34	9.3%
Rheumatoid Arthritis/Osteoarthritis	32	8.8%
Stroke/TIA ³	*****	*****
Breast Cancer	0	0.0%
Colorectal Cancer	11	3.0%
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	12	3.3%
Anemia	118	32.3%
Asthma	31	8.5%
Benign Prostatic Hyperplasia	14	3.8%
Chronic Kidney Disease	66	18.1%
COPD ⁴ and Bronchiectasis	24	6.6%
Glaucoma	20	5.5%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	34	9.3%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	20	5.5%
Smoking: diagnosed or identified by smoking cessation procedures	96	26.3%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	12	3.3%
Drug Abuse or Dependence	41	11.2%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	13	3.6%
Liver Disease Based on CCW ⁵ Definition	25	6.8%
Liver Disease Extended Definition (CCW + Additional Codes)	25	6.8%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	18.3	22.1
Mean number of emergency room encounters	0.7	1.4
Mean number of inpatient hospital encounters	0.5	1.2
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	12.5	25.2
Mean number of filled prescriptions	42.4	28.4

Table 1e. Aggregated Characteristics of Ibalizumab-uiyk in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Ibalizumab-uiyk		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	13.0	6.3
Mean number of unique drug classes dispensed	10.0	5.2

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1f. Aggregated Characteristics of Tildrakizumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Tildrakizumab		
Patient Characteristics	Number	Percent
Unique patients	12,838	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	68.6	9.6
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	530	4.1%
41-64 years	1,549	12.1%
≥ 65 years	10,675	83.2%
Sex		
Female	6,870	53.5%
Male	5,968	46.5%
Race ²		
American Indian or Alaska Native	21	0.2%
Asian	202	1.6%
Black or African American	336	2.6%
Multi-racial	45	0.4%
Native Hawaiian or Other Pacific Islander	11	0.1%
Unknown	1,251	9.7%
White	10,972	85.5%
Hispanic origin		
Yes	169	1.3%
No	11,001	85.7%
Unknown	1,668	13.0%
Year		
2018	40	0.3%
2019	942	7.3%
2020	1,550	12.1%
2021	2,510	19.6%
2022	2,957	23.0%
2023	3,085	24.0%
2024	1,754	13.7%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	34	0.3%
Alzheimer's Disease	81	0.6%
Non-Alzheimer's Dementia	221	1.7%
Atrial Fibrillation	994	7.7%
Diabetes Mellitus	2,962	23.1%

Table 1f. Aggregated Characteristics of Tildrakizumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Tildrakizumab		
Health Characteristics	Number	Percent
Heart Failure	965	7.5%
Hyperlipidemia	4,665	36.3%
Hypertension	5,466	42.6%
Depression	2,181	17.0%
Ischemic Heart Disease	2,283	17.8%
Rheumatoid Arthritis/Osteoarthritis	3,332	26.0%
Stroke/TIA ³	185	1.4%
Breast Cancer	261	2.0%
Colorectal Cancer	60	0.5%
Prostate Cancer	278	2.2%
Lung Cancer	78	0.6%
Endometrial Cancer	28	0.2%
Acquired Hypothyroidism	1,404	10.9%
Anemia	1,731	13.5%
Asthma	414	3.2%
Benign Prostatic Hyperplasia	581	4.5%
Chronic Kidney Disease	1,155	9.0%
COPD ⁴ and Bronchiectasis	876	6.8%
Glaucoma	1,076	8.4%
Osteoporosis	520	4.1%
Obesity: diagnosed or identified by weight management procedures	3,016	23.5%
Obesity: identified by weight management-related dispensings	399	3.1%
Overweight	1,121	8.7%
Smoking: diagnosed or identified by smoking cessation procedures	2,338	18.2%
Smoking: identified by smoking-related dispensings	56	0.4%
Alcohol Abuse or Dependence	280	2.2%
Drug Abuse or Dependence	262	2.0%
History of Cardiac Arrest	19	0.1%
History of Coronary Angioplasty or Bypass	605	4.7%
Liver Disease Based on CCW ⁵ Definition	444	3.5%
Liver Disease Extended Definition (CCW + Additional Codes)	451	3.5%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	13.6	12.6
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.4	6.6
Mean number of filled prescriptions	17.3	16.0

Table 1f. Aggregated Characteristics of Tildrakizumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Tildrakizumab		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	8.0	5.2
Mean number of unique drug classes dispensed	7.4	4.6

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1g. Aggregated Characteristics of Burosumab-twza in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Burosumab-twza		
Patient Characteristics	Number	Percent
Unique patients	1,374	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	25.4	15.8
Age	Number	Percent
0-17 years	749	54.5%
18-24 years	96	7.0%
25-40 years	197	14.3%
41-64 years	209	15.2%
≥ 65 years	123	9.0%
Sex		
Female	894	65.1%
Male	480	34.9%
Race ²		
American Indian or Alaska Native	12	0.9%
Asian	21	1.5%
Black or African American	148	10.8%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	522	38.0%
White	656	47.7%
Hispanic origin		
Yes	149	10.8%
No	791	57.6%
Unknown	434	31.6%
Year		
2018	154	11.2%
2019	432	31.4%
2020	265	19.3%
2021	234	17.0%
2022	107	7.8%
2023	96	7.0%
2024	86	6.3%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	11	0.8%
Diabetes Mellitus	34	2.5%

Table 1g. Aggregated Characteristics of Burosumab-twza in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Burosumab-twza		
Health Characteristics	Number	Percent
Heart Failure	24	1.7%
Hyperlipidemia	80	5.8%
Hypertension	149	10.8%
Depression	163	11.9%
Ischemic Heart Disease	28	2.0%
Rheumatoid Arthritis/Osteoarthritis	125	9.1%
Stroke/TIA ³	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	62	4.5%
Anemia	73	5.3%
Asthma	28	2.0%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	40	2.9%
COPD ⁴ and Bronchiectasis	22	1.6%
Glaucoma	13	0.9%
Osteoporosis	48	3.5%
Obesity: diagnosed or identified by weight management procedures	151	11.0%
Obesity: identified by weight management-related dispensings	13	0.9%
Overweight	48	3.5%
Smoking: diagnosed or identified by smoking cessation procedures	67	4.9%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	11	0.8%
Drug Abuse or Dependence	24	1.7%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁵ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	9.9	12.0
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of other ambulatory encounters	5.6	17.1
Mean number of filled prescriptions	10.1	12.6
Mean number of generics dispensed	4.1	4.0
Mean number of unique drug classes dispensed	3.9	3.7

Table 1g. Aggregated Characteristics of Burosumab-twza in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Burosumab-twza

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1h. Aggregated Characteristics of Fostamatinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Fostamatinib		
Patient Characteristics	Number	Percent
Unique patients	1,534	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	61.1	14.8
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	200	13.0%
41-64 years	508	33.1%
≥ 65 years	765	49.9%
Sex		
Female	838	54.6%
Male	696	45.4%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	69	4.5%
Black or African American	161	10.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	394	25.7%
White	890	58.0%
Hispanic origin		
Yes	129	8.4%
No	1,035	67.5%
Unknown	370	24.1%
Year		
2018	207	13.5%
2019	316	20.6%
2020	228	14.9%
2021	271	17.7%
2022	183	11.9%
2023	184	12.0%
2024	145	9.5%
Health Characteristics	Number	Percent
Acute Myocardial Infarction	32	2.1%
Alzheimer's Disease	14	0.9%
Non-Alzheimer's Dementia	66	4.3%
Atrial Fibrillation	164	10.7%
Diabetes Mellitus	443	28.9%

Table 1h. Aggregated Characteristics of Fostamatinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Fostamatinib		
Health Characteristics	Number	Percent
Heart Failure	235	15.3%
Hyperlipidemia	530	34.6%
Hypertension	798	52.0%
Depression	300	19.6%
Ischemic Heart Disease	322	21.0%
Rheumatoid Arthritis/Osteoarthritis	251	16.4%
Stroke/TIA ³	89	5.8%
Breast Cancer	60	3.9%
Colorectal Cancer	26	1.7%
Prostate Cancer	35	2.3%
Lung Cancer	27	1.8%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	252	16.4%
Anemia	939	61.2%
Asthma	110	7.2%
Benign Prostatic Hyperplasia	112	7.3%
Chronic Kidney Disease	269	17.5%
COPD ⁴ and Bronchiectasis	173	11.3%
Glaucoma	117	7.6%
Osteoporosis	95	6.2%
	389	25.4%
Obesity: diagnosed or identified by weight management procedures		
	37	2.4%
Obesity: identified by weight management-related dispensings		
Overweight	156	10.2%
	438	28.6%
Smoking: diagnosed or identified by smoking cessation procedures		
Smoking: identified by smoking-related dispensings	14	0.9%
Alcohol Abuse or Dependence	51	3.3%
Drug Abuse or Dependence	60	3.9%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	110	7.2%
Liver Disease Based on CCW ⁵ Definition	204	13.3%
Liver Disease Extended Definition (CCW + Additional Codes)	207	13.5%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	28.1	18.5
Mean number of emergency room encounters	0.8	1.5
Mean number of inpatient hospital encounters	0.9	1.3

Table 1h. Aggregated Characteristics of Fostamatinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Fostamatinib		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	12.9	17.9
Mean number of filled prescriptions	23.8	20.5
Mean number of generics dispensed	9.6	6.2
Mean number of unique drug classes dispensed	8.9	5.5

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1i. Aggregated Characteristics of Fosnetupitant and palonosetron in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Fosnetupitant and palonosetron		
Patient Characteristics	Number	Percent
Unique patients	35,282	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	68.8	9.1
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	977	2.8%
41-64 years	7,693	21.8%
≥ 65 years	26,501	75.1%
Sex		
Female	20,040	56.8%
Male	15,242	43.2%
Race ²		
American Indian or Alaska Native	150	0.4%
Asian	453	1.3%
Black or African American	2,956	8.4%
Multi-racial	162	0.5%
Native Hawaiian or Other Pacific Islander	39	0.1%
Unknown	4,865	13.8%
White	26,657	75.6%
Hispanic origin		
Yes	883	2.5%
No	27,905	79.1%
Unknown	6,494	18.4%
Year		
2018	61	0.2%
2019	5,240	14.9%
2020	7,025	19.9%
2021	6,952	19.7%
2022	6,047	17.1%
2023	6,037	17.1%
2024	3,920	11.1%
Health Characteristics		
Acute Myocardial Infarction	319	0.9%
Alzheimer's Disease	151	0.4%
Non-Alzheimer's Dementia	777	2.2%
Atrial Fibrillation	3,878	11.0%
Diabetes Mellitus	8,918	25.3%

Table 1i. Aggregated Characteristics of Fosnetupitant and palonosetron in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Fosnetupitant and palonosetron		
Health Characteristics	Number	Percent
Heart Failure	4,281	12.1%
Hyperlipidemia	17,209	48.8%
Hypertension	22,268	63.1%
Depression	7,473	21.2%
Ischemic Heart Disease	9,087	25.8%
Rheumatoid Arthritis/Osteoarthritis	6,802	19.3%
Stroke/TIA ³	1,199	3.4%
Breast Cancer	7,154	20.3%
Colorectal Cancer	5,073	14.4%
Prostate Cancer	1,867	5.3%
Lung Cancer	8,649	24.5%
Endometrial Cancer	1,521	4.3%
Acquired Hypothyroidism	5,631	16.0%
Anemia	15,206	43.1%
Asthma	2,118	6.0%
Benign Prostatic Hyperplasia	3,050	8.6%
Chronic Kidney Disease	4,812	13.6%
COPD ⁴ and Bronchiectasis	7,837	22.2%
Glaucoma	2,534	7.2%
Osteoporosis	1,784	5.1%
Obesity: diagnosed or identified by weight management procedures	9,354	26.5%
Obesity: identified by weight management-related dispensings	525	1.5%
Overweight	5,275	15.0%
Smoking: diagnosed or identified by smoking cessation procedures	17,230	48.8%
Smoking: identified by smoking-related dispensings	532	1.5%
Alcohol Abuse or Dependence	1,277	3.6%
Drug Abuse or Dependence	1,196	3.4%
History of Cardiac Arrest	94	0.3%
History of Coronary Angioplasty or Bypass	3,161	9.0%
Liver Disease Based on CCW ⁵ Definition	5,180	14.7%
Liver Disease Extended Definition (CCW + Additional Codes)	5,214	14.8%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	24.1	12.8
Mean number of emergency room encounters	0.6	1.2
Mean number of inpatient hospital encounters	0.6	0.9
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	7.8	10.4
Mean number of filled prescriptions	20.0	14.8

Table 1i. Aggregated Characteristics of Fosnetupitant and palonosetron in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Health Service Utilization Intensity Metrics	Fosnetupitant and palonosetron	
	Mean	Standard Deviation
Mean number of generics dispensed	10.7	5.6
Mean number of unique drug classes dispensed	9.8	4.9

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1j. Aggregated Characteristics of Lofexidine hydrochloride in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Lofexidine hydrochloride		
Patient Characteristics	Number	Percent
Unique patients	8,141	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	45.0	12.1
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	3,191	39.2%
41-64 years	3,727	45.8%
≥ 65 years	756	9.3%
Sex		
Female	4,097	50.3%
Male	4,044	49.7%
Race ²		
American Indian or Alaska Native	71	0.9%
Asian	*****	*****
Black or African American	679	8.3%
Multi-racial	68	0.8%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	2,208	27.1%
White	5,064	62.2%
Hispanic origin		
Yes	510	6.3%
No	5,608	68.9%
Unknown	2,023	24.8%
Year		
2018	611	7.5%
2019	2,437	29.9%
2020	1,602	19.7%
2021	1,730	21.3%
2022	586	7.2%
2023	643	7.9%
2024	532	6.5%
Health Characteristics		
Acute Myocardial Infarction	36	0.4%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	72	0.9%
Atrial Fibrillation	131	1.6%
Diabetes Mellitus	828	10.2%

Table 1j. Aggregated Characteristics of Lofexidine hydrochloride in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Lofexidine hydrochloride		
Health Characteristics	Number	Percent
Heart Failure	330	4.1%
Hyperlipidemia	1,014	12.5%
Hypertension	1,916	23.5%
Depression	3,534	43.4%
Ischemic Heart Disease	472	5.8%
Rheumatoid Arthritis/Osteoarthritis	1,872	23.0%
Stroke/TIA ³	72	0.9%
Breast Cancer	63	0.8%
Colorectal Cancer	28	0.3%
Prostate Cancer	24	0.3%
Lung Cancer	29	0.4%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	445	5.5%
Anemia	933	11.5%
Asthma	419	5.1%
Benign Prostatic Hyperplasia	115	1.4%
Chronic Kidney Disease	280	3.4%
COPD ⁴ and Bronchiectasis	643	7.9%
Glaucoma	137	1.7%
Osteoporosis	101	1.2%
Obesity: diagnosed or identified by weight management procedures	1,198	14.7%
Obesity: identified by weight management-related dispensings	115	1.4%
Overweight	481	5.9%
Smoking: diagnosed or identified by smoking cessation procedures	2,982	36.6%
Smoking: identified by smoking-related dispensings	563	6.9%
Alcohol Abuse or Dependence	1,242	15.3%
Drug Abuse or Dependence	5,527	67.9%
History of Cardiac Arrest	15	0.2%
History of Coronary Angioplasty or Bypass	122	1.5%
Liver Disease Based on CCW ⁵ Definition	234	2.9%
Liver Disease Extended Definition (CCW + Additional Codes)	242	3.0%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	16.9	20.6
Mean number of emergency room encounters	1.0	2.5
Mean number of inpatient hospital encounters	0.4	1.0
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	9.2	20.4
Mean number of filled prescriptions	29.6	23.7

Table 1j. Aggregated Characteristics of Lofexidine hydrochloride in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Lofexidine hydrochloride		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	10.3	6.8
Mean number of unique drug classes dispensed	9.4	6.0

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1k. Aggregated Characteristics of Erenumab-aooe in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Erenumab-aooe		
Patient Characteristics	Number	Percent
Unique patients	203,727	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	48.5	13.1
Age	Number	Percent
0-17 years	1,279	0.6%
18-24 years	11,177	5.5%
25-40 years	53,852	26.4%
41-64 years	103,105	50.6%
≥ 65 years	34,314	16.8%
Sex		
Female	173,883	85.4%
Male	29,844	14.6%
Race ²		
American Indian or Alaska Native	1,132	0.6%
Asian	1,834	0.9%
Black or African American	13,204	6.5%
Multi-racial	1,974	1.0%
Native Hawaiian or Other Pacific Islander	182	0.1%
Unknown	56,676	27.8%
White	128,725	63.2%
Hispanic origin		
Yes	7,778	3.8%
No	129,915	63.8%
Unknown	66,034	32.4%
Year		
2018	20,643	10.1%
2019	45,988	22.6%
2020	43,649	21.4%
2021	41,868	20.6%
2022	19,703	9.7%
2023	19,873	9.8%
2024	12,003	5.9%
Health Characteristics		
Acute Myocardial Infarction	293	0.1%
Alzheimer's Disease	622	0.3%
Non-Alzheimer's Dementia	2,522	1.2%
Atrial Fibrillation	3,793	1.9%
Diabetes Mellitus	23,805	11.7%

Table 1k. Aggregated Characteristics of Erenumab-aooe in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Health Characteristics	Erenumab-aooe	
	Number	Percent
Heart Failure	6,681	3.3%
Hyperlipidemia	37,586	18.4%
Hypertension	48,213	23.7%
Depression	80,560	39.5%
Ischemic Heart Disease	12,524	6.1%
Rheumatoid Arthritis/Osteoarthritis	40,177	19.7%
Stroke/TIA ³	5,110	2.5%
Breast Cancer	2,743	1.3%
Colorectal Cancer	351	0.2%
Prostate Cancer	540	0.3%
Lung Cancer	402	0.2%
Endometrial Cancer	221	0.1%
Acquired Hypothyroidism	21,341	10.5%
Anemia	25,611	12.6%
Asthma	16,024	7.9%
Benign Prostatic Hyperplasia	1,854	0.9%
Chronic Kidney Disease	8,501	4.2%
COPD ⁴ and Bronchiectasis	11,234	5.5%
Glaucoma	8,023	3.9%
Osteoporosis	5,603	2.8%
Obesity: diagnosed or identified by weight management procedures	47,508	23.3%
Obesity: identified by weight management-related dispensings	6,509	3.2%
Overweight	15,754	7.7%
Smoking: diagnosed or identified by smoking cessation procedures	33,001	16.2%
Smoking: identified by smoking-related dispensings	3,480	1.7%
Alcohol Abuse or Dependence	3,296	1.6%
Drug Abuse or Dependence	12,191	6.0%
History of Cardiac Arrest	230	0.1%
History of Coronary Angioplasty or Bypass	2,710	1.3%
Liver Disease Based on CCW ⁵ Definition	4,872	2.4%
Liver Disease Extended Definition (CCW + Additional Codes)	4,975	2.4%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	15.0	12.9
Mean number of emergency room encounters	0.7	1.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.3	12.1
Mean number of filled prescriptions	32.0	25.5

Table 1k. Aggregated Characteristics of Erenumab-aooe in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Erenumab-aooe		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	11.6	7.0
Mean number of unique drug classes dispensed	10.8	6.2

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 11. Aggregated Characteristics of Sodium zirconium cyclosilicate in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Sodium zirconium cyclosilicate		
Patient Characteristics	Number	Percent
Unique patients	135,004	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	68.7	13.9
Age	Number	Percent
0-17 years	66	0.0%
18-24 years	504	0.4%
25-40 years	6,278	4.7%
41-64 years	38,124	28.2%
≥ 65 years	90,032	66.7%
Sex		
Female	58,830	43.6%
Male	76,174	56.4%
Race ²		
American Indian or Alaska Native	1,096	0.8%
Asian	6,111	4.5%
Black or African American	27,834	20.6%
Multi-racial	429	0.3%
Native Hawaiian or Other Pacific Islander	324	0.2%
Unknown	21,140	15.7%
White	78,070	57.8%
Hispanic origin		
Yes	10,142	7.5%
No	103,055	76.3%
Unknown	21,807	16.2%
Year		
2018	*****	*****
2019	*****	*****
2020	17,422	12.9%
2021	27,516	20.4%
2022	33,616	24.9%
2023	32,154	23.8%
2024	20,119	14.9%
Health Characteristics		
Acute Myocardial Infarction	5,737	4.2%
Alzheimer's Disease	3,136	2.3%
Non-Alzheimer's Dementia	14,222	10.5%
Atrial Fibrillation	24,146	17.9%
Diabetes Mellitus	86,651	64.2%

Table 11. Aggregated Characteristics of Sodium zirconium cyclosilicate in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Sodium zirconium cyclosilicate		
Health Characteristics	Number	Percent
Heart Failure	54,704	40.5%
Hyperlipidemia	80,978	60.0%
Hypertension	118,754	88.0%
Depression	36,569	27.1%
Ischemic Heart Disease	54,169	40.1%
Rheumatoid Arthritis/Osteoarthritis	27,004	20.0%
Stroke/TIA ³	10,839	8.0%
Breast Cancer	2,781	2.1%
Colorectal Cancer	2,245	1.7%
Prostate Cancer	4,593	3.4%
Lung Cancer	1,937	1.4%
Endometrial Cancer	582	0.4%
Acquired Hypothyroidism	23,820	17.6%
Anemia	99,723	73.9%
Asthma	8,356	6.2%
Benign Prostatic Hyperplasia	14,635	10.8%
Chronic Kidney Disease	114,633	84.9%
COPD ⁴ and Bronchiectasis	24,962	18.5%
Glaucoma	14,053	10.4%
Osteoporosis	6,650	4.9%
Obesity: diagnosed or identified by weight management procedures	39,400	29.2%
Obesity: identified by weight management-related dispensings	5,004	3.7%
Overweight	14,660	10.9%
Smoking: diagnosed or identified by smoking cessation procedures	43,619	32.3%
Smoking: identified by smoking-related dispensings	693	0.5%
Alcohol Abuse or Dependence	5,523	4.1%
Drug Abuse or Dependence	7,949	5.9%
History of Cardiac Arrest	2,043	1.5%
History of Coronary Angioplasty or Bypass	19,124	14.2%
Liver Disease Based on CCW ⁵ Definition	14,019	10.4%
Liver Disease Extended Definition (CCW + Additional Codes)	14,190	10.5%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	35.9	35.2
Mean number of emergency room encounters	1.0	2.5
Mean number of inpatient hospital encounters	0.9	1.4
Mean number of non-acute institutional encounters	0.2	0.7
Mean number of other ambulatory encounters	18.4	25.0
Mean number of filled prescriptions	31.0	26.3

Table 1I. Aggregated Characteristics of Sodium zirconium cyclosilicate in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Health Service Utilization Intensity Metrics	Sodium zirconium cyclosilicate	
	Mean	Standard Deviation
Mean number of generics dispensed	11.8	6.0
Mean number of unique drug classes dispensed	10.9	5.3

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1m. Aggregated Characteristics of Avatrombopag in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Avatrombopag		
Patient Characteristics	Number	Percent
Unique patients	4,012	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	62.2	13.6
Age	Number	Percent
0-17 years	17	0.4%
18-24 years	96	2.4%
25-40 years	305	7.6%
41-64 years	1,643	41.0%
≥ 65 years	1,951	48.6%
Sex		
Female	1,929	48.1%
Male	2,083	51.9%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	140	3.5%
Black or African American	269	6.7%
Multi-racial	25	0.6%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	963	24.0%
White	2,585	64.4%
Hispanic origin		
Yes	327	8.2%
No	2,692	67.1%
Unknown	993	24.8%
Year		
2018	260	6.5%
2019	504	12.6%
2020	601	15.0%
2021	628	15.7%
2022	618	15.4%
2023	719	17.9%
2024	682	17.0%
Health Characteristics		
Acute Myocardial Infarction	63	1.6%
Alzheimer's Disease	31	0.8%
Non-Alzheimer's Dementia	144	3.6%
Atrial Fibrillation	400	10.0%
Diabetes Mellitus	1,422	35.4%

Table 1m. Aggregated Characteristics of Avatrombopag in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Avatrombopag		
Health Characteristics	Number	Percent
Heart Failure	595	14.8%
Hyperlipidemia	1,392	34.7%
Hypertension	2,102	52.4%
Depression	915	22.8%
Ischemic Heart Disease	852	21.2%
Rheumatoid Arthritis/Osteoarthritis	832	20.7%
Stroke/TIA ³	157	3.9%
Breast Cancer	132	3.3%
Colorectal Cancer	83	2.1%
Prostate Cancer	103	2.6%
Lung Cancer	51	1.3%
Endometrial Cancer	27	0.7%
Acquired Hypothyroidism	569	14.2%
Anemia	2,439	60.8%
Asthma	232	5.8%
Benign Prostatic Hyperplasia	251	6.3%
Chronic Kidney Disease	782	19.5%
COPD ⁴ and Bronchiectasis	428	10.7%
Glaucoma	290	7.2%
Osteoporosis	202	5.0%
Obesity: diagnosed or identified by weight management procedures	1,122	28.0%
Obesity: identified by weight management-related dispensings	176	4.4%
Overweight	409	10.2%
Smoking: diagnosed or identified by smoking cessation procedures	1,202	30.0%
Smoking: identified by smoking-related dispensings	46	1.1%
Alcohol Abuse or Dependence	756	18.8%
Drug Abuse or Dependence	262	6.5%
History of Cardiac Arrest	17	0.4%
History of Coronary Angioplasty or Bypass	245	6.1%
Liver Disease Based on CCW ⁵ Definition	2,019	50.3%
Liver Disease Extended Definition (CCW + Additional Codes)	2,026	50.5%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	24.1	18.9
Mean number of emergency room encounters	0.8	1.7
Mean number of inpatient hospital encounters	0.7	1.2
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	10.8	18.5
Mean number of filled prescriptions	25.4	21.0

Table 1m. Aggregated Characteristics of Avatrombopag in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Avatrombopag		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	10.1	6.1
Mean number of unique drug classes dispensed	9.3	5.4

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1n. Aggregated Characteristics of Pegvaliase-pqpz in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Pegvaliase-pqpz		
Patient Characteristics	Number	Percent
Unique patients	747	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	32.1	10.9
Age	Number	Percent
0-17 years	*****	*****
18-24 years	204	27.3%
25-40 years	317	42.4%
41-64 years	170	22.8%
≥ 65 years	*****	*****
Sex		
Female	397	53.1%
Male	350	46.9%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	254	34.0%
White	463	62.0%
Hispanic origin		
Yes	24	3.2%
No	437	58.5%
Unknown	286	38.3%
Year		
2018	73	9.8%
2019	168	22.5%
2020	142	19.0%
2021	154	20.6%
2022	72	9.6%
2023	68	9.1%
2024	70	9.4%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%
Atrial Fibrillation	*****	*****
Diabetes Mellitus	24	3.2%

Table 1n. Aggregated Characteristics of Pegvaliase-pqpz in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Pegvaliase-pqpz		
Health Characteristics	Number	Percent
Heart Failure	*****	*****
Hyperlipidemia	21	2.8%
Hypertension	37	5.0%
Depression	136	18.2%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	11	1.5%
Stroke/TIA ³	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	*****	*****
Anemia	23	3.1%
Asthma	20	2.7%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD ⁴ and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	106	14.2%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	22	2.9%
Smoking: diagnosed or identified by smoking cessation procedures	47	6.3%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	14	1.9%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁵ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	7.2	8.9
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	4.3	13.0
Mean number of filled prescriptions	11.6	12.7

Table 1n. Aggregated Characteristics of Pegvaliase-pqpz in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Pegvaliase-pqpz		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	4.9	4.5
Mean number of unique drug classes dispensed	4.6	4.1

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1o. Aggregated Characteristics of Baricitinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Baricitinib		
Patient Characteristics	Number	Percent
Unique patients	64,998	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	65.9	12.7
Age	Number	Percent
0-17 years	250	0.4%
18-24 years	815	1.3%
25-40 years	4,616	7.1%
41-64 years	20,122	31.0%
≥ 65 years	39,195	60.3%
Sex		
Female	32,536	50.1%
Male	32,462	49.9%
Race ²		
American Indian or Alaska Native	530	0.8%
Asian	909	1.4%
Black or African American	5,790	8.9%
Multi-racial	324	0.5%
Native Hawaiian or Other Pacific Islander	172	0.3%
Unknown	11,689	18.0%
White	45,584	70.1%
Hispanic origin		
Yes	3,161	4.9%
No	49,198	75.7%
Unknown	12,639	19.4%
Year		
2018	406	0.6%
2019	1,255	1.9%
2020	1,160	1.8%
2021	38,475	59.2%
2022	17,850	27.5%
2023	4,113	6.3%
2024	1,739	2.7%
Health Characteristics		
Acute Myocardial Infarction	862	1.3%
Alzheimer's Disease	947	1.5%
Non-Alzheimer's Dementia	3,456	5.3%
Atrial Fibrillation	6,810	10.5%
Diabetes Mellitus	18,395	28.3%

Table 1o. Aggregated Characteristics of Baricitinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Health Characteristics	Baricitinib	
	Number	Percent
Heart Failure	10,720	16.5%
Hyperlipidemia	21,690	33.4%
Hypertension	30,353	46.7%
Depression	12,500	19.2%
Ischemic Heart Disease	13,737	21.1%
Rheumatoid Arthritis/Osteoarthritis	14,140	21.8%
Stroke/TIA ³	2,046	3.1%
Breast Cancer	1,098	1.7%
Colorectal Cancer	549	0.8%
Prostate Cancer	1,280	2.0%
Lung Cancer	955	1.5%
Endometrial Cancer	157	0.2%
Acquired Hypothyroidism	7,652	11.8%
Anemia	12,617	19.4%
Asthma	3,223	5.0%
Benign Prostatic Hyperplasia	3,471	5.3%
Chronic Kidney Disease	9,711	14.9%
COPD ⁴ and Bronchiectasis	10,407	16.0%
Glaucoma	3,953	6.1%
Osteoporosis	2,463	3.8%
Obesity: diagnosed or identified by weight management procedures	17,727	27.3%
Obesity: identified by weight management-related dispensings	1,476	2.3%
Overweight	4,756	7.3%
Smoking: diagnosed or identified by smoking cessation procedures	14,880	22.9%
Smoking: identified by smoking-related dispensings	318	0.5%
Alcohol Abuse or Dependence	1,302	2.0%
Drug Abuse or Dependence	2,537	3.9%
History of Cardiac Arrest	213	0.3%
History of Coronary Angioplasty or Bypass	4,807	7.4%
Liver Disease Based on CCW ⁵ Definition	2,297	3.5%
Liver Disease Extended Definition (CCW + Additional Codes)	2,332	3.6%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	11.0	12.2
Mean number of emergency room encounters	0.7	1.4
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	6.3	15.6
Mean number of filled prescriptions	21.0	21.6

Table 1o. Aggregated Characteristics of Baricitinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Baricitinib		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	8.5	6.2
Mean number of unique drug classes dispensed	8.0	5.6

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 1p. Aggregated Characteristics of Moxidectin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Moxidectin		
Patient Characteristics	Number	Percent
Unique patients	0	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	-	-
Age	Number	Percent
0-17 years	-	-
18-24 years	-	-
25-40 years	-	-
41-64 years	-	-
≥ 65 years	-	-
Sex		
Female	-	-
Male	-	-
Race ²		
American Indian or Alaska Native	-	-
Asian	-	-
Black or African American	-	-
Multi-racial	-	-
Native Hawaiian or Other Pacific Islander	-	-
Unknown	-	-
White	-	-
Hispanic origin		
Yes	-	-
No	-	-
Unknown	-	-
Year		
2018	-	-
2019	-	-
2020	-	-
2021	-	-
2022	-	-
2023	-	-
2024	-	-
Health Characteristics		
Acute Myocardial Infarction	-	-
Alzheimer's Disease	-	-
Non-Alzheimer's Dementia	-	-
Atrial Fibrillation	-	-
Diabetes Mellitus	-	-

Table 1p. Aggregated Characteristics of Moxidectin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Moxidectin		
Health Characteristics	Number	Percent
Heart Failure	-	-
Hyperlipidemia	-	-
Hypertension	-	-
Depression	-	-
Ischemic Heart Disease	-	-
Rheumatoid Arthritis/Osteoarthritis	-	-
Stroke/TIA ³	-	-
Breast Cancer	-	-
Colorectal Cancer	-	-
Prostate Cancer	-	-
Lung Cancer	-	-
Endometrial Cancer	-	-
Acquired Hypothyroidism	-	-
Anemia	-	-
Asthma	-	-
Benign Prostatic Hyperplasia	-	-
Chronic Kidney Disease	-	-
COPD ⁴ and Bronchiectasis	-	-
Glaucoma	-	-
Osteoporosis	-	-
Obesity: diagnosed or identified by weight management procedures	-	-
Obesity: identified by weight management-related dispensings	-	-
Overweight	-	-
Smoking: diagnosed or identified by smoking cessation procedures	-	-
Smoking: identified by smoking-related dispensings	-	-
Alcohol Abuse or Dependence	-	-
Drug Abuse or Dependence	-	-
History of Cardiac Arrest	-	-
History of Coronary Angioplasty or Bypass	-	-
Liver Disease Based on CCW ⁵ Definition	-	-
Liver Disease Extended Definition (CCW + Additional Codes)	-	-
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	-	-
Mean number of emergency room encounters	-	-
Mean number of inpatient hospital encounters	-	-
Mean number of non-acute institutional encounters	-	-
Mean number of other ambulatory encounters	-	-
Mean number of filled prescriptions	-	-

Table 1p. Aggregated Characteristics of Moxidectin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Moxidectin		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	-	-
Mean number of unique drug classes dispensed	-	-

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 1q. Aggregated Characteristics of Cannabidiol in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Cannabidiol		
Patient Characteristics	Number	Percent
Unique patients	27,440	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	20.0	11.0
Age	Number	Percent
0-17 years	14,798	53.9%
18-24 years	4,538	16.5%
25-40 years	5,498	20.0%
41-64 years	2,390	8.7%
≥ 65 years	216	0.8%
Sex		
Female	12,451	45.4%
Male	14,989	54.6%
Race ²		
American Indian or Alaska Native	168	0.6%
Asian	681	2.5%
Black or African American	2,268	8.3%
Multi-racial	257	0.9%
Native Hawaiian or Other Pacific Islander	61	0.2%
Unknown	10,284	37.5%
White	13,721	50.0%
Hispanic origin		
Yes	4,059	14.8%
No	16,827	61.3%
Unknown	6,554	23.9%
Year		
2018	858	3.1%
2019	12,387	45.1%
2020	6,088	22.2%
2021	5,295	19.3%
2022	1,109	4.0%
2023	983	3.6%
2024	720	2.6%
Health Characteristics		
Acute Myocardial Infarction	15	0.1%
Alzheimer's Disease	26	0.1%
Non-Alzheimer's Dementia	304	1.1%
Atrial Fibrillation	53	0.2%
Diabetes Mellitus	424	1.5%

Table 1q. Aggregated Characteristics of Cannabidiol in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Cannabidiol		
Health Characteristics	Number	Percent
Heart Failure	262	1.0%
Hyperlipidemia	760	2.8%
Hypertension	1,048	3.8%
Depression	1,825	6.7%
Ischemic Heart Disease	142	0.5%
Rheumatoid Arthritis/Osteoarthritis	256	0.9%
Stroke/TIA ³	335	1.2%
Breast Cancer	20	0.1%
Colorectal Cancer	26	0.1%
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	1,015	3.7%
Anemia	1,646	6.0%
Asthma	1,497	5.5%
Benign Prostatic Hyperplasia	68	0.2%
Chronic Kidney Disease	333	1.2%
COPD ⁴ and Bronchiectasis	543	2.0%
Glaucoma	215	0.8%
	354	1.3%
Osteoporosis		
Obesity: diagnosed or identified by weight management procedures	1,261	4.6%
Obesity: identified by weight management-related dispensings	31	0.1%
Overweight	567	2.1%
Smoking: diagnosed or identified by smoking cessation procedures	566	2.1%
Smoking: identified by smoking-related dispensings	29	0.1%
Alcohol Abuse or Dependence	113	0.4%
Drug Abuse or Dependence	295	1.1%
History of Cardiac Arrest	121	0.4%
History of Coronary Angioplasty or Bypass	28	0.1%
Liver Disease Based on CCW ⁵ Definition	210	0.8%
Liver Disease Extended Definition (CCW + Additional Codes)	215	0.8%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	15.8	22.6
Mean number of emergency room encounters	0.7	1.5
Mean number of inpatient hospital encounters	0.3	0.9
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	47.7	55.0

Table 1q. Aggregated Characteristics of Cannabidiol in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Cannabidiol		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	29.8	23.4
Mean number of generics dispensed	7.8	5.3
Mean number of unique drug classes dispensed	7.4	4.8

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1r. Aggregated Characteristics of Plazomicin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Plazomicin		
Patient Characteristics	Number	Percent
Unique patients	285	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	72.2	12.1
Age	Number	Percent
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	220	77.2%
Sex		
Female	188	66.0%
Male	97	34.0%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	35	12.3%
White	233	81.8%
Hispanic origin		
Yes	11	3.9%
No	232	81.4%
Unknown	42	14.7%
Year		
2018	13	4.6%
2019	51	17.9%
2020	76	26.7%
2021	71	24.9%
2022	37	13.0%
2023	21	7.4%
2024	16	5.6%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	22	7.7%
Atrial Fibrillation	65	22.8%
Diabetes Mellitus	99	34.7%

Table 1r. Aggregated Characteristics of Plazomicin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Health Characteristics	Plazomicin	
	Number	Percent
Heart Failure	71	24.9%
Hyperlipidemia	148	51.9%
Hypertension	188	66.0%
Depression	88	30.9%
Ischemic Heart Disease	83	29.1%
Rheumatoid Arthritis/Osteoarthritis	93	32.6%
Stroke/TIA ³	16	5.6%
Breast Cancer	23	8.1%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	74	26.0%
Anemia	115	40.4%
Asthma	27	9.5%
Benign Prostatic Hyperplasia	45	15.8%
Chronic Kidney Disease	83	29.1%
COPD ⁴ and Bronchiectasis	52	18.2%
Glaucoma	31	10.9%
Osteoporosis	34	11.9%
Obesity: diagnosed or identified by weight management procedures	88	30.9%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	31	10.9%
Smoking: diagnosed or identified by smoking cessation procedures	88	30.9%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	21	7.4%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	33	11.6%
Liver Disease Based on CCW ⁵ Definition	20	7.0%
Liver Disease Extended Definition (CCW + Additional Codes)	21	7.4%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	30.6	22.8
Mean number of emergency room encounters	1.0	1.9
Mean number of inpatient hospital encounters	0.8	1.3
Mean number of non-acute institutional encounters	0.2	0.7
Mean number of other ambulatory encounters	15.8	23.5
Mean number of filled prescriptions	29.0	29.1

Table 1r. Aggregated Characteristics of Plazomicin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Plazomicin		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	12.6	6.1
Mean number of unique drug classes dispensed	11.5	5.4

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1s. Aggregated Characteristics of Binimetinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Binimetinib		
Patient Characteristics	Number	Percent
Unique patients	3,829	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	63.0	12.4
Age	Number	Percent
0-17 years	35	0.9%
18-24 years	42	1.1%
25-40 years	310	8.1%
41-64 years	1,304	34.1%
≥ 65 years	2,138	55.8%
Sex		
Female	1,700	44.4%
Male	2,129	55.6%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	37	1.0%
Black or African American	59	1.5%
Multi-racial	22	0.6%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	789	20.6%
White	2,908	75.9%
Hispanic origin		
Yes	79	2.1%
No	2,772	72.4%
Unknown	978	25.5%
Year		
2018	308	8.0%
2019	641	16.7%
2020	796	20.8%
2021	712	18.6%
2022	537	14.0%
2023	373	9.7%
2024	462	12.1%
Health Characteristics		
Acute Myocardial Infarction	30	0.8%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	98	2.6%
Atrial Fibrillation	382	10.0%
Diabetes Mellitus	796	20.8%

Table 1s. Aggregated Characteristics of Binimetinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Health Characteristics	Binimetinib	
	Number	Percent
Heart Failure	422	11.0%
Hyperlipidemia	1,335	34.9%
Hypertension	1,864	48.7%
Depression	764	20.0%
Ischemic Heart Disease	712	18.6%
Rheumatoid Arthritis/Osteoarthritis	565	14.8%
Stroke/TIA ³	368	9.6%
Breast Cancer	134	3.5%
Colorectal Cancer	325	8.5%
Prostate Cancer	158	4.1%
Lung Cancer	360	9.4%
Endometrial Cancer	17	0.4%
Acquired Hypothyroidism	811	21.2%
Anemia	1,362	35.6%
Asthma	191	5.0%
Benign Prostatic Hyperplasia	294	7.7%
Chronic Kidney Disease	441	11.5%
COPD ⁴ and Bronchiectasis	368	9.6%
Glaucoma	222	5.8%
Osteoporosis	132	3.4%
Obesity: diagnosed or identified by weight management procedures	760	19.8%
Obesity: identified by weight management-related dispensings	62	1.6%
Overweight	384	10.0%
Smoking: diagnosed or identified by smoking cessation procedures	1,341	35.0%
Smoking: identified by smoking-related dispensings	41	1.1%
Alcohol Abuse or Dependence	102	2.7%
Drug Abuse or Dependence	163	4.3%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	230	6.0%
Liver Disease Based on CCW ⁵ Definition	606	15.8%
Liver Disease Extended Definition (CCW + Additional Codes)	639	16.7%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	25.3	13.2
Mean number of emergency room encounters	0.8	1.3
Mean number of inpatient hospital encounters	0.7	1.1
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	9.1	12.8
Mean number of filled prescriptions	23.0	17.2

Table 1s. Aggregated Characteristics of Binimetinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Binimetinib		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	10.4	5.8
Mean number of unique drug classes dispensed	9.5	5.0

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1t. Aggregated Characteristics of Encorafenib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Encorafenib		
Patient Characteristics	Number	Percent
Unique patients	4,755	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	64.5	11.7
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	337	7.1%
41-64 years	1,603	33.7%
≥ 65 years	2,777	58.4%
Sex		
Female	2,275	47.8%
Male	2,480	52.2%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	68	1.4%
Black or African American	112	2.4%
Multi-racial	25	0.5%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	961	20.2%
White	3,570	75.1%
Hispanic origin		
Yes	89	1.9%
No	3,444	72.4%
Unknown	1,222	25.7%
Year		
2018	300	6.3%
2019	621	13.1%
2020	911	19.2%
2021	982	20.7%
2022	724	15.2%
2023	586	12.3%
2024	631	13.3%
Health Characteristics		
Acute Myocardial Infarction	38	0.8%
Alzheimer's Disease	20	0.4%
Non-Alzheimer's Dementia	127	2.7%
Atrial Fibrillation	484	10.2%
Diabetes Mellitus	1,001	21.1%

Table 1t. Aggregated Characteristics of Encorafenib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Encorafenib		
Health Characteristics	Number	Percent
Heart Failure	526	11.1%
Hyperlipidemia	1,672	35.2%
Hypertension	2,356	49.5%
Depression	967	20.3%
Ischemic Heart Disease	923	19.4%
Rheumatoid Arthritis/Osteoarthritis	704	14.8%
Stroke/TIA ³	407	8.6%
Breast Cancer	183	3.8%
Colorectal Cancer	1,503	31.6%
Prostate Cancer	175	3.7%
Lung Cancer	385	8.1%
Endometrial Cancer	22	0.5%
Acquired Hypothyroidism	936	19.7%
Anemia	1,939	40.8%
Asthma	237	5.0%
Benign Prostatic Hyperplasia	353	7.4%
Chronic Kidney Disease	547	11.5%
COPD ⁴ and Bronchiectasis	467	9.8%
Glaucoma	270	5.7%
Osteoporosis	184	3.9%
Obesity: diagnosed or identified by weight management procedures	936	19.7%
	63	1.3%
Obesity: identified by weight management-related dispensings		
Overweight	496	10.4%
Smoking: diagnosed or identified by smoking cessation procedures	1,674	35.2%
Smoking: identified by smoking-related dispensings	48	1.0%
Alcohol Abuse or Dependence	112	2.4%
Drug Abuse or Dependence	198	4.2%
History of Cardiac Arrest	15	0.3%
History of Coronary Angioplasty or Bypass	292	6.1%
Liver Disease Based on CCW ⁵ Definition	905	19.0%
Liver Disease Extended Definition (CCW + Additional Codes)	936	19.7%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	26.1	13.2
Mean number of emergency room encounters	0.8	1.3
Mean number of inpatient hospital encounters	0.7	1.0
Mean number of non-acute institutional encounters	0.1	0.3

Table 1t. Aggregated Characteristics of Encorafenib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Encorafenib		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of other ambulatory encounters	9.8	12.6
Mean number of filled prescriptions	22.8	16.7
Mean number of generics dispensed	10.4	5.7
Mean number of unique drug classes dispensed	9.5	5.0

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1u. Aggregated Characteristics of Tecovirimat in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Tecovirimat		
Patient Characteristics	Number	Percent
Unique patients	39	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	36.6	9.9
Age	Number	Percent
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	23	59.0%
41-64 years	*****	*****
≥ 65 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	27	69.2%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	27	69.2%
Year		
2018	0	0.0%
2019	0	0.0%
2020	0	0.0%
2021	0	0.0%
2022	*****	*****
2023	*****	*****
2024	*****	*****
Health Characteristics	Mean	Standard Deviation
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****

Table 1u. Aggregated Characteristics of Tecovirimat in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Tecovirimat		
Health Characteristics	Number	Percent
Heart Failure	0	0.0%
Hyperlipidemia	0	0.0%
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA ³	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	*****	*****
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD ⁴ and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁵ Definition	0	0.0%
Liver Disease Extended Definition (CCW + Additional Codes)	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	6.2	4.3
Mean number of emergency room encounters	0.7	1.0
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	5.1	4.3

Table 1u. Aggregated Characteristics of Tecovirimat in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Tecovirimat		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of filled prescriptions	11.8	8.4
Mean number of generics dispensed	5.1	2.9
Mean number of unique drug classes dispensed	4.9	2.7

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1v. Aggregated Characteristics of Ivosidenib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Ivosidenib		
Patient Characteristics	Number	Percent
Unique patients	2,585	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	66.5	13.0
Age	Number	Percent
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	228	8.8%
41-64 years	598	23.1%
≥ 65 years	1,731	67.0%
Sex		
Female	1,334	51.6%
Male	1,251	48.4%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	63	2.4%
Black or African American	137	5.3%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	484	18.7%
White	1,876	72.6%
Hispanic origin		
Yes	87	3.4%
No	1,896	73.3%
Unknown	602	23.3%
Year		
2018	113	4.4%
2019	187	7.2%
2020	332	12.8%
2021	454	17.6%
2022	458	17.7%
2023	572	22.1%
2024	469	18.1%
Health Characteristics		
Acute Myocardial Infarction	47	1.8%
Alzheimer's Disease	14	0.5%
Non-Alzheimer's Dementia	99	3.8%
Atrial Fibrillation	330	12.8%
Diabetes Mellitus	568	22.0%

Table 1v. Aggregated Characteristics of Ivosidenib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Ivosidenib		
Health Characteristics	Number	Percent
Heart Failure	417	16.1%
Hyperlipidemia	1,029	39.8%
Hypertension	1,442	55.8%
Depression	593	22.9%
Ischemic Heart Disease	579	22.4%
Rheumatoid Arthritis/Osteoarthritis	416	16.1%
Stroke/TIA ³	161	6.2%
Breast Cancer	124	4.8%
Colorectal Cancer	74	2.9%
Prostate Cancer	110	4.3%
Lung Cancer	51	2.0%
Endometrial Cancer	20	0.8%
Acquired Hypothyroidism	400	15.5%
Anemia	1,743	67.4%
Asthma	146	5.6%
Benign Prostatic Hyperplasia	216	8.4%
Chronic Kidney Disease	421	16.3%
COPD ⁴ and Bronchiectasis	278	10.8%
Glaucoma	168	6.5%
Osteoporosis	147	5.7%
Obesity: diagnosed or identified by weight management procedures	508	19.7%
Obesity: identified by weight management-related dispensings	27	1.0%
Overweight	292	11.3%
Smoking: diagnosed or identified by smoking cessation procedures	878	34.0%
Smoking: identified by smoking-related dispensings	17	0.7%
Alcohol Abuse or Dependence	84	3.2%
Drug Abuse or Dependence	97	3.8%
History of Cardiac Arrest	19	0.7%
History of Coronary Angioplasty or Bypass	185	7.2%
Liver Disease Based on CCW ⁵ Definition	596	23.1%
Liver Disease Extended Definition (CCW + Additional Codes)	600	23.2%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	32.3	19.3
Mean number of emergency room encounters	0.8	1.4
Mean number of inpatient hospital encounters	1.0	1.3
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	13.6	16.9
Mean number of filled prescriptions	23.4	15.8

Table 1v. Aggregated Characteristics of Ivosidenib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Ivosidenib		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	10.9	6.0
Mean number of unique drug classes dispensed	10.1	5.3

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1w. Aggregated Characteristics of Tafenoquine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Tafenoquine		
Patient Characteristics	Number	Percent
Unique patients	366	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	43.8	14.2
Age	Number	Percent
0-17 years	16	4.4%
18-24 years	32	8.7%
25-40 years	111	30.3%
41-64 years	179	48.9%
≥ 65 years	28	7.7%
Sex		
Female	229	62.6%
Male	137	37.4%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	12	3.3%
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	220	60.1%
White	120	32.8%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	239	65.3%
Year		
2018	0	0.0%
2019	69	18.9%
2020	36	9.8%
2021	42	11.5%
2022	53	14.5%
2023	76	20.8%
2024	90	24.6%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%
Atrial Fibrillation	*****	*****
Diabetes Mellitus	15	4.1%

Table 1w. Aggregated Characteristics of Tafenoquine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Tafenoquine		
Health Characteristics	Number	Percent
Heart Failure	*****	*****
Hyperlipidemia	29	7.9%
Hypertension	28	7.7%
Depression	67	18.3%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	30	8.2%
Stroke/TIA ³	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	38	10.4%
Anemia	45	12.3%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD ⁴ and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	26	7.1%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	16	4.4%
Smoking: diagnosed or identified by smoking cessation procedures	12	3.3%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁵ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	11.6	14.1
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	4.5	10.4
Mean number of filled prescriptions	20.7	23.3

Table 1w. Aggregated Characteristics of Tafenoquine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Tafenoquine		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	7.8	6.6
Mean number of unique drug classes dispensed	7.2	5.9

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1x. Aggregated Characteristics of Elagolix sodium in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Elagolix sodium		
Patient Characteristics	Number	Percent
Unique patients	37,541	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	34.1	8.5
Age	Number	Percent
0-17 years	*****	*****
18-24 years	6,004	16.0%
25-40 years	22,278	59.3%
41-64 years	8,796	23.4%
≥ 65 years	*****	*****
Sex		
Female	37,493	99.9%
Male	48	0.1%
Race ²		
American Indian or Alaska Native	214	0.6%
Asian	874	2.3%
Black or African American	4,237	11.3%
Multi-racial	773	2.1%
Native Hawaiian or Other Pacific Islander	37	0.1%
Unknown	15,447	41.1%
White	15,959	42.5%
Hispanic origin		
Yes	2,723	7.3%
No	18,707	49.8%
Unknown	16,111	42.9%
Year		
2018	1,160	3.1%
2019	7,951	21.2%
2020	8,669	23.1%
2021	9,152	24.4%
2022	4,357	11.6%
2023	3,719	9.9%
2024	2,533	6.7%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	26	0.1%
Atrial Fibrillation	41	0.1%
Diabetes Mellitus	1,232	3.3%

Table 1x. Aggregated Characteristics of Elagolix sodium in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Elagolix sodium		
Health Characteristics	Number	Percent
Heart Failure	173	0.5%
Hyperlipidemia	1,388	3.7%
Hypertension	2,623	7.0%
Depression	9,389	25.0%
Ischemic Heart Disease	215	0.6%
Rheumatoid Arthritis/Osteoarthritis	1,495	4.0%
Stroke/TIA ³	83	0.2%
Breast Cancer	89	0.2%
Colorectal Cancer	23	0.1%
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	1,494	4.0%
Anemia	4,557	12.1%
Asthma	1,869	5.0%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	233	0.6%
COPD ⁴ and Bronchiectasis	220	0.6%
Glaucoma	338	0.9%
Osteoporosis	23	0.1%
Obesity: diagnosed or identified by weight management procedures	6,444	17.2%
Obesity: identified by weight management-related dispensings	776	2.1%
Overweight	2,109	5.6%
Smoking: diagnosed or identified by smoking cessation procedures	3,660	9.7%
Smoking: identified by smoking-related dispensings	419	1.1%
Alcohol Abuse or Dependence	382	1.0%
Drug Abuse or Dependence	1,163	3.1%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	27	0.1%
Liver Disease Based on CCW ⁵ Definition	525	1.4%
Liver Disease Extended Definition (CCW + Additional Codes)	534	1.4%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	11.3	10.8
Mean number of emergency room encounters	0.7	1.6
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.3	8.6
Mean number of filled prescriptions	15.1	16.0

Table 1x. Aggregated Characteristics of Elagolix sodium in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Elagolix sodium		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	7.1	5.6
Mean number of unique drug classes dispensed	6.6	5.0

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1y. Aggregated Characteristics of Fish oil triglycerides in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Fish oil triglycerides		
Patient Characteristics	Number	Percent
Unique patients	286	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	17.2	12.8
Age	Number	Percent
0-17 years	180	62.9%
18-24 years	*****	*****
25-40 years	60	21.0%
41-64 years	27	9.4%
≥ 65 years	*****	*****
Sex		
Female	180	62.9%
Male	106	37.1%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	12	4.2%
Black or African American	31	10.8%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	127	44.4%
White	104	36.4%
Hispanic origin		
Yes	41	14.3%
No	144	50.3%
Unknown	101	35.3%
Year		
2018	*****	*****
2019	35	12.2%
2020	84	29.4%
2021	61	21.3%
2022	*****	*****
2023	41	14.3%
2024	44	15.4%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****

Table 1y. Aggregated Characteristics of Fish oil triglycerides in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Health Characteristics	Fish oil triglycerides	
	Number	Percent
Heart Failure	*****	*****
Hyperlipidemia	11	3.8%
Hypertension	27	9.4%
Depression	23	8.0%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA ³	*****	*****
Breast Cancer	0	0.0%
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	17	5.9%
Anemia	129	45.1%
Asthma	19	6.6%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	15	5.2%
COPD ⁴ and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	41	14.3%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	11	3.8%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁵ Definition	103	36.0%
Liver Disease Extended Definition (CCW + Additional Codes)	104	36.4%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	20.5	24.8
Mean number of emergency room encounters	1.1	1.9
Mean number of inpatient hospital encounters	1.1	1.6
Mean number of non-acute institutional encounters	0.1	1.4
Mean number of other ambulatory encounters	75.1	53.4
Mean number of filled prescriptions	43.1	70.1

Table 1y. Aggregated Characteristics of Fish oil triglycerides in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Health Service Utilization Intensity Metrics	Fish oil triglycerides	
	Mean	Standard Deviation
Mean number of generics dispensed	8.5	8.0
Mean number of unique drug classes dispensed	7.7	6.8

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 1z. Aggregated Characteristics of Lusutrombopag in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Lusutrombopag		
Patient Characteristics	Number	Percent
Unique patients	441	N/A ¹
Demographic Characteristics	Mean	Standard Deviation
Age (years)	57.2	9.7
Age	Number	Percent
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	321	72.8%
≥ 65 years	93	21.1%
Sex		
Female	197	44.7%
Male	244	55.3%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	20	4.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	164	37.2%
White	234	53.1%
Hispanic origin		
Yes	78	17.7%
No	266	60.3%
Unknown	97	22.0%
Year		
2018	*****	*****
2019	206	46.7%
2020	125	28.3%
2021	60	13.6%
2022	24	5.4%
2023	11	2.5%
2024	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	15	3.4%
Atrial Fibrillation	16	3.6%
Diabetes Mellitus	155	35.1%

Table 1z. Aggregated Characteristics of Lusutrombopag in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Health Characteristics	Lusutrombopag	
	Number	Percent
Heart Failure	46	10.4%
Hyperlipidemia	81	18.4%
Hypertension	173	39.2%
Depression	110	24.9%
Ischemic Heart Disease	56	12.7%
Rheumatoid Arthritis/Osteoarthritis	80	18.1%
Stroke/TIA ³	*****	*****
Breast Cancer	12	2.7%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	46	10.4%
Anemia	249	56.5%
Asthma	21	4.8%
Benign Prostatic Hyperplasia	14	3.2%
Chronic Kidney Disease	60	13.6%
COPD ⁴ and Bronchiectasis	32	7.3%
Glaucoma	14	3.2%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	138	31.3%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	44	10.0%
Smoking: diagnosed or identified by smoking cessation procedures	134	30.4%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	185	42.0%
Drug Abuse or Dependence	54	12.2%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	14	3.2%
Liver Disease Based on CCW ⁵ Definition	402	91.2%
Liver Disease Extended Definition (CCW + Additional Codes)	402	91.2%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	18.6	16.1
Mean number of emergency room encounters	1.1	2.9
Mean number of inpatient hospital encounters	0.7	1.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	11.0	17.7
Mean number of filled prescriptions	29.0	23.0

Table 1z. Aggregated Characteristics of Lusutrombopag in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

Lusutrombopag		
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of generics dispensed	10.6	6.2
Mean number of unique drug classes dispensed	9.8	5.5

¹N/A: Not Applicable

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³TIA: Transient Ischemic Attack

⁴COPD: Chronic Obstructive Pulmonary Disease

⁵CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>Lutetium Lu 177 dotatate</i>	19,812	19,812	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Bictegravir embicitabine tenofovir alafenamide</i>	3,872,463	3,722,726	96.1%	24,057	0.6%	123,815	3.2%	1,865	0.0%
<i>Tezacaftor and ivacaftor</i>	48,256	47,140	97.7%	510	1.1%	566	1.2%	40	0.1%
<i>Apalutamide</i>	192,784	189,498	98.3%	2,085	1.1%	1,127	0.6%	74	0.0%
<i>Ibalizumab-uiyk</i>	9,172	9,139	99.6%	14	0.2%	19	0.2%	0	0.0%
<i>Tildrakizumab</i>	79,918	75,250	94.2%	472	0.6%	4,175	5.2%	21	0.0%
<i>Burosumab-twza</i>	30,865	29,227	94.7%	1,593	5.2%	*****	*****	*****	*****
<i>Fostamatinib</i>	12,111	11,932	98.5%	105	0.9%	*****	*****	*****	*****
<i>Fosnetupitant and palonosetron</i>	198,577	198,551	100.0%	*****	*****	*****	*****	0	0.0%
<i>Lofexidine hydrochloride</i>	11,250	11,141	99.0%	94	0.8%	*****	*****	*****	*****
<i>Erenumab-aooe</i>	2,098,666	1,955,755	93.2%	17,410	0.8%	125,291	6.0%	210	0.0%
<i>Sodium zirconium</i>	500,105	417,070	83.4%	30,064	6.0%	52,731	10.5%	240	0.0%
<i>Avatrombopag</i>	20,113	19,145	95.2%	674	3.4%	283	1.4%	11	0.1%
<i>Pegvaliase-pqpz</i>	11,728	11,274	96.1%	400	3.4%	42	0.4%	12	0.1%
<i>Baricitinib</i>	114,153	111,511	97.7%	*****	*****	2,305	2.0%	*****	*****
<i>Moxidectin</i>	0	-	-	-	-	-	-	-	-
<i>Cannabidiol</i>	449,313	413,092	91.9%	31,993	7.1%	3,799	0.8%	429	0.1%
<i>Plazomicin</i>	1,753	*****	*****	0	0.0%	0	0.0%	*****	*****
<i>Binimetinib</i>	26,962	26,778	99.3%	145	0.5%	*****	*****	*****	*****
<i>Encorafenib</i>	31,713	31,301	98.7%	352	1.1%	*****	*****	*****	*****
<i>Tecovirimat</i>	51	51	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ivosidenib</i>	17,971	17,911	99.7%	45	0.3%	15	0.1%	0	0.0%
<i>Tafenoquine</i>	988	865	87.6%	90	9.1%	*****	*****	*****	*****
<i>Elagolix sodium</i>	195,046	183,841	94.3%	2,057	1.1%	9,055	4.6%	93	0.0%
<i>Fish oil triglycerides</i>	9,993	9,993	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Lusutrombopag</i>	641	*****	*****	*****	*****	0	0.0%	0	0.0%

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Lutetium Lu 177 dotatate</i>	19,812	1	1	1	1	1	1.0	0.0
<i>Bictegravir embitcitabine tenofovir alafenamide</i>	3,872,463	1	30	30	30	999	31.4	11.8
<i>Tezacaftor and ivacaftor</i>	48,256	1	28	28	28	280	28.7	8.0
<i>Apalutamide</i>	192,784	1	30	30	30	320	30.1	6.3
<i>Ibalizumab-uiyk</i>	9,172	1	1	14	28	84	12.7	12.3
<i>Tildrakizumab</i>	79,918	1	1	1	1	252	6.2	19.1
<i>Burosumab-twza</i>	30,865	1	1	1	28	168	13.3	16.2
<i>Fostamatinib</i>	12,111	1	30	30	30	205	29.8	6.9
<i>Fosnetupitant and palonosetron</i>	198,577	1	1	1	1	90	1.6	3.8
<i>Lofexidine hydrochloride</i>	11,250	1	8	9	14	126	11.6	6.8
<i>Erenumab-aooe</i>	2,098,666	1	28	30	30	389	32.5	14.7
<i>Sodium zirconium</i>	500,105	1	18	30	30	450	31.1	22.3
<i>Avatrombopag</i>	20,113	1	28	30	30	105	26.4	11.4
<i>Pegvaliase-pqpz</i>	11,728	1	28	30	30	152	28.9	8.2
<i>Baricitinib</i>	114,153	1	1	1	30	180	15.6	17.8
<i>Moxidectin</i>	0	-	-	-	-	-	-	-
<i>Cannabidiol</i>	449,313	1	30	30	30	760	29.8	7.9
<i>Plazomicin</i>	1,753	1	1	1	1	700	1.5	16.7
<i>Binimetinib</i>	26,962	1	30	30	30	280	29.3	5.1
<i>Encorafenib</i>	31,713	1	30	30	30	120	29.3	5.0
<i>Tecovirimat</i>	51	8	14	14	14	14	13.7	1.4
<i>Ivosidenib</i>	17,971	1	30	30	30	90	29.0	4.9
<i>Tafenoquine</i>	988	1	3	21	30	365	21.5	24.6
<i>Elagolix sodium</i>	195,046	1	28	28	28	280	30.3	13.0
<i>Fish oil triglycerides</i>	9,993	1	1	1	4	30	2.6	2.5
<i>Lusutrombopag</i>	641	1	7	7	7	60	7.9	4.0

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024,

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Lutetium Lu 177 dotatate	19,812	19,812	100.0%	0	NaN	0	NaN	0	NaN
Female	9,684	9,684	48.9%	0	NaN	0	NaN	0	NaN
Male	10,128	10,128	51.1%	0	NaN	0	NaN	0	NaN
Bictegravir embitcitabine tenofovir alafenamide	3,872,463	3,722,726	100.0%	24,057	100.0%	123,815	100.0%	1,865	100.0%
Female	975,720	949,010	25.5%	5,549	23.1%	20,824	16.8%	337	18.1%
Male	2,896,743	2,773,716	74.5%	18,508	76.9%	102,991	83.2%	1,528	81.9%
Tezacaftor and	48,256	47,140	100.0%	510	100.0%	566	100.0%	40	100.0%
Female	23,629	23,065	48.9%	268	52.5%	274	48.4%	22	55.0%
Male	24,627	24,075	51.1%	242	47.5%	292	51.6%	18	45.0%
Apalutamide	192,784	189,498	100.0%	2,085	100.0%	1,127	100.0%	74	100.0%
Female	22	22	0.0%	0	0.0%	0	0.0%	0	0.0%
Male	192,762	189,476	100.0%	2,085	100.0%	1,127	100.0%	74	100.0%
Ibalizumab-uiyk	9,172	9,139	100.0%	14	100.0%	19	100.0%	0	NaN
Female	2,079	*****	*****	*****	*****	*****	*****	0	NaN
Male	7,093	*****	*****	*****	*****	*****	*****	0	NaN
Tildrakizumab	79,918	75,250	100.0%	472	100.0%	4,175	100.0%	21	100.0%
Female	41,155	38,765	51.5%	*****	*****	2,165	51.9%	*****	*****
Male	38,763	36,485	48.5%	*****	*****	2,010	48.1%	*****	*****
Burosumab-twza	30,865	29,227	100.0%	1,593	100.0%	*****	*****	*****	*****
Female	19,420	18,245	62.4%	1,146	71.9%	*****	*****	*****	*****
Male	11,445	10,982	37.6%	447	28.1%	16	36.4%	0	0.0%
Fostamatinib	12,111	11,932	100.0%	105	100.0%	*****	*****	*****	*****
Female	7,048	6,963	58.4%	65	61.9%	*****	*****	*****	*****
Male	5,063	4,969	41.6%	40	38.1%	*****	*****	*****	*****
Fosnetupitant and palonosetron	198,577	198,551	100.0%	*****	*****	*****	*****	0	NaN
Female	112,440	*****	*****	*****	*****	*****	*****	0	NaN
Male	86,137	*****	*****	*****	*****	*****	*****	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024,

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Lofexidine hydrochloride	11,250	11,141	100.0%	94	100.0%	*****	*****	*****	*****
Female	5,644	5,605	50.3%	*****	*****	*****	*****	0	0.0%
Male	5,606	5,536	49.7%	*****	*****	*****	*****	*****	*****
Erenumab-aooe	2,098,666	1,955,755	100.0%	17,410	100.0%	125,291	100.0%	210	100.0%
Female	1,794,777	1,672,734	85.5%	14,894	85.5%	106,968	85.4%	181	86.2%
Male	303,889	283,021	14.5%	2,516	14.5%	18,323	14.6%	29	13.8%
Sodium zirconium cyclosilicate	500,105	417,070	100.0%	30,064	100.0%	52,731	100.0%	240	100.0%
Female	207,435	174,456	41.8%	12,399	41.2%	20,485	38.8%	95	39.6%
Male	292,670	242,614	58.2%	17,665	58.8%	32,246	61.2%	145	60.4%
Avatrombopag	20,113	19,145	100.0%	674	100.0%	283	100.0%	11	100.0%
Female	9,998	9,468	49.5%	379	56.2%	*****	*****	*****	*****
Male	10,115	9,677	50.5%	295	43.8%	*****	*****	*****	*****
Pegvaliase-pqpz	11,728	11,274	100.0%	400	100.0%	42	100.0%	12	100.0%
Female	5,887	5,679	50.4%	180	45.0%	*****	*****	*****	*****
Male	5,841	5,595	49.6%	220	55.0%	*****	*****	*****	*****
Baricitinib	114,153	111,511	100.0%	*****	*****	2,305	100.0%	*****	*****
Female	70,099	68,025	61.0%	*****	*****	1,835	79.6%	*****	*****
Male	44,054	43,486	39.0%	98	29.4%	470	20.4%	0	0.0%
Moxidectin	-	-	-	-	-	-	-	-	-
Female	-	-	-	-	-	-	-	-	-
Male	-	-	-	-	-	-	-	-	-
Cannabidiol	449,313	413,092	100.0%	31,993	100.0%	3,799	100.0%	429	100.0%
Female	200,153	183,611	44.4%	14,510	45.4%	1,820	47.9%	212	49.4%
Male	249,160	229,481	55.6%	17,483	54.6%	1,979	52.1%	217	50.6%
Plazomicin	1,753	*****	*****	0	NaN	0	NaN	*****	*****
Female	1,176	*****	*****	0	NaN	0	NaN	0	0.0%
Male	577	*****	*****	0	NaN	0	NaN	*****	*****

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024,

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Binimetinib	26,962	26,778	100.0%	145	100.0%	*****	*****	*****	*****
Female	12,076	11,988	44.8%	72	49.7%	*****	*****	*****	*****
Male	14,886	14,790	55.2%	73	50.3%	*****	*****	*****	*****
Encorafenib	31,713	31,301	100.0%	352	100.0%	*****	*****	*****	*****
Female	14,904	14,669	46.9%	214	60.8%	*****	*****	0	0.0%
Male	16,809	16,632	53.1%	138	39.2%	*****	*****	*****	*****
Tecovirimat	51	51	100.0%	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN
Ivosidenib	17,971	17,911	100.0%	45	100.0%	15	100.0%	0	NaN
Female	9,469	9,425	52.6%	*****	*****	*****	*****	0	NaN
Male	8,502	8,486	47.4%	*****	*****	*****	*****	0	NaN
Tafenoquine	988	865	100.0%	90	100.0%	*****	*****	*****	*****
Female	587	531	61.4%	45	50.0%	*****	*****	*****	*****
Male	401	334	38.6%	45	50.0%	*****	*****	*****	*****
Elagolix sodium	195,046	183,841	100.0%	2,057	100.0%	9,055	100.0%	93	100.0%
Female	194,786	*****	*****	*****	*****	*****	*****	93	100.0%
Male	260	*****	*****	*****	*****	*****	*****	0	0.0%
Fish oil triglycerides	9,993	9,993	100.0%	0	NaN	0	NaN	0	NaN
Female	5,257	5,257	52.6%	0	NaN	0	NaN	0	NaN
Male	4,736	4,736	47.4%	0	NaN	0	NaN	0	NaN
Lusutrombopag	641	*****	*****	*****	*****	0	NaN	0	NaN
Female	314	*****	*****	0	0.0%	0	NaN	0	NaN
Male	327	*****	*****	*****	*****	0	NaN	0	NaN

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Lutetium Lu 177 dotatate	19,812	1	1	1	1	1	1.0	0.0
Female	9,684	1	1	1	1	1	1.0	0.0
Male	10,128	1	1	1	1	1	1.0	0.0
Bictegravir embicitabine tenofovir alafenamide	3,872,463	1	30	30	30	999	31.4	11.8
Female	975,720	1	30	30	30	999	30.7	10.1
Male	2,896,743	1	30	30	30	899	31.6	12.3
Tezacaftor and ivacaftor	48,256	1	28	28	28	280	28.7	8.0
Female	23,629	1	28	28	28	280	28.7	7.9
Male	24,627	1	28	28	28	280	28.7	8.1
Apalutamide	192,784	1	30	30	30	320	30.1	6.3
Female	22	11	30	30	30	30	28.3	4.8
Male	192,762	1	30	30	30	320	30.1	6.3
Ibalizumab-uiyk	9,172	1	1	14	28	84	12.7	12.3
Female	2,079	1	1	1	14	84	8.8	11.3
Male	7,093	1	1	14	28	84	13.8	12.3
Tildrakizumab	79,918	1	1	1	1	252	6.2	19.1
Female	41,155	1	1	1	1	168	6.3	19.1
Male	38,763	1	1	1	1	252	6.2	19.0
Burosumab-twza	30,865	1	1	1	28	168	13.3	16.2
Female	19,420	1	1	1	28	168	14.3	16.6
Male	11,445	1	1	1	28	84	11.7	15.3
Fostamatinib	12,111	1	30	30	30	205	29.8	6.9
Female	7,048	1	30	30	30	205	29.6	6.0
Male	5,063	1	30	30	30	120	30.0	7.9
Fosnetupitant and palonosetron	198,577	1	1	1	1	90	1.6	3.8
Female	112,440	1	1	1	1	90	1.6	3.8
Male	86,137	1	1	1	1	90	1.6	3.7
Lofexidine hydrochloride	11,250	1	8	9	14	126	11.6	6.8
Female	5,644	1	8	9	14	90	11.6	6.3
Male	5,606	1	8	9	14	126	11.7	7.2
Erenumab-aooe	2,098,666	1	28	30	30	389	32.5	14.7

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	1,794,777	1	28	30	30	389	32.5	14.7
Male	303,889	1	28	30	30	360	32.6	14.8
Sodium zirconium cyclosilicate	500,105	1	18	30	30	450	31.1	22.3
Female	207,435	1	14	30	30	225	29.9	22.2
Male	292,670	1	23	30	30	450	31.9	22.3
Avatrombopag	20,113	1	28	30	30	105	26.4	11.4
Female	9,998	1	28	30	30	105	26.6	11.2
Male	10,115	1	28	30	30	105	26.1	11.6
Pegvaliase-pqpz	11,728	1	28	30	30	152	28.9	8.2
Female	5,887	1	28	30	30	152	28.7	8.0
Male	5,841	1	28	30	30	105	29.1	8.4
Baricitinib	114,153	1	1	1	30	180	15.6	17.8
Female	70,099	1	1	30	30	180	19.6	18.3
Male	44,054	1	1	1	30	90	9.4	15.2
Moxidectin	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Cannabidiol	449,313	1	30	30	30	760	29.8	7.9
Female	200,153	1	30	30	30	447	29.9	8.1
Male	249,160	1	30	30	30	760	29.6	7.8
Plazomicin	1,753	1	1	1	1	700	1.5	16.7
Female	1,176	1	1	1	1	10	1.1	0.7
Male	577	1	1	1	1	700	2.4	29.1
Binimetinib	26,962	1	30	30	30	280	29.3	5.1
Female	12,076	1	30	30	30	280	29.3	5.5
Male	14,886	1	30	30	30	180	29.3	4.8
Encorafenib	31,713	1	30	30	30	120	29.3	5.0
Female	14,904	1	30	30	30	90	29.3	4.9
Male	16,809	1	30	30	30	120	29.4	5.1
Tecovirimat	51	8	14	14	14	14	13.7	1.4
Female	*****	14	14	14	14	14	14.0	NaN
Male	*****	8	14	14	14	14	13.7	1.4

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Ivosidenib	17,971	1	30	30	30	90	29.0	4.9
Female	9,469	1	30	30	30	90	29.0	5.0
Male	8,502	1	30	30	30	90	28.9	4.7
Tafenoquine	988	1	3	21	30	365	21.5	24.6
Female	587	1	3	24	30	112	20.3	16.5
Male	401	1	3	21	30	365	23.2	33.0
Elagolix sodium	195,046	1	28	28	28	280	30.3	13.0
Female	194,786	1	28	28	28	280	30.3	13.0
Male	260	1	28	28	28	84	29.1	9.8
Fish oil triglycerides	9,993	1	1	1	4	30	2.6	2.5
Female	5,257	1	1	1	4	30	2.5	2.5
Male	4,736	1	1	1	5	14	2.7	2.6
Lusutrombopag	641	1	7	7	7	60	7.9	4.0
Female	314	1	7	7	7	30	8.1	3.6
Male	327	3	7	7	7	60	7.6	4.4

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*NaN: Not a number

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Lutetium Lu 177 dotatate	19,812	19,812	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	367	367	1.9%	0	NaN	0	NaN	0	NaN
41-64 years	4,665	4,665	23.5%	0	NaN	0	NaN	0	NaN
≥ 65 years	14,741	14,741	74.4%	0	NaN	0	NaN	0	NaN
Bictegravir embitcitabine tenofovir alafenamide	3,872,463	3,722,726	100.0%	24,057	100.0%	123,815	100.0%	1,865	100.0%
0-17 years	19,551	18,900	0.5%	*****	*****	492	0.4%	*****	*****
18-24 years	141,703	135,720	3.6%	1,544	6.4%	4,272	3.5%	167	9.0%
25-40 years	929,478	890,173	23.9%	8,257	34.3%	30,383	24.5%	665	35.7%
41-64 years	2,214,849	2,126,413	57.1%	13,062	54.3%	74,397	60.1%	977	52.4%
≥ 65 years	566,882	551,520	14.8%	*****	*****	14,271	11.5%	*****	*****
Tezacaftor and ivacaftor	48,256	47,140	100.0%	510	100.0%	566	100.0%	40	100.0%
0-17 years	18,477	18,063	38.3%	255	50.0%	*****	*****	*****	*****
18-24 years	8,267	8,027	17.0%	140	27.5%	82	14.5%	18	45.0%
25-40 years	14,479	14,237	30.2%	64	12.5%	*****	*****	*****	*****
41-64 years	6,051	5,912	12.5%	28	5.5%	*****	*****	*****	*****
≥ 65 years	982	901	1.9%	23	4.5%	58	10.2%	0	0.0%
Apalutamide	192,784	189,498	100.0%	2,085	100.0%	1,127	100.0%	74	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	25	25	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	20,393	20,120	10.6%	195	9.4%	*****	*****	*****	*****
≥ 65 years	172,366	169,353	89.4%	1,890	90.6%	*****	*****	*****	*****
Ibalizumab-uiyk	9,172	9,139	100.0%	14	100.0%	19	100.0%	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN
25-40 years	1,323	1,323	14.5%	0	0.0%	0	0.0%	0	NaN
41-64 years	6,286	*****	*****	14	100.0%	*****	*****	0	NaN
≥ 65 years	1,428	*****	*****	0	0.0%	*****	*****	0	NaN
Tildrakizumab	79,918	75,250	100.0%	472	100.0%	4,175	100.0%	21	100.0%
0-17 years	23	11	0.0%	0	0.0%	12	0.3%	0	0.0%
18-24 years	380	245	0.3%	11	2.3%	124	3.0%	0	0.0%
25-40 years	2,338	1,597	2.1%	*****	*****	644	15.4%	*****	*****
41-64 years	7,402	5,425	7.2%	*****	*****	1,674	40.1%	*****	*****
≥ 65 years	69,775	67,972	90.3%	82	17.4%	1,721	41.2%	0	0.0%
Burosumab-twza	30,865	29,227	100.0%	1,593	100.0%	*****	*****	*****	*****
0-17 years	18,336	17,769	60.8%	*****	*****	*****	*****	0	0.0%
18-24 years	1,428	1,256	4.3%	*****	*****	*****	*****	0	0.0%
25-40 years	3,773	3,474	11.9%	*****	*****	*****	*****	0	0.0%
41-64 years	4,673	4,260	14.6%	*****	*****	11	25.0%	*****	*****
≥ 65 years	2,655	2,468	8.4%	175	11.0%	12	27.3%	0	0.0%
Fostamatinib	12,111	11,932	100.0%	105	100.0%	*****	*****	*****	*****
0-17 years	58	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	407	*****	*****	*****	*****	0	0.0%	0	0.0%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	1,415	*****	*****	*****	*****	11	15.9%	0	0.0%
41-64 years	4,429	4,386	36.8%	28	26.7%	*****	*****	*****	*****
≥ 65 years	5,802	5,688	47.7%	66	62.9%	*****	*****	*****	*****
Fosnetupitant and palonosetron	198,577	198,551	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	4,636	4,636	2.3%	0	0.0%	0	0.0%	0	NaN
41-64 years	40,603	*****	*****	0	0.0%	*****	*****	0	NaN
≥ 65 years	152,783	152,759	76.9%	*****	*****	*****	*****	0	NaN
Lofexidine hydrochloride	11,250	11,141	100.0%	94	100.0%	*****	*****	*****	*****
0-17 years	21	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	596	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	4,457	4,432	39.8%	*****	*****	*****	*****	0	0.0%
41-64 years	5,107	5,054	45.4%	*****	*****	*****	*****	*****	*****
≥ 65 years	1,069	1,042	9.4%	*****	*****	*****	*****	0	0.0%
Erenumab-aooe	2,098,666	1,955,755	100.0%	17,410	100.0%	125,291	100.0%	210	100.0%
0-17 years	12,259	11,657	0.6%	87	0.5%	515	0.4%	0	0.0%
18-24 years	96,235	92,202	4.7%	613	3.5%	3,408	2.7%	12	5.7%
25-40 years	517,660	494,095	25.3%	3,786	21.7%	19,742	15.8%	37	17.6%
41-64 years	1,115,985	1,040,082	53.2%	9,104	52.3%	66,670	53.2%	129	61.4%
≥ 65 years	356,527	317,719	16.2%	3,820	21.9%	34,956	27.9%	32	15.2%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Sodium zirconium cyclosilicate	500,105	417,070	100.0%	30,064	100.0%	52,731	100.0%	240	100.0%
0-17 years	293	273	0.1%	*****	*****	*****	*****	0	0.0%
18-24 years	1,494	1,285	0.3%	*****	*****	*****	*****	0	0.0%
25-40 years	21,942	18,607	4.5%	1,326	4.4%	1,997	3.8%	12	5.0%
41-64 years	151,303	128,956	30.9%	9,066	30.2%	13,213	25.1%	68	28.3%
≥ 65 years	325,073	267,949	64.2%	19,596	65.2%	37,368	70.9%	160	66.7%
Avatrombopag	20,113	19,145	100.0%	674	100.0%	283	100.0%	11	100.0%
0-17 years	88	*****	*****	*****	*****	0	0.0%	*****	*****
18-24 years	667	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	1,664	1,597	8.3%	55	8.2%	*****	*****	*****	*****
41-64 years	7,392	7,095	37.1%	217	32.2%	*****	*****	*****	*****
≥ 65 years	10,302	9,721	50.8%	386	57.3%	*****	*****	*****	*****
Pegvaliase-pqpz	11,728	11,274	100.0%	400	100.0%	42	100.0%	12	100.0%
0-17 years	921	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	2,778	2,659	23.6%	106	26.5%	*****	*****	*****	*****
25-40 years	4,825	4,617	41.0%	181	45.3%	*****	*****	*****	*****
41-64 years	3,148	3,060	27.1%	*****	*****	*****	*****	*****	*****
≥ 65 years	56	*****	*****	*****	*****	0	0.0%	0	0.0%
Baricitinib	114,153	111,511	100.0%	*****	*****	2,305	100.0%	*****	*****
0-17 years	1,645	1,561	1.4%	68	20.4%	16	0.7%	0	0.0%
18-24 years	3,429	3,374	3.0%	*****	*****	40	1.7%	*****	*****
25-40 years	11,851	11,673	10.5%	29	8.7%	149	6.5%	0	0.0%
41-64 years	45,888	44,809	40.2%	*****	*****	956	41.5%	*****	*****

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
≥ 65 years	51,340	50,094	44.9%	*****	*****	1,144	49.6%	*****	*****
Moxidectin		-	-	-	-	-	-	-	-
0-17 years		-	-	-	-	-	-	-	-
18-24 years		-	-	-	-	-	-	-	-
25-40 years		-	-	-	-	-	-	-	-
41-64 years		-	-	-	-	-	-	-	-
≥ 65 years		-	-	-	-	-	-	-	-
Cannabidiol	449,313	413,092	100.0%	31,993	100.0%	3,799	100.0%	429	100.0%
0-17 years	226,934	206,858	50.1%	18,354	57.4%	1,445	38.0%	277	64.6%
18-24 years	68,353	63,975	15.5%	3,864	12.1%	*****	*****	*****	*****
25-40 years	99,469	92,276	22.3%	5,995	18.7%	1,143	30.1%	55	12.8%
41-64 years	51,495	47,108	11.4%	3,627	11.3%	710	18.7%	50	11.7%
≥ 65 years	3,062	2,875	0.7%	153	0.5%	*****	*****	*****	*****
Plazomicin	1,753	*****	*****	0	NaN	0	NaN	*****	*****
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	0.0%
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	0.0%
25-40 years	76	*****	*****	0	NaN	0	NaN	*****	*****
41-64 years	238	238	13.6%	0	NaN	0	NaN	0	0.0%
≥ 65 years	1,439	1,439	82.1%	0	NaN	0	NaN	0	0.0%
Binimetinib	26,962	26,778	100.0%	145	100.0%	*****	*****	*****	*****
0-17 years	260	238	0.9%	*****	*****	*****	*****	*****	*****
18-24 years	305	*****	*****	*****	*****	0	0.0%	*****	*****
25-40 years	2,280	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	9,644	9,583	35.8%	*****	*****	*****	*****	0	0.0%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
≥ 65 years	14,473	14,386	53.7%	68	46.9%	19	55.9%	0	0.0%
Encorafenib	31,713	31,301	100.0%	352	100.0%	*****	*****	*****	*****
0-17 years	34	34	0.1%	0	0.0%	0	0.0%	0	0.0%
18-24 years	244	244	0.8%	0	0.0%	0	0.0%	0	0.0%
25-40 years	2,453	2,434	7.8%	19	5.4%	0	0.0%	0	0.0%
41-64 years	11,153	11,010	35.2%	127	36.1%	16	27.1%	0	0.0%
≥ 65 years	17,829	17,579	56.2%	206	58.5%	*****	*****	*****	*****
Tecovirimat	51	51	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	12	12	23.5%	0	NaN	0	NaN	0	NaN
25-40 years	27	27	52.9%	0	NaN	0	NaN	0	NaN
41-64 years	12	12	23.5%	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
Ivosidenib	17,971	17,911	100.0%	45	100.0%	15	100.0%	0	NaN
0-17 years	14	14	0.1%	0	0.0%	0	0.0%	0	NaN
18-24 years	222	222	1.2%	0	0.0%	0	0.0%	0	NaN
25-40 years	1,642	1,621	9.1%	21	46.7%	0	0.0%	0	NaN
41-64 years	4,095	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	11,998	*****	*****	*****	*****	*****	*****	0	NaN
Tafenoquine	988	865	100.0%	90	100.0%	*****	*****	*****	*****
0-17 years	52	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	77	56	6.5%	*****	*****	*****	*****	0	0.0%
25-40 years	346	322	37.2%	*****	*****	*****	*****	0	0.0%
41-64 years	459	401	46.4%	45	50.0%	*****	*****	*****	*****

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
≥ 65 years	54	*****	*****	*****	*****	*****	*****	0	0.0%
Elagolix sodium	195,046	183,841	100.0%	2,057	100.0%	9,055	100.0%	93	100.0%
0-17 years	3,168	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	31,310	29,547	16.1%	*****	*****	1,450	16.0%	*****	*****
25-40 years	113,679	107,586	58.5%	1,224	59.5%	4,807	53.1%	62	66.7%
41-64 years	46,827	43,653	23.7%	521	25.3%	2,638	29.1%	15	16.1%
≥ 65 years	62	*****	*****	*****	*****	*****	*****	0	0.0%
Fish oil triglycerides	9,993	9,993	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	8,393	8,393	84.0%	0	NaN	0	NaN	0	NaN
18-24 years	892	892	8.9%	0	NaN	0	NaN	0	NaN
25-40 years	318	318	3.2%	0	NaN	0	NaN	0	NaN
41-64 years	208	208	2.1%	0	NaN	0	NaN	0	NaN
≥ 65 years	182	182	1.8%	0	NaN	0	NaN	0	NaN
Lusutrombopag	641	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	483	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	119	119	18.6%	0	0.0%	0	NaN	0	NaN

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Lutetium Lu 177 dotatate	19,812	1	1	1	1	1	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	367	1	1	1	1	1	1.0	0.0
41-64 years	4,665	1	1	1	1	1	1.0	0.0
≥ 65 years	14,741	1	1	1	1	1	1.0	0.0
Bictegravir embitcitabine tenofovir alafenamide	3,872,463	1	30	30	30	999	31.4	11.8
0-17 years	19,551	1	30	30	30	210	31.0	10.9
18-24 years	141,703	1	30	30	30	300	31.4	12.3
25-40 years	929,478	1	30	30	30	360	31.4	12.2
41-64 years	2,214,849	1	30	30	30	899	31.5	12.0
≥ 65 years	566,882	1	30	30	30	999	30.8	10.4
Tezacaftor and ivacaftor	48,256	1	28	28	28	280	28.7	8.0
0-17 years	18,477	1	28	28	28	224	28.6	6.8
18-24 years	8,267	1	28	28	28	280	28.8	10.2
25-40 years	14,479	1	28	28	28	210	28.5	7.1
41-64 years	6,051	1	28	28	28	140	28.9	8.1
≥ 65 years	982	4	28	28	28	84	31.8	13.8
Apalutamide	192,784	1	30	30	30	320	30.1	6.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	25	7	30	30	30	30	28.4	5.1
41-64 years	20,393	1	30	30	30	211	29.7	5.8
≥ 65 years	172,366	1	30	30	30	320	30.1	6.4

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Ibalizumab-uiyk	9,172	1	1	14	28	84	12.7	12.3
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	14	84	9.2	15.5
25-40 years	1,323	1	1	2	25	30	11.0	11.2
41-64 years	6,286	1	1	14	28	84	13.2	12.4
≥ 65 years	1,428	1	1	14	28	84	12.2	12.1
Tildrakizumab	79,918	1	1	1	1	252	6.2	19.1
0-17 years	23	1	1	84	84	84	49.3	38.3
18-24 years	380	1	1	1	84	87	32.6	37.0
25-40 years	2,338	1	1	1	84	151	28.9	35.7
41-64 years	7,402	1	1	1	31	252	24.9	34.4
≥ 65 years	69,775	1	1	1	1	90	3.3	13.1
Burosumab-twza	30,865	1	1	1	28	168	13.3	16.2
0-17 years	18,336	1	1	1	28	90	14.3	14.9
18-24 years	1,428	1	1	1	28	84	14.6	19.6
25-40 years	3,773	1	1	1	28	84	11.3	17.1
41-64 years	4,673	1	1	1	28	168	12.2	17.9
≥ 65 years	2,655	1	1	1	28	84	10.3	16.8
Fostamatinib	12,111	1	30	30	30	205	29.8	6.9
0-17 years	58	14	30	30	30	42	29.5	3.5
18-24 years	407	2	30	30	30	60	27.9	5.7
25-40 years	1,415	1	30	30	30	90	29.7	7.0
41-64 years	4,429	1	30	30	30	205	29.4	6.4
≥ 65 years	5,802	1	30	30	30	120	30.2	7.2

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Fosnetupitant and palonosetron	198,577	1	1	1	1	90	1.6	3.8
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	4,636	1	1	1	1	28	1.3	2.8
41-64 years	40,603	1	1	1	1	90	1.3	2.8
≥ 65 years	152,783	1	1	1	1	90	1.7	4.0
Lofexidine hydrochloride	11,250	1	8	9	14	126	11.6	6.8
0-17 years	21	2	8	14	14	32	12.3	5.7
18-24 years	596	1	8	9	12	36	10.6	4.8
25-40 years	4,457	1	8	9	14	90	11.3	5.9
41-64 years	5,107	1	8	9	14	126	11.7	6.8
≥ 65 years	1,069	1	8	9	14	90	12.9	9.9
Erenumab-aooe	2,098,666	1	28	30	30	389	32.5	14.7
0-17 years	12,259	1	28	30	30	90	31.2	12.8
18-24 years	96,235	1	28	30	30	180	30.8	12.0
25-40 years	517,660	1	28	30	30	360	31.1	12.2
41-64 years	1,115,985	1	28	30	30	389	32.5	14.7
≥ 65 years	356,527	1	30	30	30	365	35.2	18.1
Sodium zirconium cyclosilicate	500,105	1	18	30	30	450	31.1	22.3
0-17 years	293	1	30	30	30	90	31.5	16.5
18-24 years	1,494	1	28	30	30	90	31.4	20.5
25-40 years	21,942	1	28	30	30	180	32.0	20.0
41-64 years	151,303	1	24	30	30	225	30.8	20.5
≥ 65 years	325,073	1	14	30	30	450	31.1	23.2

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Avatrombopag	20,113	1	28	30	30	105	26.4	11.4
0-17 years	88	5	29	30	30	105	30.2	12.6
18-24 years	667	3	30	30	30	90	28.1	8.0
25-40 years	1,664	1	30	30	30	105	27.2	9.0
41-64 years	7,392	1	15	30	30	105	24.3	12.0
≥ 65 years	10,302	1	29	30	30	105	27.6	11.2
Pegvaliase-pqpz	11,728	1	28	30	30	152	28.9	8.2
0-17 years	921	1	28	30	30	90	28.6	9.2
18-24 years	2,778	1	28	30	30	152	28.6	8.9
25-40 years	4,825	1	28	30	30	105	29.2	8.5
41-64 years	3,148	1	28	30	30	93	28.8	6.7
≥ 65 years	56	7	30	30	30	42	29.4	4.2
Baricitinib	114,153	1	1	1	30	180	15.6	17.8
0-17 years	1,645	1	30	30	30	90	28.7	11.9
18-24 years	3,429	1	30	30	30	150	26.3	12.6
25-40 years	11,851	1	1	30	30	90	21.4	15.5
41-64 years	45,888	1	1	30	30	120	19.9	17.3
≥ 65 years	51,340	1	1	1	1	180	9.4	17.1
Moxidectin	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Cannabidiol	449,313	1	30	30	30	760	29.8	7.9
0-17 years	226,934	1	30	30	30	760	30.0	7.7
18-24 years	68,353	1	30	30	30	366	29.7	7.2
25-40 years	99,469	1	30	30	30	243	29.7	8.0
41-64 years	51,495	1	30	30	30	300	29.1	9.4
≥ 65 years	3,062	1	27	30	30	100	27.8	9.5
Plazomicin	1,753	1	1	1	1	700	1.5	16.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	76	1	1	1	1	700	10.3	80.2
41-64 years	238	1	1	1	1	7	1.3	1.2
≥ 65 years	1,439	1	1	1	1	10	1.1	0.7
Binimetinib	26,962	1	30	30	30	280	29.3	5.1
0-17 years	260	1	29	30	30	280	31.8	25.1
18-24 years	305	5	30	30	30	120	29.1	7.7
25-40 years	2,280	1	30	30	30	90	29.1	4.4
41-64 years	9,644	1	30	30	30	90	29.2	4.6
≥ 65 years	14,473	1	30	30	30	90	29.4	4.3
Encorafenib	31,713	1	30	30	30	120	29.3	5.0
0-17 years	34	2	30	30	30	30	27.7	6.8
18-24 years	244	5	30	30	30	30	28.4	4.9
25-40 years	2,453	2	30	30	30	60	29.2	4.2
41-64 years	11,153	1	30	30	30	90	29.2	5.2
≥ 65 years	17,829	1	30	30	30	120	29.5	5.0

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Tecovirimat	51	8	14	14	14	14	13.7	1.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	12	9	14	14	14	14	13.6	1.4
25-40 years	27	8	14	14	14	14	13.6	1.6
41-64 years	12	14	14	14	14	14	14.0	0.0
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Ivosidenib	17,971	1	30	30	30	90	29.0	4.9
0-17 years	14	1	21	28	30	30	23.6	9.6
18-24 years	222	1	30	30	30	30	28.7	4.9
25-40 years	1,642	1	30	30	30	60	28.8	5.9
41-64 years	4,095	1	30	30	30	84	28.8	4.9
≥ 65 years	11,998	1	30	30	30	90	29.1	4.7
Tafenoquine	988	1	3	21	30	365	21.5	24.6
0-17 years	52	1	7	27	30	199	28.1	32.5
18-24 years	77	1	16	28	31	90	28.6	20.3
25-40 years	346	1	2	14	28	84	15.6	14.4
41-64 years	459	1	7	26	30	365	23.5	29.2
≥ 65 years	54	1	3	27	28	90	25.0	23.2
Elagolix sodium	195,046	1	28	28	28	280	30.3	13.0
0-17 years	3,168	1	28	28	28	140	30.2	12.8
18-24 years	31,310	1	28	28	28	168	30.3	12.6
25-40 years	113,679	1	28	28	28	280	30.1	12.7
41-64 years	46,827	1	28	28	28	280	30.9	13.8
≥ 65 years	62	1	28	28	28	84	32.9	16.4

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Fish oil triglycerides	9,993	1	1	1	4	30	2.6	2.5
0-17 years	8,393	1	1	1	4	30	2.7	2.5
18-24 years	892	1	1	1	1	14	2.1	2.3
25-40 years	318	1	1	1	7	28	3.9	3.6
41-64 years	208	1	1	1	1	30	1.6	3.1
≥ 65 years	182	1	1	1	1	6	1.0	0.4
Lusutrombopag	641	1	7	7	7	60	7.9	4.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	4	7	7	7	7	6.4	1.3
25-40 years	*****	7	7	7	7	30	7.7	3.9
41-64 years	483	1	7	7	7	60	8.1	4.5
≥ 65 years	119	7	7	7	7	14	7.2	1.2

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Lutetium Lu 177 dotatate</i>	6,363	6,363	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Bictegravir embitcitabine tenofovir</i>	244,961	20,751	8.5%	29,199	11.9%	79,226	32.3%	55,281	22.6%	60,504	24.7%
<i>Tezacaftor and ivacaftor</i>	4,020	272	6.8%	479	11.9%	1,701	42.3%	1,315	32.7%	253	6.3%
<i>Apalutamide</i>	17,467	2,225	12.7%	3,154	18.1%	6,736	38.6%	3,203	18.3%	2,149	12.3%
<i>Ibalizumab-uiyk</i>	365	119	32.6%	66	18.1%	83	22.7%	39	10.7%	58	15.9%
<i>Tildrakizumab</i>	12,838	11,461	89.3%	251	2.0%	772	6.0%	245	1.9%	109	0.8%
<i>Burosumab-twza</i>	1,374	542	39.4%	234	17.0%	200	14.6%	175	12.7%	223	16.2%
<i>Fostamatinib</i>	1,534	320	20.9%	426	27.8%	501	32.7%	173	11.3%	114	7.4%
<i>Fosnetupitant and palonosetron</i>	35,282	33,944	96.2%	817	2.3%	488	1.4%	*****	*****	*****	*****
<i>Lofexidine hydrochloride</i>	8,141	7,636	93.8%	417	5.1%	*****	*****	*****	*****	*****	*****
<i>Erenumab-aooe</i>	203,727	28,175	13.8%	39,205	19.2%	74,811	36.7%	34,292	16.8%	27,244	13.4%
<i>Sodium zirconium cyclosilicate</i>	135,004	65,217	48.3%	28,437	21.1%	30,397	22.5%	8,188	6.1%	2,765	2.0%
<i>Avatrombopag</i>	4,012	2,103	52.4%	605	15.1%	873	21.8%	287	7.2%	144	3.6%
<i>Pegvaliase-pqpz</i>	747	60	8.0%	104	13.9%	255	34.1%	170	22.8%	158	21.2%
<i>Baricitinib</i>	64,998	59,425	91.4%	1,377	2.1%	2,689	4.1%	1,075	1.7%	432	0.7%
<i>Moxidectin</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Cannabidiol</i>	27,440	2,129	7.8%	3,416	12.4%	8,545	31.1%	6,169	22.5%	7,181	26.2%
<i>Plazomicin</i>	285	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Binimetinib</i>	3,829	877	22.9%	933	24.4%	1,440	37.6%	376	9.8%	203	5.3%
<i>Encorafenib</i>	4,755	1,118	23.5%	1,117	23.5%	1,868	39.3%	442	9.3%	210	4.4%
<i>Tecovirimat</i>	39	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
<i>Ivosidenib</i>	2,585	550	21.3%	694	26.8%	950	36.8%	264	10.2%	127	4.9%
<i>Tafenoquine</i>	366	212	57.9%	97	26.5%	*****	*****	*****	*****	*****	*****
<i>Elagolix sodium</i>	37,541	10,351	27.6%	9,749	26.0%	13,435	35.8%	3,265	8.7%	741	2.0%

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Fish oil triglycerides</i>	286	160	55.9%	55	19.2%	50	17.5%	*****	*****	*****	*****
<i>Lusutrombopag</i>	441	424	96.1%	*****	*****	*****	*****	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Lutetium Lu 177 dotatate</i>	6,363	1	2	4	4	11	3.1	1.3
<i>Bictegravir embitcitabine tenofovir alafenamide</i>	244,961	1	120	336	723	2,509	495.8	482.9
<i>Tezacaftor and ivacaftor</i>	4,020	1	138	280	504	2,230	344.6	285.8
<i>Apalutamide</i>	17,467	1	87	193	450	2,300	331.7	365.0
<i>Ibalizumab-uiyk</i>	365	1	17	84	414	2,230	317.0	464.2
<i>Tildrakizumab</i>	12,838	1	3	6	12	1,857	38.7	131.0
<i>Burosumab-twza</i>	1,374	1	16	55	495	2,251	298.7	430.3
<i>Fostamatinib</i>	1,534	2	60	116	270	2,362	235.0	326.9
<i>Fosnetupitant and palonosetron</i>	35,282	1	3	4	7	749	9.1	26.2
<i>Lofexidine hydrochloride</i>	8,141	1	9	12	15	860	16.1	26.7
<i>Erenumab-aooe</i>	203,727	1	78	180	450	2,344	335.2	385.4
<i>Sodium zirconium cyclosilicate</i>	135,004	1	11	35	124	1,962	115.1	185.1
<i>Avatrombopag</i>	4,012	1	5	30	150	1,714	132.2	230.7
<i>Pegvaliase-pqpz</i>	747	3	105	319	661	2,102	453.8	449.2
<i>Baricitinib</i>	64,998	1	1	1	1	2,151	27.5	124.0
<i>Moxidectin</i>	0	-	-	-	-	-	-	-
<i>Cannabidiol</i>	27,440	1	120	355	755	2,233	487.2	444.4
<i>Plazomicin</i>	285	1	3	5	7	700	9.3	42.2
<i>Binimetinib</i>	3,829	1	45	119	249	2,274	206.4	268.5
<i>Encorafenib</i>	4,755	1	42	120	240	2,274	195.7	253.1
<i>Tecovirimat</i>	39	9	14	14	14	112	17.9	16.1
<i>Ivosidenib</i>	2,585	1	50	108	240	2,040	201.6	258.0
<i>Tafenoquine</i>	366	1	8	30	62	1,165	58.0	104.4
<i>Elagolix sodium</i>	37,541	1	28	84	196	1,999	157.5	186.2
<i>Fish oil triglycerides</i>	286	1	7	21	89	1,051	90.4	173.2
<i>Lusutrombopag</i>	441	3	7	7	7	350	11.5	20.0

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Lutetium Lu 177 dotatate	6,363	6,363	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	3,080	3,080	48.4%	0	NaN	0	NaN	0	NaN	0	NaN
Male	3,283	3,283	51.6%	0	NaN	0	NaN	0	NaN	0	NaN
Bictegravir embicitabine tenofovir alafenamide	244,961	20,751	100.0%	29,199	100.0%	79,226	100.0%	55,281	100.0%	60,504	100.0%
Female	63,660	5,831	28.1%	7,866	26.9%	20,421	25.8%	14,582	26.4%	14,960	24.7%
Male	181,301	14,920	71.9%	21,333	73.1%	58,805	74.2%	40,699	73.6%	45,544	75.3%
Tezacaftor and ivacaftor	4,020	272	100.0%	479	100.0%	1,701	100.0%	1,315	100.0%	253	100.0%
Female	1,998	130	47.8%	251	52.4%	857	50.4%	639	48.6%	121	47.8%
Male	2,022	142	52.2%	228	47.6%	844	49.6%	676	51.4%	132	52.2%
Apalutamide	17,467	*****	*****	3,154	100.0%	*****	*****	3,203	100.0%	2,149	100.0%
Female	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
Male	*****	*****	*****	3,154	100.0%	*****	*****	3,203	100.0%	2,149	100.0%
Ibalizumab-uiyk	365	119	100.0%	66	100.0%	83	100.0%	39	100.0%	58	100.0%
Female	89	38	31.9%	17	25.8%	20	24.1%	*****	*****	*****	*****
Male	276	81	68.1%	49	74.2%	63	75.9%	*****	*****	*****	*****
Tildrakizumab	12,838	11,461	100.0%	251	100.0%	772	100.0%	245	100.0%	109	100.0%
Female	6,870	6,141	53.6%	147	58.6%	395	51.2%	128	52.2%	59	54.1%
Male	5,968	5,320	46.4%	104	41.4%	377	48.8%	117	47.8%	50	45.9%
Burosumab-twza	1,374	542	100.0%	234	100.0%	200	100.0%	175	100.0%	223	100.0%
Female	894	359	66.2%	134	57.3%	136	68.0%	113	64.6%	152	68.2%
Male	480	183	33.8%	100	42.7%	64	32.0%	62	35.4%	71	31.8%
Fostamatinib	1,534	320	100.0%	426	100.0%	501	100.0%	173	100.0%	114	100.0%
Female	838	169	52.8%	231	54.2%	276	55.1%	97	56.1%	65	57.0%
Male	696	151	47.2%	195	45.8%	225	44.9%	76	43.9%	49	43.0%
Fosnetupitant and palonosetron	35,282	33,944	100.0%	817	100.0%	488	100.0%	*****	*****	*****	*****
Female	20,040	19,266	56.8%	460	56.3%	*****	*****	*****	*****	0	0.0%
Male	15,242	14,678	43.2%	357	43.7%	*****	*****	*****	*****	*****	*****

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Lofexidine hydrochloride	8,141	7,636	100.0%	417	100.0%	*****	*****	*****	*****	*****	*****
Female	4,097	3,846	50.4%	212	50.8%	*****	*****	*****	*****	*****	*****
Male	4,044	3,790	49.6%	205	49.2%	*****	*****	*****	*****	*****	*****
Erenumab-aooe	203,727	28,175	100.0%	39,205	100.0%	74,811	100.0%	34,292	100.0%	27,244	100.0%
Female	173,883	23,721	84.2%	33,290	84.9%	64,143	85.7%	29,488	86.0%	23,241	85.3%
Male	29,844	4,454	15.8%	5,915	15.1%	10,668	14.3%	4,804	14.0%	4,003	14.7%
Sodium zirconium cyclosilicate	135,004	65,217	100.0%	28,437	100.0%	30,397	100.0%	8,188	100.0%	2,765	100.0%
Female	58,830	29,888	45.8%	12,331	43.4%	12,418	40.9%	3,145	38.4%	1,048	37.9%
Male	76,174	35,329	54.2%	16,106	56.6%	17,979	59.1%	5,043	61.6%	1,717	62.1%
Avatrombopag	4,012	2,103	100.0%	605	100.0%	873	100.0%	287	100.0%	144	100.0%
Female	1,929	943	44.8%	307	50.7%	469	53.7%	141	49.1%	69	47.9%
Male	2,083	1,160	55.2%	298	49.3%	404	46.3%	146	50.9%	75	52.1%
Pegvaliase-pqpz	747	60	100.0%	104	100.0%	255	100.0%	170	100.0%	158	100.0%
Female	397	32	53.3%	54	51.9%	143	56.1%	93	54.7%	75	47.5%
Male	350	28	46.7%	50	48.1%	112	43.9%	77	45.3%	83	52.5%
Baricitinib	64,998	59,425	100.0%	1,377	100.0%	2,689	100.0%	1,075	100.0%	432	100.0%
Female	32,536	28,238	47.5%	1,060	77.0%	2,053	76.3%	841	78.2%	344	79.6%
Male	32,462	31,187	52.5%	317	23.0%	636	23.7%	234	21.8%	88	20.4%
Moxidectin	-	-	-	-	-	-	-	-	-	-	-
Female	-	-	-	-	-	-	-	-	-	-	-
Male	-	-	-	-	-	-	-	-	-	-	-
Cannabidiol	27,440	2,129	100.0%	3,416	100.0%	8,545	100.0%	6,169	100.0%	7,181	100.0%
Female	12,451	998	46.9%	1,576	46.1%	3,909	45.7%	2,786	45.2%	3,182	44.3%
Male	14,989	1,131	53.1%	1,840	53.9%	4,636	54.3%	3,383	54.8%	3,999	55.7%
Plazomicin	285	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Female	188	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Male	97	*****	*****	*****	*****	0	0.0%	*****	*****	0	NaN
Binimetinib	3,829	877	100.0%	933	100.0%	1,440	100.0%	376	100.0%	203	100.0%
Female	1,700	403	46.0%	421	45.1%	614	42.6%	164	43.6%	98	48.3%
Male	2,129	474	54.0%	512	54.9%	826	57.4%	212	56.4%	105	51.7%

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Encorafenib	4,755	1,118	100.0%	1,117	100.0%	1,868	100.0%	442	100.0%	210	100.0%
Female	2,275	565	50.5%	536	48.0%	880	47.1%	196	44.3%	98	46.7%
Male	2,480	553	49.5%	581	52.0%	988	52.9%	246	55.7%	112	53.3%
Tecovirimat	39	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Ivosidenib	2,585	550	100.0%	694	100.0%	950	100.0%	264	100.0%	127	100.0%
Female	1,334	290	52.7%	349	50.3%	489	51.5%	135	51.1%	71	55.9%
Male	1,251	260	47.3%	345	49.7%	461	48.5%	129	48.9%	56	44.1%
Tafenoquine	366	212	100.0%	97	100.0%	*****	*****	*****	*****	*****	*****
Female	229	131	61.8%	62	63.9%	*****	*****	*****	*****	0	0.0%
Male	137	81	38.2%	35	36.1%	*****	*****	*****	*****	*****	*****
Elagolix sodium	37,541	10,351	100.0%	9,749	100.0%	13,435	100.0%	3,265	100.0%	741	100.0%
Female	37,493	10,339	99.9%	9,734	99.8%	*****	*****	*****	*****	*****	*****
Male	48	12	0.1%	15	0.2%	*****	*****	*****	*****	*****	*****
Fish oil triglycerides	286	160	100.0%	55	100.0%	50	100.0%	*****	*****	*****	*****
Female	180	113	70.6%	33	60.0%	25	50.0%	*****	*****	*****	*****
Male	106	47	29.4%	22	40.0%	25	50.0%	*****	*****	*****	*****
Lusutrombopag	441	424	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	197	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	244	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lutetium Lu 177 dotatate	6,363	1	2	4	4	11	3.1	1.3
Female	3,080	1	2	4	4	8	3.1	1.3
Male	3,283	1	2	4	4	11	3.1	1.3
Bictegravir embitcitabine tenofovir alafenamide	244,961	1	120	336	723	2,509	495.8	482.9
Female	63,660	1	120	330	701	2,505	470.4	451.2
Male	181,301	1	120	341	734	2,509	504.7	493.3
Tezacaftor and ivacaftor	4,020	1	138	280	504	2,230	344.6	285.8
Female	1,998	3	128	280	504	2,230	339.6	282.8
Male	2,022	1	140	295	504	2,162	349.5	288.6
Apalutamide	17,467	1	87	193	450	2,300	331.7	365.0
Female	*****	101	111	147	201	228	155.5	57.1
Male	*****	1	87	193	450	2,300	331.8	365.0
Ibalizumab-uiyk	365	1	17	84	414	2,230	317.0	464.2
Female	89	1	10	45	247	1,610	205.2	342.6
Male	276	1	24	113	459	2,230	353.1	492.3
Tildrakizumab	12,838	1	3	6	12	1,857	38.7	131.0
Female	6,870	1	3	6	11	1,837	37.6	128.6
Male	5,968	1	3	6	12	1,857	39.9	133.8
Burosumab-twza	1,374	1	16	55	495	2,251	298.7	430.3
Female	894	1	15	56	519	2,103	309.4	441.1
Male	480	1	18	53	447	2,251	278.7	409.1
Fostamatinib	1,534	2	60	116	270	2,362	235.0	326.9
Female	838	4	60	120	282	2,362	249.2	356.5
Male	696	2	50	93	264	2,160	217.9	286.6

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Fosnetupitant and palonosetron	35,282	1	3	4	7	749	9.1	26.2
Female	20,040	1	3	4	6	719	9.2	27.0
Male	15,242	1	2	4	7	749	8.9	25.0
Lofexidine hydrochloride	8,141	1	9	12	15	860	16.1	26.7
Female	4,097	1	9	12	15	816	16.0	26.1
Male	4,044	1	9	12	15	860	16.2	27.4
Erenumab-aooe	203,727	1	78	180	450	2,344	335.2	385.4
Female	173,883	1	81	180	450	2,344	335.8	384.4
Male	29,844	1	62	177	448	2,267	332.1	391.1
Sodium zirconium cyclosilicate	135,004	1	11	35	124	1,962	115.1	185.1
Female	58,830	1	10	30	120	1,962	105.4	175.1
Male	76,174	1	15	44	143	1,944	122.5	192.1
Avatrombopag	4,012	1	5	30	150	1,714	132.2	230.7
Female	1,929	1	5	37	154	1,714	138.0	231.4
Male	2,083	1	5	30	132	1,601	126.8	230.0
Pegvaliase-pqpz	747	3	105	319	661	2,102	453.8	449.2
Female	397	3	105	262	619	2,102	426.2	428.9
Male	350	3	106	333	712	2,001	485.2	469.9
Baricitinib	64,998	1	1	1	1	2,151	27.5	124.0
Female	32,536	1	1	1	1	2,130	42.2	153.2
Male	32,462	1	1	1	1	2,151	12.7	82.8
Moxidectin	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Cannabidiol	27,440	1	120	355	755	2,233	487.2	444.4
Female	12,451	1	120	343	746	2,170	481.2	443.2
Male	14,989	1	124	360	766	2,233	492.2	445.4
Plazomicin	285	1	3	5	7	700	9.3	42.2
Female	188	1	3	5	7	92	6.8	9.7
Male	97	1	2	5	7	700	14.0	71.2
Binimetinib	3,829	1	45	119	249	2,274	206.4	268.5
Female	1,700	1	42	108	269	2,274	208.1	273.4
Male	2,129	1	51	120	240	2,173	204.9	264.6
Encorafenib	4,755	1	42	120	240	2,274	195.7	253.1
Female	2,275	1	32	109	240	2,274	192.0	250.6
Male	2,480	1	49	120	240	2,173	199.0	255.3
Tecovirimat	39	9	14	14	14	112	17.9	16.1
Female	*****	14	14	14	14	14	14.0	NaN
Male	*****	9	14	14	14	112	18.0	16.3
Ivosidenib	2,585	1	50	108	240	2,040	201.6	258.0
Female	1,334	1	50	115	248	1,845	206.2	260.3
Male	1,251	2	49	105	240	2,040	196.7	255.6
Tafenoquine	366	1	8	30	62	1,165	58.0	104.4
Female	229	1	10	30	62	575	51.9	72.0
Male	137	1	7	27	61	1,165	68.1	142.8
Elagolix sodium	37,541	1	28	84	196	1,999	157.5	186.2
Female	37,493	1	28	84	196	1,999	157.5	186.3
Male	48	4	33	84	238	784	157.8	173.1

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Fish oil triglycerides	286	1	7	21	89	1,051	90.4	173.2
Female	180	1	7	14	51	1,051	73.2	163.9
Male	106	1	9	46	137	972	119.7	185.2
Lusutrombopag	441	3	7	7	7	350	11.5	20.0
Female	197	7	7	7	7	350	13.0	28.3
Male	244	3	7	7	7	74	10.2	8.7

*NaN: Not a number

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Lutetium Lu 177 dotatate	6,363	6,363	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	136	136	2.1%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	1,553	1,553	24.4%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	4,656	4,656	73.2%	0	NaN	0	NaN	0	NaN	0	NaN
Bictegravir embicitabine tenofovir alafenamide	244,961	20,751	100.0%	29,199	100.0%	79,226	100.0%	55,281	100.0%	60,504	100.0%
0-17 years	1,507	159	0.8%	139	0.5%	526	0.7%	441	0.8%	242	0.4%
18-24 years	13,116	1,586	7.6%	1,838	6.3%	5,044	6.4%	3,030	5.5%	1,618	2.7%
25-40 years	77,234	8,119	39.1%	11,154	38.2%	28,627	36.1%	17,293	31.3%	12,041	19.9%
41-64 years	126,324	9,064	43.7%	13,327	45.6%	37,709	47.6%	29,168	52.8%	37,056	61.2%
≥ 65 years	26,780	1,823	8.8%	2,741	9.4%	7,320	9.2%	5,349	9.7%	9,547	15.8%
Tezacaftor and ivacaftor	4,020	272	100.0%	479	100.0%	1,701	100.0%	1,315	100.0%	253	100.0%
0-17 years	1,493	86	31.6%	151	31.5%	624	36.7%	547	41.6%	85	33.6%
18-24 years	826	71	26.1%	129	26.9%	381	22.4%	207	15.7%	38	15.0%
25-40 years	1,263	81	29.8%	159	33.2%	549	32.3%	411	31.3%	63	24.9%
41-64 years	378	*****	*****	*****	*****	133	7.8%	129	9.8%	55	21.7%
≥ 65 years	60	*****	*****	*****	*****	14	0.8%	21	1.6%	12	4.7%
Apalutamide	17,467	2,225	100.0%	3,154	100.0%	6,736	100.0%	3,203	100.0%	2,149	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	0.0%	0	0.0%	*****	*****	*****	*****	0	0.0%
41-64 years	*****	*****	9.6%	321	10.2%	*****	*****	*****	*****	209	9.7%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	15,599	2,012	90.4%	2,833	89.8%	5,987	88.9%	2,827	88.3%	1,940	90.3%
Ibalizumab-uiyk	365	119	100.0%	66	100.0%	83	100.0%	39	100.0%	58	100.0%
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
25-40 years	65	31	26.1%	*****	*****	11	13.3%	*****	*****	*****	*****
41-64 years	242	71	59.7%	45	68.2%	61	73.5%	24	61.5%	41	70.7%
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Tildrakizumab	12,838	11,461	100.0%	251	100.0%	772	100.0%	245	100.0%	109	100.0%
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****
18-24 years	*****	*****	*****	*****	*****	27	3.5%	*****	*****	*****	*****
25-40 years	530	287	2.5%	*****	*****	149	19.3%	*****	*****	*****	*****
41-64 years	1,549	927	8.1%	131	52.2%	351	45.5%	99	40.4%	41	37.6%
≥ 65 years	10,675	10,206	89.0%	76	30.3%	245	31.7%	93	38.0%	55	50.5%
Burosumab-twza	1,374	542	100.0%	234	100.0%	200	100.0%	175	100.0%	223	100.0%
0-17 years	749	249	45.9%	114	48.7%	109	54.5%	130	74.3%	147	65.9%
18-24 years	96	50	9.2%	13	5.6%	16	8.0%	*****	*****	*****	*****
25-40 years	197	102	18.8%	34	14.5%	23	11.5%	17	9.7%	21	9.4%
41-64 years	209	81	14.9%	44	18.8%	39	19.5%	*****	*****	*****	*****
≥ 65 years	123	60	11.1%	29	12.4%	13	6.5%	*****	*****	*****	*****
Fostamatinib	1,534	320	100.0%	426	100.0%	501	100.0%	173	100.0%	114	100.0%
0-17 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	13	4.1%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	200	38	11.9%	50	11.7%	81	16.2%	*****	*****	*****	*****
41-64 years	508	92	28.8%	133	31.2%	178	35.5%	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	765	177	55.3%	226	53.1%	222	44.3%	81	46.8%	59	51.8%
Fosnetupitant and palonosetron	35,282	33,944	100.0%	817	100.0%	488	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	977	964	2.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	7,693	7,521	22.2%	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	26,501	25,348	74.7%	695	85.1%	426	87.3%	*****	*****	*****	*****
Lofexidine hydrochloride	8,141	7,636	100.0%	417	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	3,191	2,990	39.2%	168	40.3%	*****	*****	*****	*****	0	0.0%
41-64 years	3,727	3,488	45.7%	198	47.5%	*****	*****	*****	*****	*****	*****
≥ 65 years	756	709	9.3%	36	8.6%	*****	*****	*****	*****	*****	*****
Erenumab-aooe	203,727	28,175	100.0%	39,205	100.0%	74,811	100.0%	34,292	100.0%	27,244	100.0%
0-17 years	1,279	146	0.5%	248	0.6%	535	0.7%	221	0.6%	129	0.5%
18-24 years	11,177	1,634	5.8%	2,276	5.8%	4,585	6.1%	1,851	5.4%	831	3.1%
25-40 years	53,852	7,461	26.5%	10,732	27.4%	21,136	28.3%	8,935	26.1%	5,588	20.5%
41-64 years	103,105	13,496	47.9%	19,099	48.7%	37,273	49.8%	18,187	53.0%	15,050	55.2%
≥ 65 years	34,314	5,438	19.3%	6,850	17.5%	11,282	15.1%	5,098	14.9%	5,646	20.7%
Sodium zirconium	135,004	65,217	100.0%	28,437	100.0%	30,397	100.0%	8,188	100.0%	2,765	100.0%
0-17 years	66	20	0.0%	14	0.0%	*****	*****	*****	*****	*****	*****
18-24 years	504	236	0.4%	119	0.4%	*****	*****	*****	*****	*****	*****
25-40 years	6,278	2,754	4.2%	1,596	5.6%	1,500	4.9%	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	38,124	16,552	25.4%	8,708	30.6%	9,689	31.9%	2,409	29.4%	766	27.7%
≥ 65 years	90,032	45,655	70.0%	18,000	63.3%	19,048	62.7%	5,437	66.4%	1,892	68.4%
Avatrombopag	4,012	2,103	100.0%	605	100.0%	873	100.0%	287	100.0%	144	100.0%
0-17 years	17	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
18-24 years	96	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	305	128	6.1%	54	8.9%	92	10.5%	*****	*****	*****	*****
41-64 years	1,643	1,011	48.1%	202	33.4%	275	31.5%	108	37.6%	47	32.6%
≥ 65 years	1,951	939	44.7%	323	53.4%	456	52.2%	153	53.3%	80	55.6%
Pegvaliase-pqpz	747	60	100.0%	104	100.0%	255	100.0%	170	100.0%	158	100.0%
0-17 years	*****	*****	*****	*****	*****	16	6.3%	*****	*****	*****	*****
18-24 years	204	*****	*****	*****	*****	81	31.8%	50	29.4%	32	20.3%
25-40 years	317	26	43.3%	49	47.1%	109	42.7%	67	39.4%	66	41.8%
41-64 years	170	14	23.3%	25	24.0%	49	19.2%	36	21.2%	46	29.1%
≥ 65 years	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****	*****	*****
Baricitinib	64,998	59,425	100.0%	1,377	100.0%	2,689	100.0%	1,075	100.0%	432	100.0%
0-17 years	250	121	0.2%	26	1.9%	56	2.1%	*****	*****	*****	*****
18-24 years	815	452	0.8%	83	6.0%	202	7.5%	*****	*****	*****	*****
25-40 years	4,616	3,644	6.1%	243	17.6%	522	19.4%	176	16.4%	31	7.2%
41-64 years	20,122	17,229	29.0%	714	51.9%	1,392	51.8%	563	52.4%	224	51.9%
≥ 65 years	39,195	37,979	63.9%	311	22.6%	517	19.2%	231	21.5%	157	36.3%
Moxidectin		-	-	-	-	-	-	-	-	-	-
0-17 years		-	-	-	-	-	-	-	-	-	-
18-24 years		-	-	-	-	-	-	-	-	-	-
25-40 years		-	-	-	-	-	-	-	-	-	-

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years		-	-	-	-	-	-	-	-	-	-
≥ 65 years		-	-	-	-	-	-	-	-	-	-
Cannabidiol	27,440	2,129	100.0%	3,416	100.0%	8,545	100.0%	6,169	100.0%	7,181	100.0%
0-17 years	14,798	1,034	48.6%	1,790	52.4%	4,730	55.4%	3,553	57.6%	3,691	51.4%
18-24 years	4,538	402	18.9%	595	17.4%	1,470	17.2%	1,029	16.7%	1,042	14.5%
25-40 years	5,498	457	21.5%	679	19.9%	1,637	19.2%	1,139	18.5%	1,586	22.1%
41-64 years	2,390	190	8.9%	318	9.3%	655	7.7%	409	6.6%	818	11.4%
≥ 65 years	216	46	2.2%	34	1.0%	53	0.6%	39	0.6%	44	0.6%
Plazomicin	285	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	*****	*****	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	220	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Binimetinib	3,829	877	100.0%	933	100.0%	1,440	100.0%	376	100.0%	203	100.0%
0-17 years	35	*****	*****	*****	*****	21	1.5%	*****	*****	*****	*****
18-24 years	42	*****	*****	*****	*****	23	1.6%	*****	*****	*****	*****
25-40 years	310	51	5.8%	70	7.5%	144	10.0%	*****	*****	*****	*****
41-64 years	1,304	258	29.4%	318	34.1%	525	36.5%	129	34.3%	74	36.5%
≥ 65 years	2,138	557	63.5%	535	57.3%	727	50.5%	212	56.4%	107	52.7%
Encorafenib	4,755	1,118	100.0%	1,117	100.0%	1,868	100.0%	442	100.0%	210	100.0%
0-17 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	337	*****	*****	*****	*****	151	8.1%	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	1,603	332	29.7%	374	33.5%	672	36.0%	148	33.5%	77	36.7%
≥ 65 years	2,777	726	64.9%	657	58.8%	1,025	54.9%	257	58.1%	112	53.3%
Tecovirimat	39	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
25-40 years	23	23	60.5%	0	NaN	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
Ivosidenib	2,585	550	100.0%	694	100.0%	950	100.0%	264	100.0%	127	100.0%
0-17 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	228	*****	*****	*****	*****	101	10.6%	*****	*****	*****	*****
41-64 years	598	113	20.5%	166	23.9%	226	23.8%	70	26.5%	23	18.1%
≥ 65 years	1,731	386	70.2%	473	68.2%	611	64.3%	171	64.8%	90	70.9%
Tafenoquine	366	212	100.0%	97	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	16	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	32	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	111	74	34.9%	21	21.6%	*****	*****	*****	*****	0	0.0%
41-64 years	179	100	47.2%	54	55.7%	*****	*****	*****	*****	*****	*****
≥ 65 years	28	17	8.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
Elagolix sodium	37,541	10,351	100.0%	9,749	100.0%	13,435	100.0%	3,265	100.0%	741	100.0%
0-17 years	*****	*****	*****	123	1.3%	*****	*****	*****	*****	19	2.6%
18-24 years	6,004	1,600	15.5%	1,516	15.6%	2,258	16.8%	536	16.4%	94	12.7%
25-40 years	22,278	6,233	60.2%	5,845	60.0%	7,912	58.9%	1,884	57.7%	404	54.5%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	8,796	2,435	23.5%	2,265	23.2%	3,088	23.0%	784	24.0%	224	30.2%
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	0	0.0%
Fish oil triglycerides	286	160	100.0%	55	100.0%	50	100.0%	*****	*****	*****	*****
0-17 years	180	77	48.1%	39	70.9%	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
25-40 years	60	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	27	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Lusutrombopag	441	424	100.0%	15	100.0%	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	321	307	72.4%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	93	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lutetium Lu 177 dotatate	6,363	1	2	4	4	11	3.1	1.3
0-17 years	*****	1	1	1	2	3	1.4	0.8
18-24 years	*****	1	1	3	4	4	2.6	1.4
25-40 years	136	1	1	3	4	7	2.7	1.3
41-64 years	1,553	1	2	3	4	8	3.0	1.3
≥ 65 years	4,656	1	2	4	4	11	3.2	1.3
Bictegravir embitcitabine tenofovir alafenamide	244,961	1	120	336	723	2,509	495.8	482.9
0-17 years	1,507	1	124	330	614	2,008	402.4	337.0
18-24 years	13,116	1	90	240	492	2,258	338.8	320.3
25-40 years	77,234	1	91	257	540	2,509	378.3	376.5
41-64 years	126,324	1	150	397	813	2,505	551.8	507.7
≥ 65 years	26,780	1	150	450	1,015	2,489	652.6	600.4
Tezacaftor and ivacaftor	4,020	1	138	280	504	2,230	344.6	285.8
0-17 years	1,493	1	140	308	504	2,099	353.6	257.5
18-24 years	826	7	111	224	420	1,815	288.0	254.7
25-40 years	1,263	4	133	280	476	2,100	327.3	260.6
41-64 years	378	3	168	364	616	2,230	462.7	423.8
≥ 65 years	60	28	124	476	618	1,754	519.9	452.0
Apalutamide	17,467	1	87	193	450	2,300	331.7	365.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	97	97	169	444	444	236.7	183.1
41-64 years	*****	1	90	210	453	2,082	324.5	332.9
≥ 65 years	15,599	1	85	189	450	2,300	332.6	368.7

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Ibalizumab-uiyk	365	1	17	84	414	2,230	317.0	464.2
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	29	31	182	966	206.5	377.7
25-40 years	65	1	10	43	266	1,709	224.0	362.4
41-64 years	242	1	23	108	422	2,230	341.4	492.1
≥ 65 years	*****	1	28	113	491	1,905	339.4	448.6
Tildrakizumab	12,838	1	3	6	12	1,857	38.7	131.0
0-17 years	*****	1	1	3	30	1,096	188.8	444.6
18-24 years	*****	1	4	84	280	1,036	158.9	201.7
25-40 years	530	1	3	28	196	1,372	127.3	202.5
41-64 years	1,549	1	3	10	151	1,837	118.9	221.5
≥ 65 years	10,675	1	3	6	10	1,857	21.6	96.9
Burosumab-twza	1,374	1	16	55	495	2,251	298.7	430.3
0-17 years	749	1	21	109	640	2,251	350.2	425.6
18-24 years	96	1	10	29	252	1,925	217.4	382.5
25-40 years	197	1	9	30	243	2,046	216.6	397.5
41-64 years	209	1	15	51	294	2,103	273.5	463.7
≥ 65 years	123	1	7	31	122	2,047	222.3	446.8
Fostamatinib	1,534	2	60	116	270	2,362	235.0	326.9
0-17 years	*****	60	79	180	480	731	285.0	266.8
18-24 years	*****	26	60	90	251	1,088	206.4	242.7
25-40 years	200	9	60	120	260	1,980	210.4	268.9
41-64 years	508	2	60	120	296	2,362	256.3	349.6
≥ 65 years	765	4	47	90	270	2,160	228.9	330.6

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Fosnetupitant and palonosetron	35,282	1	3	4	7	749	9.1	26.2
0-17 years	*****	1	1	1	2	4	1.7	1.2
18-24 years	*****	1	2	4	7	13	5.2	3.6
25-40 years	977	1	2	4	6	308	6.3	15.9
41-64 years	7,693	1	3	4	6	427	7.0	16.0
≥ 65 years	26,501	1	3	4	7	749	9.8	28.7
Lofexidine hydrochloride	8,141	1	9	12	15	860	16.1	26.7
0-17 years	*****	8	8	11	14	152	28.7	46.8
18-24 years	*****	1	9	12	14	150	13.8	12.0
25-40 years	3,191	1	9	12	14	411	15.8	21.1
41-64 years	3,727	1	9	11	15	816	16.1	26.5
≥ 65 years	756	1	9	9	16	860	18.2	47.3
Erenumab-aooe	203,727	1	78	180	450	2,344	335.2	385.4
0-17 years	1,279	1	84	180	392	2,234	299.1	322.2
18-24 years	11,177	1	60	166	360	2,165	265.4	289.5
25-40 years	53,852	1	70	175	395	2,344	298.9	338.9
41-64 years	103,105	1	84	196	480	2,283	352.1	396.5
≥ 65 years	34,314	1	60	180	485	2,267	365.5	438.9
Sodium zirconium cyclosilicate	135,004	1	11	35	124	1,962	115.1	185.1
0-17 years	66	1	30	90	152	1,013	139.7	182.4
18-24 years	504	1	28	38	125	960	93.2	117.3
25-40 years	6,278	1	30	54	120	1,527	112.0	165.4
41-64 years	38,124	1	26	56	148	1,784	122.1	183.6
≥ 65 years	90,032	1	9	30	120	1,962	112.4	187.2

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Avatrombopag	4,012	1	5	30	150	1,714	132.2	230.7
0-17 years	17	30	35	87	180	777	156.2	184.8
18-24 years	96	5	51	116	218	1,482	195.2	259.4
25-40 years	305	3	11	60	180	1,470	148.2	216.9
41-64 years	1,643	1	5	15	110	1,585	109.4	216.1
≥ 65 years	1,951	1	5	47	166	1,714	145.5	241.7
Pegvaliase-pqpz	747	3	105	319	661	2,102	453.8	449.2
0-17 years	*****	14	166	421	726	1,574	487.0	386.0
18-24 years	204	3	95	255	566	2,096	389.3	388.9
25-40 years	317	12	102	287	629	2,102	445.1	446.7
41-64 years	170	3	102	348	778	2,001	532.7	525.0
≥ 65 years	*****	712	712	825	937	937	824.5	159.1
Baricitinib	64,998	1	1	1	1	2,151	27.5	124.0
0-17 years	250	1	1	50	281	1,713	189.0	291.2
18-24 years	815	1	1	2	180	982	110.8	167.8
25-40 years	4,616	1	1	1	2	2,116	54.8	144.6
41-64 years	20,122	1	1	1	1	2,151	45.4	158.2
≥ 65 years	39,195	1	1	1	1	1,988	12.3	91.0
Moxidectin	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Cannabidiol	27,440	1	120	355	755	2,233	487.2	444.4
0-17 years	14,798	1	133	360	729	2,233	459.4	382.7
18-24 years	4,538	1	118	320	691	2,166	447.8	418.8
25-40 years	5,498	1	120	360	808	2,228	537.3	515.1
41-64 years	2,390	1	120	387	1,019	2,042	627.2	603.9
≥ 65 years	216	3	46	181	590	1,953	394.2	461.2
Plazomicin	285	1	3	5	7	700	9.3	42.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	7	59	700	111.6	260.3
41-64 years	*****	1	1	5	7	28	5.3	5.2
≥ 65 years	220	1	3	5	7	92	7.1	10.3
Binimetinib	3,829	1	45	119	249	2,274	206.4	268.5
0-17 years	35	2	108	180	308	1,005	236.1	220.0
18-24 years	42	9	60	150	270	775	211.7	199.2
25-40 years	310	2	60	120	266	1,468	213.7	246.9
41-64 years	1,304	1	60	120	270	2,274	215.9	275.2
≥ 65 years	2,138	1	30	90	240	2,173	198.9	269.2
Encorafenib	4,755	1	42	120	240	2,274	195.7	253.1
0-17 years	*****	12	86	224	385	482	235.3	199.4
18-24 years	*****	9	60	133	277	775	204.1	200.0
25-40 years	337	2	60	120	246	1,468	212.2	244.2
41-64 years	1,603	1	52	120	240	2,274	203.0	260.5
≥ 65 years	2,777	1	30	94	227	2,173	189.2	250.3

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tecovirimat	39	9	14	14	14	112	17.9	16.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	9	14	14	14	112	32.6	44.4
25-40 years	23	14	14	14	14	30	15.9	5.1
41-64 years	*****	14	14	14	14	28	15.3	4.2
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Ivosidenib	2,585	1	50	108	240	2,040	201.6	258.0
0-17 years	*****	61	64	76	102	117	82.5	25.4
18-24 years	*****	9	60	181	363	900	265.8	266.0
25-40 years	228	3	60	120	284	1,590	207.6	248.0
41-64 years	598	2	60	120	250	1,591	197.3	231.5
≥ 65 years	1,731	1	46	95	240	2,040	201.7	268.0
Tafenoquine	366	1	8	30	62	1,165	58.0	104.4
0-17 years	16	1	11	44	90	686	91.4	166.7
18-24 years	32	1	20	42	89	485	68.8	91.1
25-40 years	111	1	5	24	60	648	48.7	83.0
41-64 years	179	1	14	30	60	1,165	60.3	116.2
≥ 65 years	28	1	2	17	72	272	48.2	63.7
Elagolix sodium	37,541	1	28	84	196	1,999	157.5	186.2
0-17 years	*****	1	56	112	280	1,654	208.9	235.8
18-24 years	6,004	1	28	84	196	1,602	158.0	174.8
25-40 years	22,278	1	28	84	196	1,999	153.5	183.1
41-64 years	8,796	1	28	84	196	1,684	164.4	197.8
≥ 65 years	*****	23	254	476	560	729	408.4	275.1

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Fish oil triglycerides	286	1	7	21	89	1,051	90.4	173.2
0-17 years	180	1	9	45	136	989	123.5	193.9
18-24 years	*****	1	10	45	79	1,051	144.4	286.6
25-40 years	60	1	3	7	15	272	20.5	42.0
41-64 years	27	1	1	7	11	60	12.5	17.2
≥ 65 years	*****	1	4	14	45	110	31.2	41.9
Lusutrombopag	441	3	7	7	7	350	11.5	20.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	4	7	7	7	7	6.4	1.3
25-40 years	*****	7	7	7	7	44	11.9	10.9
41-64 years	321	3	7	7	7	350	12.1	23.1
≥ 65 years	93	7	7	7	7	42	9.3	5.2

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Lutetium Lu 177 dotatate</i>	19,800	19,800	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Bictegravir embitcitabine</i>	1,133,058	594,673	52.5%	290,628	25.6%	182,281	16.1%	40,389	3.6%	25,087	2.2%
<i>tenofovir alafenamide</i>											
<i>Tezacaftor and ivacaftor</i>	16,189	9,073	56.0%	3,934	24.3%	2,544	15.7%	467	2.9%	171	1.1%
<i>Apalutamide</i>	59,444	29,493	49.6%	15,679	26.4%	11,676	19.6%	1,940	3.3%	656	1.1%
<i>Ibalizumab-uiyk</i>	4,891	4,348	88.9%	244	5.0%	242	4.9%	36	0.7%	21	0.4%
<i>Tildrakizumab</i>	77,156	74,142	96.1%	1,984	2.6%	909	1.2%	101	0.1%	20	0.0%
<i>Burosumab-twza</i>	21,148	19,446	92.0%	865	4.1%	608	2.9%	127	0.6%	102	0.5%
<i>Fostamatinib</i>	4,331	2,298	53.1%	1,202	27.8%	696	16.1%	103	2.4%	32	0.7%
<i>Fosnetupitant and palonosetron</i>	193,360	192,179	99.4%	922	0.5%	*****	*****	*****	*****	0	0.0%
<i>Lofexidine hydrochloride</i>	10,404	10,175	97.8%	201	1.9%	*****	*****	*****	*****	0	0.0%
<i>Erenumab-aooe</i>	800,153	431,788	54.0%	214,740	26.8%	126,674	15.8%	19,159	2.4%	7,792	1.0%
<i>Sodium zirconium cyclosilicate</i>	321,730	222,401	69.1%	72,280	22.5%	23,943	7.4%	2,504	0.8%	602	0.2%
<i>Avatrombopag</i>	9,712	6,629	68.3%	1,894	19.5%	1,006	10.4%	150	1.5%	33	0.3%
<i>Pegvaliase-pqpz</i>	4,868	3,211	66.0%	1,065	21.9%	459	9.4%	85	1.7%	48	1.0%
<i>Baricitinib</i>	79,878	70,280	88.0%	5,481	6.9%	3,458	4.3%	537	0.7%	122	0.2%
<i>Moxidectin</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Cannabidiol</i>	95,858	44,445	46.4%	24,610	25.7%	17,352	18.1%	5,300	5.5%	4,151	4.3%
<i>Plazomicin</i>	905	*****	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%
<i>Binimetinib</i>	11,634	6,964	59.9%	2,962	25.5%	1,499	12.9%	169	1.5%	40	0.3%
<i>Encorafenib</i>	13,660	8,002	58.6%	3,537	25.9%	1,890	13.8%	191	1.4%	40	0.3%
<i>Tecovirimat</i>	41	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
<i>Ivosidenib</i>	6,438	3,242	50.4%	1,850	28.7%	1,184	18.4%	129	2.0%	33	0.5%
<i>Tafenoquine</i>	635	468	73.7%	131	20.6%	*****	*****	*****	*****	*****	*****
<i>Elagolix sodium</i>	95,097	58,742	61.8%	23,415	24.6%	11,620	12.2%	1,114	1.2%	206	0.2%
<i>Fish oil triglycerides</i>	5,794	5,653	97.6%	90	1.6%	*****	*****	*****	*****	*****	*****
<i>Lusutrombopag</i>	600	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Lutetium Lu 177 dotatate</i>	19,800	1	1	1	1	3	1.0	0.0
<i>Bictegravir embitcitabine tenofovir alafenamide</i>	1,133,058	1	30	30	90	2,509	107.2	198.6
<i>Tezacaftor and ivacaftor</i>	16,189	1	28	28	84	2,230	85.6	144.1
<i>Apalutamide</i>	59,444	1	30	37	90	2,232	97.5	148.2
<i>Ibalizumab-uiyk</i>	4,891	1	1	1	1	2,202	23.7	96.2
<i>Tildrakizumab</i>	77,156	1	1	1	1	1,204	6.4	33.9
<i>Burosumab-twza</i>	21,148	1	1	1	1	2,046	19.4	95.8
<i>Fostamatinib</i>	4,331	1	30	30	90	2,160	83.2	128.6
<i>Fosnetupitant and palonosetron</i>	193,360	1	1	1	1	525	1.7	7.3
<i>Lofexidine hydrochloride</i>	10,404	1	8	9	14	644	12.6	13.8
<i>Erenumab-aooe</i>	800,153	1	30	30	90	2,232	85.4	139.3
<i>Sodium zirconium cyclosilicate</i>	321,730	1	15	30	60	1,943	48.3	75.2
<i>Avatrombopag</i>	9,712	1	8	30	60	1,624	54.6	96.6
<i>Pegvaliase-pqpz</i>	4,868	1	30	30	60	2,096	69.6	145.4
<i>Baricitinib</i>	79,878	1	1	1	9	1,952	22.4	71.0
<i>Moxidectin</i>	0	-	-	-	-	-	-	-
<i>Cannabidiol</i>	95,858	1	30	38	120	2,228	139.5	246.8
<i>Plazomicin</i>	905	1	1	1	2	700	2.9	23.3
<i>Binimetinib</i>	11,634	1	30	30	60	2,173	67.9	97.1
<i>Encorafenib</i>	13,660	1	30	30	60	2,173	68.1	94.4
<i>Tecovirimat</i>	41	9	14	14	14	112	17.0	15.6
<i>Ivosidenib</i>	6,438	1	30	30	90	1,570	81.0	110.8
<i>Tafenoquine</i>	635	1	2	21	31	835	33.4	64.2
<i>Elagolix sodium</i>	95,097	1	28	28	56	1,833	62.2	83.8
<i>Fish oil triglycerides</i>	5,794	1	1	1	1	975	4.5	27.1
<i>Lusutrombopag</i>	600	3	7	7	7	74	8.4	5.6

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Lutetium Lu 177 dotatate	19,800	19,800	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	9,678	9,678	48.9%	0	NaN	0	NaN	0	NaN	0	NaN
Male	10,122	10,122	51.1%	0	NaN	0	NaN	0	NaN	0	NaN
Bictegravir embitcitabine tenofovir alafenamide	1,133,058	594,673	100.0%	290,628	100.0%	182,281	100.0%	40,389	100.0%	25,087	100.0%
Female	297,942	160,587	27.0%	75,468	26.0%	46,251	25.4%	9,868	24.4%	5,768	23.0%
Male	835,116	434,086	73.0%	215,160	74.0%	136,030	74.6%	30,521	75.6%	19,319	77.0%
Tezacaftor and ivacaftor	16,189	9,073	100.0%	3,934	100.0%	2,544	100.0%	467	100.0%	171	100.0%
Female	8,126	4,614	50.9%	1,951	49.6%	1,254	49.3%	230	49.3%	77	45.0%
Male	8,063	4,459	49.1%	1,983	50.4%	1,290	50.7%	237	50.7%	94	55.0%
Apalutamide	59,444	29,493	100.0%	15,679	100.0%	11,676	100.0%	1,940	100.0%	656	100.0%
Female	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Male	*****	*****	*****	*****	*****	*****	*****	1,940	100.0%	656	100.0%
Ibalizumab-uiyk	4,891	4,348	100.0%	244	100.0%	242	100.0%	36	100.0%	21	100.0%
Female	1,509	1,400	32.2%	56	23.0%	*****	*****	*****	*****	0	0.0%
Male	3,382	2,948	67.8%	188	77.0%	*****	*****	*****	*****	21	100.0%
Tildrakizumab	77,156	74,142	100.0%	1,984	100.0%	909	100.0%	101	100.0%	20	100.0%
Female	39,709	38,140	51.4%	1,034	52.1%	471	51.8%	*****	*****	*****	*****
Male	37,447	36,002	48.6%	950	47.9%	438	48.2%	*****	*****	*****	*****
Burosumab-twza	21,148	19,446	100.0%	865	100.0%	608	100.0%	127	100.0%	102	100.0%
Female	12,843	11,697	60.2%	571	66.0%	427	70.2%	76	59.8%	72	70.6%
Male	8,305	7,749	39.8%	294	34.0%	181	29.8%	51	40.2%	30	29.4%
Fostamatinib	4,331	2,298	100.0%	1,202	100.0%	696	100.0%	103	100.0%	32	100.0%
Female	2,601	1,400	60.9%	733	61.0%	396	56.9%	55	53.4%	17	53.1%
Male	1,730	898	39.1%	469	39.0%	300	43.1%	48	46.6%	15	46.9%

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Fosnetupitant and palonosetron	193,360	192,179	100.0%	922	100.0%	*****	*****	*****	*****	0	NaN
Female	109,332	108,623	56.5%	550	59.7%	*****	*****	*****	*****	0	NaN
Male	84,028	83,556	43.5%	372	40.3%	*****	*****	*****	*****	0	NaN
Lofexidine hydrochloride	10,404	10,175	100.0%	201	100.0%	*****	*****	*****	*****	0	NaN
Female	5,202	5,095	50.1%	96	47.8%	*****	*****	*****	*****	0	NaN
Male	5,202	5,080	49.9%	105	52.2%	*****	*****	*****	*****	0	NaN
Erenumab-aooe	800,153	431,788	100.0%	214,740	100.0%	126,674	100.0%	19,159	100.0%	7,792	100.0%
Female	685,697	370,126	85.7%	184,233	85.8%	108,406	85.6%	16,311	85.1%	6,621	85.0%
Male	114,456	61,662	14.3%	30,507	14.2%	18,268	14.4%	2,848	14.9%	1,171	15.0%
Sodium zirconium cyclosilicate	321,730	222,401	100.0%	72,280	100.0%	23,943	100.0%	2,504	100.0%	602	100.0%
Female	136,336	96,480	43.4%	29,320	40.6%	9,395	39.2%	912	36.4%	229	38.0%
Male	185,394	125,921	56.6%	42,960	59.4%	14,548	60.8%	1,592	63.6%	373	62.0%
Avatrombopag	9,712	6,629	100.0%	1,894	100.0%	1,006	100.0%	150	100.0%	33	100.0%
Female	4,810	3,271	49.3%	954	50.4%	495	49.2%	69	46.0%	21	63.6%
Male	4,902	3,358	50.7%	940	49.6%	511	50.8%	81	54.0%	12	36.4%
Pegvaliase-pqpz	4,868	3,211	100.0%	1,065	100.0%	459	100.0%	85	100.0%	48	100.0%
Female	2,391	1,514	47.2%	558	52.4%	256	55.8%	41	48.2%	22	45.8%
Male	2,477	1,697	52.8%	507	47.6%	203	44.2%	44	51.8%	26	54.2%
Baricitinib	79,878	70,280	100.0%	5,481	100.0%	3,458	100.0%	537	100.0%	122	100.0%
Female	43,654	36,119	51.4%	4,353	79.4%	2,670	77.2%	421	78.4%	91	74.6%
Male	36,224	34,161	48.6%	1,128	20.6%	788	22.8%	116	21.6%	31	25.4%

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Moxidectin		-	-	-	-	-	-	-	-	-	-
Female		-	-	-	-	-	-	-	-	-	-
Male		-	-	-	-	-	-	-	-	-	-
Cannabidiol	95,858	44,445	100.0%	24,610	100.0%	17,352	100.0%	5,300	100.0%	4,151	100.0%
Female	42,524	19,707	44.3%	10,943	44.5%	7,586	43.7%	2,398	45.2%	1,890	45.5%
Male	53,334	24,738	55.7%	13,667	55.5%	9,766	56.3%	2,902	54.8%	2,261	54.5%
Plazomicin	905	*****	*****	0	NaN	0	NaN	*****	*****	0	NaN
Female	589	589	65.2%	0	NaN	0	NaN	0	0.0%	0	NaN
Male	316	*****	*****	0	NaN	0	NaN	*****	*****	0	NaN
Binimetinib	11,634	6,964	100.0%	2,962	100.0%	1,499	100.0%	169	100.0%	40	100.0%
Female	5,310	3,213	46.1%	1,350	45.6%	653	43.6%	78	46.2%	16	40.0%
Male	6,324	3,751	53.9%	1,612	54.4%	846	56.4%	91	53.8%	24	60.0%
Encorafenib	13,660	8,002	100.0%	3,537	100.0%	1,890	100.0%	191	100.0%	40	100.0%
Female	6,581	3,897	48.7%	1,685	47.6%	899	47.6%	85	44.5%	15	37.5%
Male	7,079	4,105	51.3%	1,852	52.4%	991	52.4%	106	55.5%	25	62.5%
Tecovirimat	41	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Ivosidenib	6,438	3,242	100.0%	1,850	100.0%	1,184	100.0%	129	100.0%	33	100.0%
Female	3,489	1,806	55.7%	958	51.8%	641	54.1%	70	54.3%	14	42.4%
Male	2,949	1,436	44.3%	892	48.2%	543	45.9%	59	45.7%	19	57.6%
Tafenoquine	635	468	100.0%	131	100.0%	*****	*****	*****	*****	*****	*****
Female	397	292	62.4%	83	63.4%	*****	*****	*****	*****	0	0.0%
Male	238	176	37.6%	48	36.6%	*****	*****	*****	*****	*****	*****

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Elagolix sodium	95,097	58,742	100.0%	23,415	100.0%	11,620	100.0%	1,114	100.0%	206	100.0%
Female	94,969	58,658	99.9%	23,389	99.9%	*****	*****	*****	*****	206	100.0%
Male	128	84	0.1%	26	0.1%	*****	*****	*****	*****	0	0.0%
Fish oil triglycerides	5,794	5,653	100.0%	90	100.0%	*****	*****	*****	*****	*****	*****
Female	3,141	3,071	54.3%	46	51.1%	*****	*****	*****	*****	*****	*****
Male	2,653	2,582	45.7%	44	48.9%	*****	*****	*****	*****	*****	*****
Lusutrombopag	600	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	296	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	304	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lutetium Lu 177 dotatate	19,800	1	1	1	1	3	1.0	0.0
Female	9,678	1	1	1	1	2	1.0	0.0
Male	10,122	1	1	1	1	3	1.0	0.0
Bictegravir embicitabine tenofovir alafenamide	1,133,058	1	30	30	90	2,509	107.2	198.6
Female	297,942	1	30	30	90	2,461	100.5	181.2
Male	835,116	1	30	30	90	2,509	109.6	204.4
Tezacaftor and ivacaftor	16,189	1	28	28	84	2,230	85.6	144.1
Female	8,126	1	28	28	84	2,230	83.5	140.2
Male	8,063	1	28	28	84	2,099	87.6	147.8
Apalutamide	59,444	1	30	37	90	2,232	97.5	148.2
Female	*****	30	41	90	143	228	103.7	75.5
Male	*****	1	30	37	90	2,232	97.5	148.2
Ibalizumab-uiyk	4,891	1	1	1	1	2,202	23.7	96.2
Female	1,509	1	1	1	1	602	12.1	47.2
Male	3,382	1	1	1	1	2,202	28.8	111.0
Tildrakizumab	77,156	1	1	1	1	1,204	6.4	33.9
Female	39,709	1	1	1	1	1,174	6.5	33.5
Male	37,447	1	1	1	1	1,204	6.4	34.3
Burosumab-twza	21,148	1	1	1	1	2,046	19.4	95.8
Female	12,843	1	1	1	1	2,046	21.5	102.2
Male	8,305	1	1	1	1	1,779	16.1	84.9
Fostamatinib	4,331	1	30	30	90	2,160	83.2	128.6
Female	2,601	1	30	30	90	1,574	80.3	120.0
Male	1,730	1	30	30	90	2,160	87.7	140.6

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Fosnetupitant and palonosetron	193,360	1	1	1	1	525	1.7	7.3
Female	109,332	1	1	1	1	525	1.7	7.5
Male	84,028	1	1	1	1	448	1.6	7.0
Lofexidine hydrochloride	10,404	1	8	9	14	644	12.6	13.8
Female	5,202	1	8	9	14	644	12.6	15.2
Male	5,202	1	8	9	14	348	12.6	12.3
Erenumab-aooe	800,153	1	30	30	90	2,232	85.4	139.3
Female	685,697	1	30	30	90	2,232	85.1	138.9
Male	114,456	1	30	30	90	2,192	86.6	141.3
Sodium zirconium cyclosilicate	321,730	1	15	30	60	1,943	48.3	75.2
Female	136,336	1	14	30	52	1,896	45.5	71.8
Male	185,394	1	20	30	60	1,943	50.3	77.5
Avatrombopag	9,712	1	8	30	60	1,624	54.6	96.6
Female	4,810	1	11	30	60	1,624	55.3	102.1
Male	4,902	1	5	30	60	1,294	53.9	90.8
Pegvaliase-pqpz	4,868	1	30	30	60	2,096	69.6	145.4
Female	2,391	1	30	30	60	2,096	70.8	141.1
Male	2,477	1	30	30	58	1,997	68.6	149.5
Baricitinib	79,878	1	1	1	9	1,952	22.4	71.0
Female	43,654	1	1	1	30	1,952	31.4	83.1
Male	36,224	1	1	1	1	1,620	11.4	50.7
Moxidectin	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Cannabidiol	95,858	1	30	38	120	2,228	139.5	246.8
Female	42,524	1	30	38	120	2,170	140.9	249.5
Male	53,334	1	30	38	120	2,228	138.3	244.6
Plazomicin	905	1	1	1	2	700	2.9	23.3
Female	589	1	1	1	3	20	2.2	2.2
Male	316	1	1	1	2	700	4.3	39.3
Binimetinib	11,634	1	30	30	60	2,173	67.9	97.1
Female	5,310	1	30	30	60	1,860	66.6	94.3
Male	6,324	1	30	30	60	2,173	69.0	99.4
Encorafenib	13,660	1	30	30	60	2,173	68.1	94.4
Female	6,581	1	30	30	60	1,860	66.4	87.9
Male	7,079	1	30	30	60	2,173	69.7	100.1
Tecovirimat	41	9	14	14	14	112	17.0	15.6
Female	*****	14	14	14	14	14	14.0	NaN
Male	*****	9	14	14	14	112	17.1	15.8
Ivosidenib	6,438	1	30	30	90	1,570	81.0	110.8
Female	3,489	1	30	30	90	1,389	78.8	103.1
Male	2,949	1	30	39	90	1,570	83.5	119.2
Tafenoquine	635	1	2	21	31	835	33.4	64.2
Female	397	1	1	21	31	575	30.0	45.9
Male	238	1	2	21	31	835	39.2	86.4
Elagolix sodium	95,097	1	28	28	56	1,833	62.2	83.8
Female	94,969	1	28	28	56	1,833	62.2	83.8
Male	128	4	28	28	56	476	59.2	70.0

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Fish oil triglycerides	5,794	1	1	1	1	975	4.5	27.1
Female	3,141	1	1	1	1	975	4.2	26.6
Male	2,653	1	1	1	1	737	4.8	27.6
Lusutrombopag	600	3	7	7	7	74	8.4	5.6
Female	296	7	7	7	7	57	8.6	5.0
Male	304	3	7	7	7	74	8.2	6.2

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Lutetium Lu 177 dotatate	19,800	19,800	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	364	364	1.8%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	4,658	4,658	23.5%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	14,739	14,739	74.4%	0	NaN	0	NaN	0	NaN	0	NaN
Bictegravir embicitabine tenofovir alafenamide	1,133,058	594,673	100.0%	290,628	100.0%	182,281	100.0%	40,389	100.0%	25,087	100.0%
0-17 years	6,060	3,247	0.5%	1,480	0.5%	988	0.5%	238	0.6%	107	0.4%
18-24 years	55,832	32,529	5.5%	14,003	4.8%	7,444	4.1%	1,387	3.4%	469	1.9%
25-40 years	341,681	194,842	32.8%	86,452	29.7%	47,408	26.0%	9,013	22.3%	3,966	15.8%
41-64 years	599,501	303,397	51.0%	154,743	53.2%	101,378	55.6%	23,942	59.3%	16,041	63.9%
≥ 65 years	129,984	60,658	10.2%	33,950	11.7%	25,063	13.7%	5,809	14.4%	4,504	18.0%
Tezacaftor and ivacaftor	16,189	9,073	100.0%	3,934	100.0%	2,544	100.0%	467	100.0%	171	100.0%
0-17 years	5,856	3,180	35.0%	1,436	36.5%	980	38.5%	195	41.8%	65	38.0%
18-24 years	3,100	1,853	20.4%	732	18.6%	417	16.4%	68	14.6%	30	17.5%
25-40 years	5,413	3,157	34.8%	1,328	33.8%	758	29.8%	131	28.1%	39	22.8%
41-64 years	1,607	810	8.9%	390	9.9%	315	12.4%	*****	*****	*****	*****
≥ 65 years	213	73	0.8%	48	1.2%	74	2.9%	*****	*****	*****	*****
Apalutamide	59,444	29,493	100.0%	15,679	100.0%	11,676	100.0%	1,940	100.0%	656	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	16	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	6,304	*****	*****	*****	*****	*****	*****	223	11.5%	72	11.0%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	53,124	26,268	89.1%	14,023	89.4%	10,532	90.2%	1,717	88.5%	584	89.0%
Ibalizumab-uiyk	4,891	4,348	100.0%	244	100.0%	242	100.0%	36	100.0%	21	100.0%
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	803	718	16.5%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	3,244	2,861	65.8%	179	73.4%	164	67.8%	*****	*****	*****	*****
≥ 65 years	744	675	15.5%	26	10.7%	31	12.8%	*****	*****	*****	*****
Tildrakizumab	77,156	74,142	100.0%	1,984	100.0%	909	100.0%	101	100.0%	20	100.0%
0-17 years	18	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	307	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	1,941	1,425	1.9%	344	17.3%	160	17.6%	12	11.9%	0	0.0%
41-64 years	6,225	4,906	6.6%	903	45.5%	364	40.0%	*****	*****	*****	*****
≥ 65 years	68,665	67,581	91.2%	679	34.2%	351	38.6%	*****	*****	*****	*****
Burosumab-twza	21,148	19,446	100.0%	865	100.0%	608	100.0%	127	100.0%	102	100.0%
0-17 years	11,799	10,616	54.6%	606	70.1%	439	72.2%	88	69.3%	50	49.0%
18-24 years	1,033	952	4.9%	44	5.1%	20	3.3%	*****	*****	*****	*****
25-40 years	2,840	2,697	13.9%	69	8.0%	47	7.7%	*****	*****	*****	*****
41-64 years	3,397	3,193	16.4%	99	11.4%	74	12.2%	12	9.4%	19	18.6%
≥ 65 years	2,079	1,988	10.2%	47	5.4%	28	4.6%	*****	*****	*****	*****
Fostamatinib	4,331	2,298	100.0%	1,202	100.0%	696	100.0%	103	100.0%	32	100.0%
0-17 years	25	14	0.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	176	107	4.7%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	593	379	16.5%	113	9.4%	87	12.5%	*****	*****	*****	*****
41-64 years	1,556	816	35.5%	437	36.4%	256	36.8%	*****	*****	*****	*****

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	1,981	982	42.7%	595	49.5%	333	47.8%	*****	*****	*****	*****
Fosnetupitant and palonosetron	193,360	192,179	100.0%	922	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	4,589	4,574	2.4%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	40,144	40,020	20.8%	100	10.8%	24	9.4%	0	0.0%	0	NaN
≥ 65 years	148,072	147,030	76.5%	*****	*****	*****	*****	*****	*****	0	NaN
Lofexidine hydrochloride	10,404	10,175	100.0%	201	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	15	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	573	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	4,099	4,020	39.5%	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	4,725	4,608	45.3%	104	51.7%	*****	*****	*****	*****	0	NaN
≥ 65 years	992	967	9.5%	*****	*****	*****	*****	0	0.0%	0	NaN
Erenumab-aooe	800,153	431,788	100.0%	214,740	100.0%	126,674	100.0%	19,159	100.0%	7,792	100.0%
0-17 years	4,516	2,496	0.6%	1,148	0.5%	705	0.6%	125	0.7%	42	0.5%
18-24 years	40,254	22,991	5.3%	10,644	5.0%	5,662	4.5%	730	3.8%	227	2.9%
25-40 years	203,640	113,409	26.3%	53,918	25.1%	30,542	24.1%	4,231	22.1%	1,540	19.8%
41-64 years	415,226	223,130	51.7%	110,744	51.6%	66,321	52.4%	10,532	55.0%	4,499	57.7%
≥ 65 years	136,517	69,762	16.2%	38,286	17.8%	23,444	18.5%	3,541	18.5%	1,484	19.0%
Sodium zirconium cyclosilicate	321,730	222,401	100.0%	72,280	100.0%	23,943	100.0%	2,504	100.0%	602	100.0%
0-17 years	150	96	0.0%	37	0.1%	*****	*****	*****	*****	0	0.0%
18-24 years	1,018	705	0.3%	231	0.3%	*****	*****	*****	*****	0	0.0%
25-40 years	14,131	9,712	4.4%	3,262	4.5%	*****	*****	*****	*****	24	4.0%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	92,931	63,534	28.6%	21,128	29.2%	7,279	30.4%	803	32.1%	187	31.1%
≥ 65 years	213,500	148,354	66.7%	47,622	65.9%	15,546	64.9%	1,587	63.4%	391	65.0%
Avatrombopag	9,712	6,629	100.0%	1,894	100.0%	1,006	100.0%	150	100.0%	33	100.0%
0-17 years	39	21	0.3%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	359	241	3.6%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	813	551	8.3%	158	8.3%	94	9.3%	*****	*****	*****	*****
41-64 years	3,757	2,750	41.5%	623	32.9%	315	31.3%	*****	*****	*****	*****
≥ 65 years	4,744	3,066	46.3%	1,018	53.7%	562	55.9%	79	52.7%	19	57.6%
Pegvaliase-pqpz	4,868	3,211	100.0%	1,065	100.0%	459	100.0%	85	100.0%	48	100.0%
0-17 years	287	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	1,305	881	27.4%	295	27.7%	101	22.0%	*****	*****	*****	*****
25-40 years	1,998	1,351	42.1%	413	38.8%	177	38.6%	35	41.2%	22	45.8%
41-64 years	1,267	803	25.0%	294	27.6%	140	30.5%	17	20.0%	13	27.1%
≥ 65 years	11	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
Baricitinib	79,878	70,280	100.0%	5,481	100.0%	3,458	100.0%	537	100.0%	122	100.0%
0-17 years	579	358	0.5%	111	2.0%	85	2.5%	*****	*****	*****	*****
18-24 years	1,696	1,166	1.7%	310	5.7%	198	5.7%	*****	*****	*****	*****
25-40 years	6,956	5,485	7.8%	884	16.1%	510	14.7%	*****	*****	*****	*****
41-64 years	27,677	22,691	32.3%	2,823	51.5%	1,830	52.9%	269	50.1%	64	52.5%
≥ 65 years	42,970	40,580	57.7%	1,353	24.7%	835	24.1%	160	29.8%	42	34.4%
Moxidectin	-	-	-	-	-	-	-	-	-	-	-
0-17 years	-	-	-	-	-	-	-	-	-	-	-
18-24 years	-	-	-	-	-	-	-	-	-	-	-
25-40 years	-	-	-	-	-	-	-	-	-	-	-

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years		-	-	-	-	-	-	-	-	-	-
≥ 65 years		-	-	-	-	-	-	-	-	-	-
Cannabidiol	95,858	44,445	100.0%	24,610	100.0%	17,352	100.0%	5,300	100.0%	4,151	100.0%
0-17 years	47,703	21,603	48.6%	12,164	49.4%	8,815	50.8%	2,957	55.8%	2,164	52.1%
18-24 years	15,784	7,538	17.0%	3,995	16.2%	2,879	16.6%	820	15.5%	552	13.3%
25-40 years	21,018	10,021	22.5%	5,353	21.8%	3,692	21.3%	1,016	19.2%	936	22.5%
41-64 years	10,557	4,859	10.9%	2,902	11.8%	1,845	10.6%	473	8.9%	478	11.5%
≥ 65 years	796	424	1.0%	196	0.8%	121	0.7%	34	0.6%	21	0.5%
Plazomicin	905	*****	*****	0	NaN	0	NaN	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	*****	*****	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	0.0%	0	NaN
≥ 65 years	756	756	83.6%	0	NaN	0	NaN	0	0.0%	0	NaN
Binimetinib	11,634	6,964	100.0%	2,962	100.0%	1,499	100.0%	169	100.0%	40	100.0%
0-17 years	83	45	0.6%	17	0.6%	16	1.1%	*****	*****	*****	*****
18-24 years	110	63	0.9%	27	0.9%	16	1.1%	*****	*****	*****	*****
25-40 years	1,041	642	9.2%	263	8.9%	119	7.9%	*****	*****	*****	*****
41-64 years	4,077	2,460	35.3%	994	33.6%	548	36.6%	*****	*****	*****	*****
≥ 65 years	6,323	3,754	53.9%	1,661	56.1%	800	53.4%	90	53.3%	18	45.0%
Encorafenib	13,660	8,002	100.0%	3,537	100.0%	1,890	100.0%	191	100.0%	40	100.0%
0-17 years	14	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	88	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	1,084	653	8.2%	275	7.8%	134	7.1%	*****	*****	*****	*****

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	4,639	2,698	33.7%	1,190	33.6%	668	35.3%	*****	*****	*****	*****
≥ 65 years	7,835	4,594	57.4%	2,048	57.9%	1,070	56.6%	106	55.5%	17	42.5%
Tecovirimat	41	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
25-40 years	24	24	60.0%	0	NaN	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
Ivosidenib	6,438	3,242	100.0%	1,850	100.0%	1,184	100.0%	129	100.0%	33	100.0%
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	574	287	8.9%	156	8.4%	*****	*****	*****	*****	*****	*****
41-64 years	1,431	745	23.0%	404	21.8%	232	19.6%	*****	*****	*****	*****
≥ 65 years	4,331	2,153	66.4%	1,257	67.9%	827	69.8%	75	58.1%	19	57.6%
Tafenoquine	635	468	100.0%	131	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	31	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	43	*****	*****	16	12.2%	*****	*****	*****	*****	0	0.0%
25-40 years	209	*****	*****	28	21.4%	*****	*****	*****	*****	0	0.0%
41-64 years	306	218	46.6%	71	54.2%	*****	*****	*****	*****	*****	*****
≥ 65 years	46	33	7.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
Elagolix sodium	95,097	58,742	100.0%	23,415	100.0%	11,620	100.0%	1,114	100.0%	206	100.0%
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	15,690	9,877	16.8%	3,808	16.3%	1,794	15.4%	*****	*****	*****	*****
25-40 years	55,981	34,825	59.3%	13,667	58.4%	6,774	58.3%	604	54.2%	111	53.9%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	21,986	13,166	22.4%	5,587	23.9%	2,872	24.7%	305	27.4%	56	27.2%
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
Fish oil triglycerides	5,794	5,653	100.0%	90	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	4,897	4,768	84.3%	85	94.4%	*****	*****	*****	*****	*****	*****
18-24 years	421	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	231	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	189	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	56	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
Lusutrombopag	600	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	449	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	114	114	19.2%	0	0.0%	0	NaN	0	NaN	0	NaN

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lutetium Lu 177 dotatate	19,800	1	1	1	1	3	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	364	1	1	1	1	3	1.0	0.1
41-64 years	4,658	1	1	1	1	3	1.0	0.0
≥ 65 years	14,739	1	1	1	1	2	1.0	0.0
Bictegravir embitcitabine tenofovir alafenamide	1,133,058	1	30	30	90	2,509	107.2	198.6
0-17 years	6,060	1	30	30	90	1,779	100.1	165.0
18-24 years	55,832	1	30	30	67	2,258	79.6	129.0
25-40 years	341,681	1	30	30	90	2,509	85.5	147.8
41-64 years	599,501	1	30	30	90	2,467	116.3	214.4
≥ 65 years	129,984	1	30	60	120	2,473	134.5	251.7
Tezacaftor and ivacaftor	16,189	1	28	28	84	2,230	85.6	144.1
0-17 years	5,856	1	28	28	84	2,099	90.1	147.8
18-24 years	3,100	1	28	28	56	1,815	76.7	137.6
25-40 years	5,413	1	28	28	78	1,652	76.4	124.2
41-64 years	1,607	3	28	28	112	2,230	108.8	188.0
≥ 65 years	213	11	28	84	168	1,064	146.5	178.0
Apalutamide	59,444	1	30	37	90	2,232	97.5	148.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	16	19	30	30	60	120	44.4	25.2
41-64 years	6,304	1	30	30	90	1,518	96.0	145.9
≥ 65 years	53,124	1	30	40	90	2,232	97.7	148.4

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Ibalizumab-uiyk	4,891	1	1	1	1	2,202	23.7	96.2
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	406	12.5	55.6
25-40 years	803	1	1	1	1	588	18.1	56.2
41-64 years	3,244	1	1	1	1	2,202	25.5	104.8
≥ 65 years	744	1	1	1	1	1,351	23.3	95.5
Tildrakizumab	77,156	1	1	1	1	1,204	6.4	33.9
0-17 years	18	1	1	30	84	252	62.9	82.5
18-24 years	307	1	1	1	84	700	40.4	81.1
25-40 years	1,941	1	1	1	34	534	34.8	66.4
41-64 years	6,225	1	1	1	28	952	29.6	71.3
≥ 65 years	68,665	1	1	1	1	1,204	3.4	24.2
Burosumab-twza	21,148	1	1	1	1	2,046	19.4	95.8
0-17 years	11,799	1	1	1	1	1,893	22.2	90.5
18-24 years	1,033	1	1	1	1	1,729	20.2	100.5
25-40 years	2,840	1	1	1	1	2,046	15.0	101.3
41-64 years	3,397	1	1	1	1	2,003	16.8	105.6
≥ 65 years	2,079	1	1	1	1	1,869	13.2	97.8
Fostamatinib	4,331	1	30	30	90	2,160	83.2	128.6
0-17 years	25	29	30	30	79	300	68.4	71.2
18-24 years	176	11	30	30	60	719	64.5	90.9
25-40 years	593	1	30	30	60	871	71.0	105.5
41-64 years	1,556	2	30	30	90	1,890	83.7	132.1
≥ 65 years	1,981	1	30	39	90	2,160	88.4	135.1

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Fosnetupitant and palonosetron	193,360	1	1	1	1	525	1.7	7.3
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	4,589	1	1	1	1	141	1.3	5.0
41-64 years	40,144	1	1	1	1	229	1.3	4.8
≥ 65 years	148,072	1	1	1	1	525	1.8	7.9
Lofexidine hydrochloride	10,404	1	8	9	14	644	12.6	13.8
0-17 years	15	8	11	14	14	70	17.2	15.7
18-24 years	573	1	8	9	13	60	11.0	5.7
25-40 years	4,099	1	8	10	14	411	12.3	12.3
41-64 years	4,725	1	8	9	14	644	12.7	14.3
≥ 65 years	992	1	8	9	14	348	13.9	19.4
Erenumab-aooe	800,153	1	30	30	90	2,232	85.4	139.3
0-17 years	4,516	1	28	30	88	1,762	84.7	136.7
18-24 years	40,254	1	30	30	84	1,995	73.7	111.9
25-40 years	203,640	1	30	30	84	2,232	79.0	125.7
41-64 years	415,226	1	30	30	90	2,206	87.4	144.5
≥ 65 years	136,517	1	30	30	90	2,177	91.9	148.7
Sodium zirconium cyclosilicate	321,730	1	15	30	60	1,943	48.3	75.2
0-17 years	150	1	30	30	60	533	61.5	79.3
18-24 years	1,018	1	28	30	60	548	46.1	54.1
25-40 years	14,131	1	28	30	60	1,340	49.7	73.4
41-64 years	92,931	1	22	30	60	1,784	50.1	77.8
≥ 65 years	213,500	1	14	30	60	1,943	47.4	74.2

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Avatrombopag	9,712	1	8	30	60	1,624	54.6	96.6
0-17 years	39	15	30	30	60	310	68.1	69.3
18-24 years	359	3	30	30	60	1,006	52.2	76.5
25-40 years	813	1	30	30	60	914	55.6	83.0
41-64 years	3,757	1	5	30	42	1,585	47.8	95.2
≥ 65 years	4,744	1	21	30	60	1,624	59.9	101.0
Pegvaliase-pqpz	4,868	1	30	30	60	2,096	69.6	145.4
0-17 years	287	7	30	30	63	1,226	91.6	172.8
18-24 years	1,305	1	28	30	60	2,096	60.8	123.0
25-40 years	1,998	1	30	30	58	1,997	70.6	153.1
41-64 years	1,267	1	30	30	60	1,886	71.5	146.8
≥ 65 years	11	7	30	60	300	480	149.9	176.7
Baricitinib	79,878	1	1	1	9	1,952	22.4	71.0
0-17 years	579	1	30	30	66	1,205	81.6	151.1
18-24 years	1,696	1	6	30	60	833	53.3	79.2
25-40 years	6,956	1	1	1	30	1,566	36.4	75.4
41-64 years	27,677	1	1	1	30	1,812	33.0	84.6
≥ 65 years	42,970	1	1	1	1	1,952	11.2	54.5
Moxidectin	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Cannabidiol	95,858	1	30	38	120	2,228	139.5	246.8
0-17 years	47,703	1	30	42	120	2,170	142.5	235.0
18-24 years	15,784	1	30	35	120	2,166	128.8	225.5
25-40 years	21,018	1	30	36	118	2,228	140.6	269.3
41-64 years	10,557	1	30	37	108	2,042	142.0	282.4
≥ 65 years	796	2	30	30	90	1,946	107.0	201.8
Plazomicin	905	1	1	1	2	700	2.9	23.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	66	1	1	1	1	700	11.8	86.0
41-64 years	83	1	1	3	7	13	3.7	2.8
≥ 65 years	756	1	1	1	2	20	2.1	2.1
Binimetinib	11,634	1	30	30	60	2,173	67.9	97.1
0-17 years	83	2	30	30	120	1,005	99.5	160.5
18-24 years	110	7	30	30	90	771	80.8	123.4
25-40 years	1,041	2	30	30	60	1,052	63.6	86.7
41-64 years	4,077	1	30	30	60	2,119	69.1	104.7
≥ 65 years	6,323	1	30	30	60	2,173	67.3	91.8
Encorafenib	13,660	1	30	30	60	2,173	68.1	94.4
0-17 years	14	12	30	31	90	270	67.2	68.0
18-24 years	88	7	30	30	86	771	78.9	115.2
25-40 years	1,084	2	30	30	60	1,109	66.0	93.2
41-64 years	4,639	1	30	30	60	2,119	70.2	104.8
≥ 65 years	7,835	1	30	30	60	2,173	67.1	87.7

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Tecovirimat	41	9	14	14	14	112	17.0	15.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	9	14	14	14	112	32.6	44.4
25-40 years	*****	14	14	14	14	30	15.3	4.2
41-64 years	12	14	14	14	14	14	14.0	0.0
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Ivosidenib	6,438	1	30	30	90	1,570	81.0	110.8
0-17 years	*****	28	30	36	61	86	47.1	21.1
18-24 years	*****	1	30	30	60	750	67.2	96.7
25-40 years	574	3	30	31	90	1,570	82.5	117.5
41-64 years	1,431	2	30	30	90	1,200	82.5	117.1
≥ 65 years	4,331	1	30	33	90	1,440	80.6	108.1
Tafenoquine	635	1	2	21	31	835	33.4	64.2
0-17 years	31	1	1	14	36	404	47.2	90.2
18-24 years	43	1	7	30	56	485	51.2	81.4
25-40 years	209	1	1	10	30	610	25.9	54.5
41-64 years	306	1	2	23	42	835	35.3	67.6
≥ 65 years	46	1	3	21	54	112	29.3	31.5
Elagolix sodium	95,097	1	28	28	56	1,833	62.2	83.8
0-17 years	*****	1	28	28	56	1,094	66.9	100.7
18-24 years	15,690	1	28	28	56	1,316	60.5	80.3
25-40 years	55,981	1	28	28	56	1,833	61.1	81.5
41-64 years	21,986	1	28	28	73	1,684	65.8	90.3
≥ 65 years	*****	23	28	112	280	729	204.2	227.1
Fish oil triglycerides	5,794	1	1	1	1	975	4.5	27.1
0-17 years	4,897	1	1	1	1	975	4.5	27.2

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	421	1	1	1	1	643	4.5	34.3
25-40 years	231	1	1	1	7	272	5.3	20.8
41-64 years	189	1	1	1	1	60	1.8	4.6
≥ 65 years	56	1	1	1	1	96	3.3	12.8
Lusutrombopag	600	3	7	7	7	74	8.4	5.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	4	7	7	7	7	6.4	1.3
25-40 years	*****	7	7	7	7	30	8.2	4.7
41-64 years	449	3	7	7	7	74	8.7	6.3
≥ 65 years	114	7	7	7	7	14	7.6	1.9

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Lutetium Lu 177 dotatate</i>	6,363	6,363	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Bictegravir embitcitabine tenofovir alafenamide</i>	244,961	104,520	42.7%	58,593	23.9%	51,939	21.2%	16,214	6.6%	13,695	5.6%
<i>Tezacaftor and ivacaftor</i>	4,020	1,837	45.7%	881	21.9%	864	21.5%	296	7.4%	142	3.5%
<i>Apalutamide</i>	17,467	7,508	43.0%	4,428	25.4%	4,289	24.6%	870	5.0%	372	2.1%
<i>Ibalizumab-uiyk</i>	365	274	75.1%	47	12.9%	*****	*****	*****	*****	*****	*****
<i>Tildrakizumab</i>	12,838	12,109	94.3%	379	3.0%	306	2.4%	*****	*****	*****	*****
<i>Burosumab-twza</i>	1,374	1,050	76.4%	144	10.5%	100	7.3%	32	2.3%	48	3.5%
<i>Fostamatinib</i>	1,534	766	49.9%	430	28.0%	270	17.6%	51	3.3%	17	1.1%
<i>Fosnetupitant and palonosetron</i>	35,282	34,800	98.6%	372	1.1%	*****	*****	*****	*****	0	0.0%
<i>Lofexidine hydrochloride</i>	8,141	8,020	98.5%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Erenumab-aooe</i>	203,727	105,629	51.8%	51,606	25.3%	36,532	17.9%	6,683	3.3%	3,277	1.6%
<i>Sodium zirconium cyclosilicate</i>	135,004	98,952	73.3%	25,795	19.1%	8,897	6.6%	1,055	0.8%	305	0.2%
<i>Avatrombopag</i>	4,012	2,918	72.7%	624	15.6%	383	9.5%	67	1.7%	20	0.5%
<i>Pegvaliase-pqpz</i>	747	374	50.1%	219	29.3%	105	14.1%	24	3.2%	25	3.3%
<i>Baricitinib</i>	64,998	61,620	94.8%	1,676	2.6%	1,341	2.1%	303	0.5%	58	0.1%
<i>Moxidectin</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Cannabidiol</i>	27,440	9,845	35.9%	6,274	22.9%	6,297	22.9%	2,492	9.1%	2,532	9.2%
<i>Plazomicin</i>	285	*****	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%
<i>Binimetinib</i>	3,829	2,187	57.1%	968	25.3%	584	15.3%	70	1.8%	20	0.5%
<i>Encorafenib</i>	4,755	2,708	57.0%	1,191	25.0%	762	16.0%	74	1.6%	20	0.4%
<i>Tecovirimat</i>	39	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
<i>Ivosidenib</i>	2,585	1,315	50.9%	709	27.4%	487	18.8%	60	2.3%	14	0.5%

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Tafenoquine</i>	366	257	70.2%	84	23.0%	*****	*****	*****	*****	0	0.0%
<i>Elagolix sodium</i>	37,541	22,155	59.0%	9,221	24.6%	5,391	14.4%	637	1.7%	137	0.4%
<i>Fish oil triglycerides</i>	286	257	89.9%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Lusutrombopag</i>	441	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Lutetium Lu 177 dotatate</i>	6,363	1	1	1	1	3	1.0	0.0
<i>Bictegravir embitcitabine tenofovir alafenamide</i>	244,961	1	30	60	150	2,509	172.6	301.0
<i>Tezacaftor and ivacaftor</i>	4,020	1	28	56	140	2,230	145.1	233.8
<i>Apalutamide</i>	17,467	1	30	60	135	2,232	125.2	190.8
<i>Ibalizumab-uiyk</i>	365	1	1	14	30	972	52.3	131.1
<i>Tildrakizumab</i>	12,838	1	1	1	1	1,204	10.7	46.3
<i>Burosumab-twza</i>	1,374	1	1	1	28	2,046	77.3	225.6
<i>Fostamatinib</i>	1,534	2	30	33	90	2,160	94.4	153.6
<i>Fosnetupitant and palonosetron</i>	35,282	1	1	1	1	399	2.4	10.5
<i>Lofexidine hydrochloride</i>	8,141	1	8	9	14	411	11.9	9.4
<i>Erenumab-aooe</i>	203,727	1	30	30	90	2,206	100.0	172.3
<i>Sodium zirconium cyclosilicate</i>	135,004	1	7	30	39	1,943	43.9	78.1
<i>Avatrombopag</i>	4,012	1	5	30	56	1,585	51.1	108.1
<i>Pegvaliase-pqpz</i>	747	3	28	30	70	2,096	118.0	265.8
<i>Baricitinib</i>	64,998	1	1	1	1	1,952	11.3	56.3
<i>Moxidectin</i>	0	-	-	-	-	-	-	-
<i>Cannabidiol</i>	27,440	1	30	60	240	2,228	219.8	334.9
<i>Plazomicin</i>	285	1	1	3	5	700	6.0	41.3
<i>Binimetinib</i>	3,829	1	30	30	79	2,173	74.6	113.1
<i>Encorafenib</i>	4,755	1	30	30	80	2,173	73.0	107.8
<i>Tecovirimat</i>	39	9	14	14	14	112	17.2	16.0
<i>Ivosidenib</i>	2,585	1	30	30	90	1,570	82.6	115.8
<i>Tafenoquine</i>	366	1	3	25	42	575	35.9	56.4
<i>Elagolix sodium</i>	37,541	1	28	28	84	1,833	70.2	99.7
<i>Fish oil triglycerides</i>	286	1	1	1	7	643	16.6	61.2
<i>Lusutrombopag</i>	441	3	7	7	7	74	8.1	5.8

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Lutetium Lu 177 dotatate	6,363	6,363	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	3,080	3,080	48.4%	0	NaN	0	NaN	0	NaN	0	NaN
Male	3,283	3,283	51.6%	0	NaN	0	NaN	0	NaN	0	NaN
Bictegravir embicitabine tenofovir alafenamide	244,961	104,520	100.0%	58,593	100.0%	51,939	100.0%	16,214	100.0%	13,695	100.0%
Female	63,660	28,406	27.2%	15,203	25.9%	12,926	24.9%	3,943	24.3%	3,182	23.2%
Male	181,301	76,114	72.8%	43,390	74.1%	39,013	75.1%	12,271	75.7%	10,513	76.8%
Tezacaftor and ivacaftor	4,020	1,837	100.0%	881	100.0%	864	100.0%	296	100.0%	142	100.0%
Female	1,998	931	50.7%	430	48.8%	428	49.5%	145	49.0%	64	45.1%
Male	2,022	906	49.3%	451	51.2%	436	50.5%	151	51.0%	78	54.9%
Apalutamide	17,467	7,508	100.0%	4,428	100.0%	4,289	100.0%	870	100.0%	372	100.0%
Female	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Male	*****	*****	*****	*****	*****	*****	*****	870	100.0%	372	100.0%
Ibalizumab-uiyk	365	274	100.0%	47	100.0%	*****	*****	*****	*****	*****	*****
Female	89	71	25.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
Male	276	203	74.1%	*****	*****	*****	*****	*****	*****	*****	*****
Tildrakizumab	12,838	12,109	100.0%	379	100.0%	306	100.0%	*****	*****	*****	*****
Female	6,870	6,482	53.5%	208	54.9%	151	49.3%	*****	*****	*****	*****
Male	5,968	5,627	46.5%	171	45.1%	155	50.7%	*****	*****	*****	*****
Burosumab-twza	1,374	1,050	100.0%	144	100.0%	100	100.0%	32	100.0%	48	100.0%
Female	894	664	63.2%	104	72.2%	74	74.0%	17	53.1%	35	72.9%
Male	480	386	36.8%	40	27.8%	26	26.0%	15	46.9%	13	27.1%
Fostamatinib	1,534	766	100.0%	430	100.0%	270	100.0%	51	100.0%	17	100.0%
Female	838	435	56.8%	235	54.7%	137	50.7%	*****	*****	*****	*****

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	696	331	43.2%	195	45.3%	133	49.3%	*****	*****	*****	*****
Fosnetupitant and palonosetron	35,282	34,800	100.0%	372	100.0%	*****	*****	*****	*****	0	NaN
Female	20,040	19,758	56.8%	216	58.1%	*****	*****	*****	*****	0	NaN
Male	15,242	15,042	43.2%	156	41.9%	*****	*****	0	0.0%	0	NaN
Lofexidine hydrochloride	8,141	8,020	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Female	4,097	4,038	50.3%	*****	*****	*****	*****	*****	*****	0	NaN
Male	4,044	3,982	49.7%	*****	*****	*****	*****	0	0.0%	0	NaN
Erenumab-aooe	203,727	105,629	100.0%	51,606	100.0%	36,532	100.0%	6,683	100.0%	3,277	100.0%
Female	173,883	89,945	85.2%	44,129	85.5%	31,299	85.7%	5,712	85.5%	2,798	85.4%
Male	29,844	15,684	14.8%	7,477	14.5%	5,233	14.3%	971	14.5%	479	14.6%
Sodium zirconium cyclosilicate	135,004	98,952	100.0%	25,795	100.0%	8,897	100.0%	1,055	100.0%	305	100.0%
Female	58,830	44,054	44.5%	10,792	41.8%	3,485	39.2%	387	36.7%	112	36.7%
Male	76,174	54,898	55.5%	15,003	58.2%	5,412	60.8%	668	63.3%	193	63.3%
Avatrombopag	4,012	2,918	100.0%	624	100.0%	383	100.0%	67	100.0%	20	100.0%
Female	1,929	1,382	47.4%	313	50.2%	192	50.1%	*****	*****	*****	*****
Male	2,083	1,536	52.6%	311	49.8%	191	49.9%	*****	*****	*****	*****
Pegvaliase-pqpz	747	374	100.0%	219	100.0%	105	100.0%	24	100.0%	25	100.0%
Female	397	194	51.9%	123	56.2%	57	54.3%	11	45.8%	12	48.0%
Male	350	180	48.1%	96	43.8%	48	45.7%	13	54.2%	13	52.0%
Baricitinib	64,998	61,620	100.0%	1,676	100.0%	1,341	100.0%	303	100.0%	58	100.0%
Female	32,536	29,903	48.5%	1,325	79.1%	1,024	76.4%	241	79.5%	43	74.1%
Male	32,462	31,717	51.5%	351	20.9%	317	23.6%	62	20.5%	15	25.9%

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Moxidectin		-	-	-	-	-	-	-	-	-	-
Female		-	-	-	-	-	-	-	-	-	-
Male		-	-	-	-	-	-	-	-	-	-
Cannabidiol	27,440	9,845	100.0%	6,274	100.0%	6,297	100.0%	2,492	100.0%	2,532	100.0%
Female	12,451	4,428	45.0%	2,844	45.3%	2,847	45.2%	1,168	46.9%	1,164	46.0%
Male	14,989	5,417	55.0%	3,430	54.7%	3,450	54.8%	1,324	53.1%	1,368	54.0%
Plazomicin	285	*****	*****	0	NaN	0	NaN	*****	*****	0	NaN
Female	188	*****	*****	0	NaN	0	NaN	0	0.0%	0	NaN
Male	97	*****	*****	0	NaN	0	NaN	*****	*****	0	NaN
Binimetinib	3,829	2,187	100.0%	968	100.0%	584	100.0%	70	100.0%	20	100.0%
Female	1,700	989	45.2%	430	44.4%	246	42.1%	*****	*****	*****	*****
Male	2,129	1,198	54.8%	538	55.6%	338	57.9%	*****	*****	*****	*****
Encorafenib	4,755	2,708	100.0%	1,191	100.0%	762	100.0%	74	100.0%	20	100.0%
Female	2,275	1,345	49.7%	556	46.7%	342	44.9%	*****	*****	*****	*****
Male	2,480	1,363	50.3%	635	53.3%	420	55.1%	*****	*****	*****	*****
Tecovirimat	39	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
Ivosidenib	2,585	1,315	100.0%	709	100.0%	487	100.0%	60	100.0%	14	100.0%
Female	1,334	692	52.6%	359	50.6%	245	50.3%	*****	*****	*****	*****
Male	1,251	623	47.4%	350	49.4%	242	49.7%	*****	*****	*****	*****
Tafenoquine	366	257	100.0%	84	100.0%	*****	*****	*****	*****	0	NaN
Female	229	159	61.9%	*****	*****	*****	*****	*****	*****	0	NaN
Male	137	98	38.1%	*****	*****	*****	*****	*****	*****	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Elagolix sodium	37,541	22,155	100.0%	9,221	100.0%	5,391	100.0%	637	100.0%	137	100.0%
Female	37,493	22,126	99.9%	*****	*****	*****	*****	*****	*****	137	100.0%
Male	48	29	0.1%	*****	*****	*****	*****	*****	*****	0	0.0%
Fish oil triglycerides	286	257	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Female	180	165	64.2%	*****	*****	*****	*****	*****	*****	0	NaN
Male	106	92	35.8%	*****	*****	*****	*****	*****	*****	0	NaN
Lusutrombopag	441	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	197	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	244	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Lutetium Lu 177 dotatate	6,363	1	1	1	1	3	1.0	0.0
Female	3,080	1	1	1	1	2	1.0	0.0
Male	3,283	1	1	1	1	3	1.0	0.1
Bictegravir embicitabine tenofovir alafenamide	244,961	1	30	60	150	2,509	172.6	301.0
Female	63,660	1	30	60	150	2,461	158.1	273.0
Male	181,301	1	30	60	167	2,509	177.6	310.1
Tezacaftor and ivacaftor	4,020	1	28	56	140	2,230	145.1	233.8
Female	1,998	3	28	56	140	2,230	141.6	229.0
Male	2,022	1	28	56	140	2,099	148.6	238.4
Apalutamide	17,467	1	30	60	135	2,232	125.2	190.8
Female	*****	30	45	90	174	228	109.5	87.4
Male	*****	1	30	60	135	2,232	125.2	190.8
Ibalizumab-uiyk	365	1	1	14	30	972	52.3	131.1
Female	89	1	1	1	28	336	27.6	60.1
Male	276	1	1	14	42	972	60.3	146.0
Tildrakizumab	12,838	1	1	1	1	1,204	10.7	46.3
Female	6,870	1	1	1	1	1,174	10.7	47.5
Male	5,968	1	1	1	1	1,204	10.7	44.9
Burosumab-twza	1,374	1	1	1	28	2,046	77.3	225.6
Female	894	1	1	1	47	2,046	82.7	239.7
Male	480	1	1	1	28	1,559	67.2	196.6
Fostamatinib	1,534	2	30	33	90	2,160	94.4	153.6
Female	838	4	30	30	90	1,574	88.3	138.5
Male	696	2	30	52	90	2,160	101.6	169.8

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Fosnetupitant and palonosetron	35,282	1	1	1	1	399	2.4	10.5
Female	20,040	1	1	1	1	399	2.4	10.9
Male	15,242	1	1	1	1	315	2.3	10.0
Lofexidine hydrochloride	8,141	1	8	9	14	411	11.9	9.4
Female	4,097	1	8	9	14	411	12.0	9.7
Male	4,044	1	8	9	14	240	11.9	9.1
Erenumab-aooe	203,727	1	30	30	90	2,206	100.0	172.3
Female	173,883	1	30	30	90	2,206	100.1	172.5
Male	29,844	1	30	30	90	2,192	99.2	171.0
Sodium zirconium cyclosilicate	135,004	1	7	30	39	1,943	43.9	78.1
Female	58,830	1	5	30	31	1,784	40.8	73.3
Male	76,174	1	10	30	49	1,943	46.2	81.6
Avatrombopag	4,012	1	5	30	56	1,585	51.1	108.1
Female	1,929	1	5	30	60	1,585	53.9	118.5
Male	2,083	1	5	28	45	1,294	48.4	97.4
Pegvaliase-pqpz	747	3	28	30	70	2,096	118.0	265.8
Female	397	3	28	35	69	2,096	110.3	246.2
Male	350	3	28	30	70	1,997	126.7	286.6
Baricitinib	64,998	1	1	1	1	1,952	11.3	56.3
Female	32,536	1	1	1	1	1,952	17.0	69.6
Male	32,462	1	1	1	1	1,620	5.6	37.9
Moxidectin	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Cannabidiol	27,440	1	30	60	240	2,228	219.8	334.9
Female	12,451	1	30	60	240	2,170	222.4	336.5
Male	14,989	1	30	60	234	2,228	217.6	333.5
Plazomicin	285	1	1	3	5	700	6.0	41.3
Female	188	1	1	3	5	20	3.6	2.8
Male	97	1	1	3	6	700	10.8	70.8
Binimetinib	3,829	1	30	30	79	2,173	74.6	113.1
Female	1,700	1	30	30	60	1,384	70.2	97.5
Male	2,129	1	30	30	90	2,173	78.2	124.1
Encorafenib	4,755	1	30	30	80	2,173	73.0	107.8
Female	2,275	1	30	30	60	1,050	66.3	82.9
Male	2,480	1	30	30	90	2,173	79.2	126.2
Tecovirimat	39	9	14	14	14	112	17.2	16.0
Female	*****	14	14	14	14	14	14.0	NaN
Male	*****	9	14	14	14	112	17.2	16.2
Ivosidenib	2,585	1	30	30	90	1,570	82.6	115.8
Female	1,334	1	30	30	90	1,389	81.7	110.9
Male	1,251	2	30	33	90	1,570	83.5	120.8
Tafenoquine	366	1	3	25	42	575	35.9	56.4
Female	229	1	5	28	42	575	35.4	53.0
Male	137	1	2	21	38	485	36.7	61.8
Elagolix sodium	37,541	1	28	28	84	1,833	70.2	99.7
Female	37,493	1	28	28	84	1,833	70.2	99.7
Male	48	4	28	28	82	476	65.4	80.4

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Fish oil triglycerides	286	1	1	1	7	643	16.6	61.2
Female	180	1	1	1	7	643	13.6	54.3
Male	106	1	1	1	9	502	21.7	71.5
Lusutrombopag	441	3	7	7	7	74	8.1	5.8
Female	197	7	7	7	7	57	8.0	4.8
Male	244	3	7	7	7	74	8.3	6.5

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Lutetium Lu 177 dotatate	6,363	6,363	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	136	136	2.1%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	1,553	1,553	24.4%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	4,656	4,656	73.2%	0	NaN	0	NaN	0	NaN	0	NaN
Bictegravir embicitabine tenofovir alafenamide	244,961	104,520	100.0%	58,593	100.0%	51,939	100.0%	16,214	100.0%	13,695	100.0%
0-17 years	1,507	602	0.6%	336	0.6%	350	0.7%	136	0.8%	83	0.6%
18-24 years	13,116	6,169	5.9%	3,249	5.5%	2,698	5.2%	708	4.4%	292	2.1%
25-40 years	77,234	36,687	35.1%	19,393	33.1%	15,045	29.0%	3,871	23.9%	2,238	16.3%
41-64 years	126,324	50,823	48.6%	29,538	50.4%	27,731	53.4%	9,419	58.1%	8,813	64.4%
≥ 65 years	26,780	10,239	9.8%	6,077	10.4%	6,115	11.8%	2,080	12.8%	2,269	16.6%
Tezacaftor and ivacaftor	4,020	1,837	100.0%	881	100.0%	864	100.0%	296	100.0%	142	100.0%
0-17 years	1,493	652	35.5%	313	35.5%	349	40.4%	124	41.9%	55	38.7%
18-24 years	826	404	22.0%	194	22.0%	152	17.6%	50	16.9%	26	18.3%
25-40 years	1,263	603	32.8%	281	31.9%	266	30.8%	82	27.7%	31	21.8%
41-64 years	378	159	8.7%	81	9.2%	77	8.9%	*****	*****	*****	*****
≥ 65 years	60	19	1.0%	12	1.4%	20	2.3%	*****	*****	*****	*****
Apalutamide	17,467	7,508	100.0%	4,428	100.0%	4,289	100.0%	870	100.0%	372	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	*****	*****	438	10.2%	120	13.8%	41	11.0%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	15,599	6,696	89.2%	3,971	89.7%	3,851	89.8%	750	86.2%	331	89.0%
Ibalizumab-uiyk	365	274	100.0%	47	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	242	179	65.3%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	51	38	13.9%	*****	*****	*****	*****	*****	*****	*****	*****
Tildrakizumab	12,838	12,109	100.0%	379	100.0%	306	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	530	402	3.3%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	1,549	1,226	10.1%	190	50.1%	113	36.9%	*****	*****	*****	*****
≥ 65 years	10,675	10,419	86.0%	110	29.0%	130	42.5%	*****	*****	*****	*****
Burosumab-twza	1,374	1,050	100.0%	144	100.0%	100	100.0%	32	100.0%	48	100.0%
0-17 years	749	562	53.5%	91	63.2%	61	61.0%	15	46.9%	20	41.7%
18-24 years	96	75	7.1%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	197	158	15.0%	16	11.1%	*****	*****	*****	*****	*****	*****
41-64 years	209	155	14.8%	20	13.9%	20	20.0%	*****	*****	*****	*****
≥ 65 years	123	100	9.5%	*****	*****	*****	*****	*****	*****	*****	*****
Fostamatinib	1,534	766	100.0%	430	100.0%	270	100.0%	51	100.0%	17	100.0%
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	200	117	15.3%	39	9.1%	*****	*****	*****	*****	*****	*****
41-64 years	508	242	31.6%	143	33.3%	96	35.6%	*****	*****	*****	*****

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	765	371	48.4%	233	54.2%	132	48.9%	*****	*****	*****	*****
Fosnetupitant and palonosetron	35,282	34,800	100.0%	372	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	977	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	7,693	7,637	21.9%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	26,501	26,082	74.9%	325	87.4%	*****	*****	*****	*****	0	NaN
Lofexidine hydrochloride	8,141	8,020	100.0%	112	100.0%	8	100.0%	1	100.0%	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	3,191	3,141	39.2%	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	3,727	3,666	45.7%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	756	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Erenumab-aooe	203,727	105,629	100.0%	51,606	100.0%	36,532	100.0%	6,683	100.0%	3,277	100.0%
0-17 years	1,279	636	0.6%	331	0.6%	239	0.7%	49	0.7%	24	0.7%
18-24 years	11,177	5,998	5.7%	2,809	5.4%	1,918	5.3%	333	5.0%	119	3.6%
25-40 years	53,852	28,154	26.7%	13,596	26.3%	9,774	26.8%	1,648	24.7%	680	20.8%
41-64 years	103,105	52,951	50.1%	25,947	50.3%	18,677	51.1%	3,633	54.4%	1,897	57.9%
≥ 65 years	34,314	17,890	16.9%	8,923	17.3%	5,924	16.2%	1,020	15.3%	557	17.0%
Sodium zirconium cyclosilicate	135,004	98,952	100.0%	25,795	100.0%	8,897	100.0%	1,055	100.0%	305	100.0%
0-17 years	66	35	0.0%	21	0.1%	*****	*****	*****	*****	0	0.0%
18-24 years	504	361	0.4%	106	0.4%	*****	*****	*****	*****	0	0.0%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	6,278	4,552	4.6%	1,261	4.9%	*****	*****	*****	*****	14	4.6%
41-64 years	38,124	27,100	27.4%	7,716	29.9%	2,846	32.0%	360	34.1%	102	33.4%
≥ 65 years	90,032	66,904	67.6%	16,691	64.7%	5,613	63.1%	635	60.2%	189	62.0%
Avatrombopag	4,012	2,918	100.0%	624	100.0%	383	100.0%	67	100.0%	20	100.0%
0-17 years	17	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	96	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	305	223	7.6%	46	7.4%	*****	*****	*****	*****	*****	*****
41-64 years	1,643	1,292	44.3%	196	31.4%	122	31.9%	*****	*****	*****	*****
≥ 65 years	1,951	1,339	45.9%	347	55.6%	218	56.9%	36	53.7%	*****	*****
Pegvaliase-pqpz	747	374	100.0%	219	100.0%	105	100.0%	24	100.0%	25	100.0%
0-17 years	*****	24	6.4%	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	204	103	27.5%	58	26.5%	31	29.5%	*****	*****	*****	*****
25-40 years	317	167	44.7%	83	37.9%	*****	*****	*****	*****	13	52.0%
41-64 years	170	80	21.4%	64	29.2%	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
Baricitinib	64,998	61,620	100.0%	1,676	100.0%	1,341	100.0%	303	100.0%	58	100.0%
0-17 years	250	172	0.3%	38	2.3%	25	1.9%	*****	*****	*****	*****
18-24 years	815	629	1.0%	80	4.8%	89	6.6%	*****	*****	*****	*****
25-40 years	4,616	4,060	6.6%	279	16.6%	233	17.4%	*****	*****	*****	*****
41-64 years	20,122	18,333	29.8%	893	53.3%	704	52.5%	160	52.8%	32	55.2%
≥ 65 years	39,195	38,426	62.4%	386	23.0%	290	21.6%	*****	*****	*****	*****
Moxidectin	-	-	-	-	-	-	-	-	-	-	-
0-17 years	-	-	-	-	-	-	-	-	-	-	-
18-24 years	-	-	-	-	-	-	-	-	-	-	-

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years		-	-	-	-	-	-	-	-	-	-
41-64 years		-	-	-	-	-	-	-	-	-	-
≥ 65 years		-	-	-	-	-	-	-	-	-	-
Cannabidiol	27,440	9,845	100.0%	6,274	100.0%	6,297	100.0%	2,492	100.0%	2,532	100.0%
0-17 years	14,798	5,147	52.3%	3,315	52.8%	3,449	54.8%	1,490	59.8%	1,397	55.2%
18-24 years	4,538	1,767	17.9%	1,081	17.2%	1,007	16.0%	357	14.3%	326	12.9%
25-40 years	5,498	1,988	20.2%	1,276	20.3%	1,224	19.4%	452	18.1%	558	22.0%
41-64 years	2,390	840	8.5%	554	8.8%	571	9.1%	*****	*****	*****	*****
≥ 65 years	216	103	1.0%	48	0.8%	46	0.7%	*****	*****	*****	*****
Plazomicin	285	*****	*****	0	NaN	0	NaN	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	*****	*****	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	0.0%	0	NaN
≥ 65 years	220	220	77.5%	0	NaN	0	NaN	0	0.0%	0	NaN
Binimetinib	3,829	2,187	100.0%	968	100.0%	584	100.0%	70	100.0%	20	100.0%
0-17 years	35	15	0.7%	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	42	22	1.0%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	310	184	8.4%	70	7.2%	*****	*****	*****	*****	*****	*****
41-64 years	1,304	710	32.5%	342	35.3%	217	37.2%	*****	*****	*****	*****
≥ 65 years	2,138	1,256	57.4%	545	56.3%	294	50.3%	*****	*****	*****	*****
Encorafenib	4,755	2,708	100.0%	1,191	100.0%	762	100.0%	74	100.0%	20	100.0%
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	337	198	7.3%	*****	*****	*****	*****	*****	*****	*****	*****

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	1,603	846	31.2%	421	35.3%	299	39.2%	*****	*****	*****	*****
≥ 65 years	2,777	1,644	60.7%	691	58.0%	395	51.8%	*****	*****	*****	*****
Tecovirimat	39	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
25-40 years	23	23	60.5%	0	NaN	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
Ivosidenib	2,585	1,315	100.0%	709	100.0%	487	100.0%	60	100.0%	14	100.0%
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	228	129	9.8%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	598	295	22.4%	173	24.4%	105	21.6%	*****	*****	*****	*****
≥ 65 years	1,731	876	66.6%	484	68.3%	330	67.8%	*****	*****	*****	*****
Tafenoquine	366	257	100.0%	84	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	16	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	32	15	5.8%	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	111	90	35.0%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	179	122	47.5%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	28	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Elagolix sodium	37,541	22,155	100.0%	9,221	100.0%	5,391	100.0%	637	100.0%	137	100.0%
0-17 years	*****	*****	*****	107	1.2%	*****	*****	*****	*****	*****	*****
18-24 years	6,004	3,595	16.2%	1,455	15.8%	824	15.3%	*****	*****	*****	*****
25-40 years	22,278	13,212	59.6%	5,476	59.4%	3,168	58.8%	347	54.5%	75	54.7%
41-64 years	8,796	5,084	22.9%	2,183	23.7%	1,324	24.6%	165	25.9%	40	29.2%
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	0	0.0%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Fish oil triglycerides	286	257	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	180	156	60.7%	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	*****	*****	0	NaN
25-40 years	60	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
41-64 years	27	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
Lusutrombopag	441	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	321	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	93	93	21.3%	0	0.0%	0	NaN	0	NaN	0	NaN

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lutetium Lu 177 dotatate	6,363	1	1	1	1	3	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	136	1	1	1	1	3	1.0	0.2
41-64 years	1,553	1	1	1	1	3	1.0	0.1
≥ 65 years	4,656	1	1	1	1	1	1.0	0.0
Bictegravir embitcitabine tenofovir alafenamide	244,961	1	30	60	150	2,509	172.6	301.0
0-17 years	1,507	1	30	60	180	1,641	174.7	251.7
18-24 years	13,116	1	30	60	120	2,258	121.2	191.8
25-40 years	77,234	1	30	60	120	2,509	127.0	218.3
41-64 years	126,324	1	30	60	180	2,467	194.5	328.3
≥ 65 years	26,780	1	30	60	210	2,473	225.3	385.9
Tezacaftor and ivacaftor	4,020	1	28	56	140	2,230	145.1	233.8
0-17 years	1,493	1	28	56	140	2,099	153.1	235.0
18-24 years	826	7	28	56	112	1,815	128.7	224.5
25-40 years	1,263	4	28	56	112	1,652	127.4	202.8
41-64 years	378	3	28	56	196	2,230	200.1	317.7
≥ 65 years	60	28	28	84	252	1,064	198.3	250.6
Apalutamide	17,467	1	30	60	135	2,232	125.2	190.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	60	60	40.0	17.3
41-64 years	*****	1	30	60	150	1,518	129.9	188.1
≥ 65 years	15,599	1	30	60	130	2,232	124.7	191.1

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Ibalizumab-uiyk	365	1	1	14	30	972	52.3	131.1
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	154	336	82.3	138.5
25-40 years	*****	1	1	1	28	316	30.0	61.3
41-64 years	242	1	1	14	42	972	54.7	138.3
≥ 65 years	51	1	1	14	32	938	66.7	158.6
Tildrakizumab	12,838	1	1	1	1	1,204	10.7	46.3
0-17 years	*****	1	1	1	28	30	10.3	14.5
18-24 years	*****	1	1	28	56	700	55.6	121.3
25-40 years	530	1	1	1	30	532	38.8	71.3
41-64 years	1,549	1	1	1	28	845	34.7	78.3
≥ 65 years	10,675	1	1	1	1	1,204	5.5	34.2
Burosumab-twza	1,374	1	1	1	28	2,046	77.3	225.6
0-17 years	749	1	1	14	28	1,893	69.2	191.6
18-24 years	96	1	1	1	28	987	78.3	197.5
25-40 years	197	1	1	1	28	2,046	87.7	273.7
41-64 years	209	1	1	1	42	2,003	85.1	242.3
≥ 65 years	123	1	1	1	28	1,869	96.2	309.7
Fostamatinib	1,534	2	30	33	90	2,160	94.4	153.6
0-17 years	*****	30	30	30	79	136	55.8	43.9
18-24 years	*****	15	30	30	90	719	84.3	131.9
25-40 years	200	9	30	30	90	871	91.2	138.9
41-64 years	508	2	30	58	90	1,574	102.8	171.1
≥ 65 years	765	4	30	48	90	2,160	90.6	146.9

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Fosnetupitant and palonosetron	35,282	1	1	1	1	399	2.4	10.5
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	977	1	1	1	1	141	1.7	7.7
41-64 years	7,693	1	1	1	1	229	1.8	8.0
≥ 65 years	26,501	1	1	1	1	399	2.6	11.2
Lofexidine hydrochloride	8,141	1	8	9	14	411	11.9	9.4
0-17 years	*****	8	8	11	14	32	13.1	7.5
18-24 years	*****	1	8	10	12	36	10.8	4.7
25-40 years	3,191	1	8	9	14	411	11.9	10.3
41-64 years	3,727	1	9	9	14	240	12.0	8.4
≥ 65 years	756	1	8	9	14	224	12.3	11.7
Erenumab-aooe	203,727	1	30	30	90	2,206	100.0	172.3
0-17 years	1,279	1	30	40	90	1,762	105.9	176.5
18-24 years	11,177	1	30	30	90	1,995	89.0	140.8
25-40 years	53,852	1	30	30	90	2,140	94.2	155.8
41-64 years	103,105	1	30	30	90	2,206	104.2	181.8
≥ 65 years	34,314	1	30	30	90	2,177	99.8	176.3
Sodium zirconium cyclosilicate	135,004	1	7	30	39	1,943	43.9	78.1
0-17 years	66	1	30	30	79	390	68.4	77.0
18-24 years	504	1	15	30	52	548	44.0	58.7
25-40 years	6,278	1	20	30	44	1,340	47.3	78.1
41-64 years	38,124	1	12	30	52	1,784	48.2	84.4
≥ 65 years	90,032	1	5	30	33	1,943	41.8	75.3

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Avatrombopag	4,012	1	5	30	56	1,585	51.1	108.1
0-17 years	17	30	30	30	60	240	60.4	57.9
18-24 years	96	5	30	30	60	1,006	65.4	116.9
25-40 years	305	3	6	30	60	870	50.9	86.7
41-64 years	1,643	1	5	5	30	1,585	43.0	109.8
≥ 65 years	1,951	1	5	30	60	1,466	57.1	109.1
Pegvaliase-pqpz	747	3	28	30	70	2,096	118.0	265.8
0-17 years	*****	7	28	35	150	1,226	172.2	308.5
18-24 years	204	3	28	30	73	2,096	103.7	231.3
25-40 years	317	6	28	30	77	1,997	128.2	284.7
41-64 years	170	3	28	35	63	1,886	98.0	253.7
≥ 65 years	*****	70	70	185	300	300	185.0	162.6
Baricitinib	64,998	1	1	1	1	1,952	11.3	56.3
0-17 years	250	1	1	30	60	1,142	80.0	177.9
18-24 years	815	1	1	2	30	833	44.8	89.5
25-40 years	4,616	1	1	1	2	870	22.7	67.3
41-64 years	20,122	1	1	1	1	1,812	18.5	72.6
≥ 65 years	39,195	1	1	1	1	1,952	5.1	39.0
Moxidectin	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Cannabidiol	27,440	1	30	60	240	2,228	219.8	334.9
0-17 years	14,798	1	30	63	264	2,170	220.3	311.1
18-24 years	4,538	1	30	60	180	2,166	191.0	308.5
25-40 years	5,498	1	30	60	240	2,228	235.6	382.7
41-64 years	2,390	1	30	60	238	2,042	243.2	402.8
≥ 65 years	216	3	30	36	120	1,946	131.8	235.5
Plazomicin	285	1	1	3	5	700	6.0	41.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	7	700	102.6	263.5
41-64 years	*****	1	1	3	7	13	3.7	2.8
≥ 65 years	220	1	1	3	5	20	3.6	2.8
Binimetinib	3,829	1	30	30	79	2,173	74.6	113.1
0-17 years	35	2	28	60	180	1,005	162.3	226.7
18-24 years	42	9	30	30	107	771	111.8	164.6
25-40 years	310	2	30	30	89	1,052	69.3	92.9
41-64 years	1,304	1	30	30	90	2,119	79.1	123.1
≥ 65 years	2,138	1	30	30	60	2,173	70.5	104.5
Encorafenib	4,755	1	30	30	80	2,173	73.0	107.8
0-17 years	*****	12	21	75	120	120	70.5	57.6
18-24 years	*****	9	30	30	120	771	108.6	153.6
25-40 years	337	2	30	30	84	1,052	71.4	97.5
41-64 years	1,603	1	30	30	90	2,119	80.3	125.2
≥ 65 years	2,777	1	30	30	60	2,173	68.6	96.8

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tecovirimat	39	9	14	14	14	112	17.2	16.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	9	14	14	14	112	32.6	44.4
25-40 years	*****	14	14	14	14	30	15.3	4.3
41-64 years	11	14	14	14	14	14	14.0	0.0
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Ivosidenib	2,585	1	30	30	90	1,570	82.6	115.8
0-17 years	*****	30	33	48	74	86	53.0	25.9
18-24 years	*****	9	30	30	75	425	79.8	108.2
25-40 years	228	3	30	30	90	1,570	86.2	143.2
41-64 years	598	2	30	38	90	992	86.2	115.9
≥ 65 years	1,731	1	30	30	90	1,390	81.0	111.9
Tafenoquine	366	1	3	25	42	575	35.9	56.4
0-17 years	16	1	4	18	60	282	51.1	80.5
18-24 years	32	1	20	31	66	485	62.4	91.0
25-40 years	111	1	1	20	30	214	26.9	35.8
41-64 years	179	1	7	28	42	575	35.8	57.8
≥ 65 years	28	1	1	17	57	112	33.3	36.7
Elagolix sodium	37,541	1	28	28	84	1,833	70.2	99.7
0-17 years	*****	1	28	28	84	784	77.8	107.0
18-24 years	6,004	1	28	28	84	1,316	69.7	97.4
25-40 years	22,278	1	28	28	84	1,833	68.7	96.2
41-64 years	8,796	1	28	28	84	1,684	74.0	108.7
≥ 65 years	*****	23	28	254	280	729	262.8	287.4

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Fish oil triglycerides	286	1	1	1	7	643	16.6	61.2
0-17 years	180	1	1	1	9	502	17.3	56.4
18-24 years	*****	1	1	1	5	643	56.2	177.2
25-40 years	60	1	1	7	7	272	12.0	39.5
41-64 years	27	1	1	1	7	60	5.8	11.4
≥ 65 years	*****	1	1	1	1	6	1.8	2.0
Lusutrombopag	441	3	7	7	7	74	8.1	5.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	4	7	7	7	7	6.4	1.3
25-40 years	*****	7	7	7	7	21	7.6	3.0
41-64 years	321	3	7	7	7	74	8.4	6.6
≥ 65 years	93	7	7	7	7	14	7.5	1.8

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Lutetium Lu 177 dotatate</i>	13,437	13,437	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Bictegravir embicitabine tenofovir alafenamide</i>	888,097	490,153	55.2%	232,035	26.1%	130,342	14.7%	24,175	2.7%	11,392	1.3%
<i>Tezacaftor and ivacaftor</i>	12,169	7,236	59.5%	3,053	25.1%	1,680	13.8%	171	1.4%	29	0.2%
<i>Apalutamide</i>	41,977	21,985	52.4%	11,251	26.8%	7,387	17.6%	1,070	2.5%	284	0.7%
<i>Ibalizumab-uiyk</i>	4,526	4,074	90.0%	197	4.4%	208	4.6%	31	0.7%	16	0.4%
<i>Tildrakizumab</i>	64,318	62,033	96.4%	1,605	2.5%	603	0.9%	61	0.1%	16	0.0%
<i>Burosumab-twza</i>	19,774	18,396	93.0%	721	3.6%	508	2.6%	95	0.5%	54	0.3%
<i>Fostamatinib</i>	2,797	1,532	54.8%	772	27.6%	426	15.2%	52	1.9%	15	0.5%
<i>Fosnetupitant and palonosetron</i>	158,078	157,379	99.6%	550	0.3%	*****	*****	*****	*****	0	0.0%
<i>Lofexidine hydrochloride</i>	2,263	2,155	95.2%	89	3.9%	*****	*****	*****	*****	0	0.0%
<i>Erenumab-aooe</i>	596,426	326,159	54.7%	163,134	27.4%	90,142	15.1%	12,476	2.1%	4,515	0.8%
<i>Sodium zirconium cyclosilicate</i>	186,726	123,449	66.1%	46,485	24.9%	15,046	8.1%	1,449	0.8%	297	0.2%
<i>Avatrombopag</i>	5,700	3,711	65.1%	1,270	22.3%	623	10.9%	83	1.5%	13	0.2%
<i>Pegvaliase-papz</i>	4,121	2,837	68.8%	846	20.5%	354	8.6%	61	1.5%	23	0.6%
<i>Baricitinib</i>	14,880	8,660	58.2%	3,805	25.6%	2,117	14.2%	234	1.6%	64	0.4%
<i>Moxidectin</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Cannabidiol</i>	68,418	34,600	50.6%	18,336	26.8%	11,055	16.2%	2,808	4.1%	1,619	2.4%
<i>Plazomicin</i>	620	620	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Binimetinib</i>	7,805	4,777	61.2%	1,994	25.5%	915	11.7%	99	1.3%	20	0.3%
<i>Encorafenib</i>	8,905	5,294	59.4%	2,346	26.3%	1,128	12.7%	117	1.3%	20	0.2%
<i>Tecovirimat</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ivosidenib</i>	3,853	1,927	50.0%	1,141	29.6%	697	18.1%	69	1.8%	19	0.5%
<i>Tafenoquine</i>	269	211	78.4%	47	17.5%	*****	*****	*****	*****	*****	*****
<i>Elagolix sodium</i>	57,556	36,587	63.6%	14,194	24.7%	6,229	10.8%	477	0.8%	69	0.1%
<i>Fish oil triglycerides</i>	5,508	5,396	98.0%	70	1.3%	*****	*****	*****	*****	*****	*****
<i>Lusutrombopag</i>	159	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Lutetium Lu 177 dotatate</i>	13,437	1	1	1	1	2	1.0	0.0
<i>Bictegravir embitcitabine tenofovir alafenamide</i>	888,097	1	30	30	90	2,409	89.2	154.4
<i>Tezacaftor and ivacaftor</i>	12,169	1	28	28	56	1,428	65.9	89.5
<i>Apalutamide</i>	41,977	1	30	30	90	2,042	85.9	124.4
<i>Ibalizumab-uiyk</i>	4,526	1	1	1	1	2,202	21.4	92.5
<i>Tildrakizumab</i>	64,318	1	1	1	1	1,092	5.6	30.7
<i>Burosumab-twza</i>	19,774	1	1	1	1	1,809	15.4	77.7
<i>Fostamatinib</i>	2,797	1	30	30	90	1,890	77.1	112.2
<i>Fosnetupitant and palonosetron</i>	158,078	1	1	1	1	525	1.5	6.3
<i>Lofexidine hydrochloride</i>	2,263	1	8	12	15	644	14.8	23.5
<i>Erenumab-aooe</i>	596,426	1	30	30	86	2,232	80.4	125.6
<i>Sodium zirconium cyclosilicate</i>	186,726	1	28	30	60	1,896	51.5	72.8
<i>Avatrombopag</i>	5,700	1	30	30	60	1,624	57.1	87.6
<i>Pegvaliase-pqpz</i>	4,121	1	30	30	60	1,638	60.9	108.1
<i>Baricitinib</i>	14,880	1	30	30	90	1,566	70.6	101.7
<i>Moxidectin</i>	0	-	-	-	-	-	-	-
<i>Cannabidiol</i>	68,418	1	30	30	90	2,092	107.2	191.7
<i>Plazomicin</i>	620	1	1	1	1	12	1.5	1.5
<i>Binimetinib</i>	7,805	1	30	30	60	1,860	64.6	88.0
<i>Encorafenib</i>	8,905	1	30	30	60	1,860	65.5	86.3
<i>Tecovirimat</i>	*****	14	14	14	14	14	14.0	0.0
<i>Ivosidenib</i>	3,853	1	30	30	90	1,440	79.8	107.3
<i>Tafenoquine</i>	269	1	1	14	30	835	30.0	73.5
<i>Elagolix sodium</i>	57,556	1	28	28	56	1,513	56.9	71.1
<i>Fish oil triglycerides</i>	5,508	1	1	1	1	975	3.8	23.8
<i>Lusutrombopag</i>	159	7	7	7	7	37	9.2	5.2

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Lutetium Lu 177 dotatate	13,437	13,437	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	6,598	6,598	49.1%	0	NaN	0	NaN	0	NaN	0	NaN
Male	6,839	6,839	50.9%	0	NaN	0	NaN	0	NaN	0	NaN
Bictegravir embitcitabine tenofovir alafenamide	888,097	490,153	100.0%	232,035	100.0%	130,342	100.0%	24,175	100.0%	11,392	100.0%
Female	234,282	132,181	27.0%	60,265	26.0%	33,325	25.6%	5,925	24.5%	2,586	22.7%
Male	653,815	357,972	73.0%	171,770	74.0%	97,017	74.4%	18,250	75.5%	8,806	77.3%
Tezacaftor and ivacaftor	12,169	7,236	100.0%	3,053	100.0%	1,680	100.0%	171	100.0%	29	100.0%
Female	6,128	3,683	50.9%	1,521	49.8%	826	49.2%	85	49.7%	13	44.8%
Male	6,041	3,553	49.1%	1,532	50.2%	854	50.8%	86	50.3%	16	55.2%
Apalutamide	41,977	21,985	100.0%	11,251	100.0%	7,387	100.0%	1,070	100.0%	284	100.0%
Female	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
Male	*****	21,985	100.0%	*****	*****	*****	*****	1,070	100.0%	284	100.0%
Ibalizumab-uiyk	4,526	4,074	100.0%	197	100.0%	208	100.0%	31	100.0%	16	100.0%
Female	1,420	1,329	32.6%	45	22.8%	*****	*****	*****	*****	0	0.0%
Male	3,106	2,745	67.4%	152	77.2%	*****	*****	*****	*****	16	100.0%
Tildrakizumab	64,318	62,033	100.0%	1,605	100.0%	603	100.0%	61	100.0%	16	100.0%
Female	32,839	31,658	51.0%	826	51.5%	320	53.1%	*****	*****	*****	*****
Male	31,479	30,375	49.0%	779	48.5%	283	46.9%	*****	*****	*****	*****
Burosumab-twza	19,774	18,396	100.0%	721	100.0%	508	100.0%	95	100.0%	54	100.0%
Female	11,949	11,033	60.0%	467	64.8%	353	69.5%	59	62.1%	37	68.5%
Male	7,825	7,363	40.0%	254	35.2%	155	30.5%	36	37.9%	17	31.5%

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Fostamatinib	2,797	1,532	100.0%	772	100.0%	426	100.0%	52	100.0%	15	100.0%
Female	1,763	965	63.0%	498	64.5%	259	60.8%	*****	*****	*****	*****
Male	1,034	567	37.0%	274	35.5%	167	39.2%	*****	*****	*****	*****
Fosnetupitant and palonosetron	158,078	157,379	100.0%	550	100.0%	*****	*****	*****	*****	0	NaN
Female	89,292	88,865	56.5%	334	60.7%	*****	*****	*****	*****	0	NaN
Male	68,786	68,514	43.5%	216	39.3%	*****	*****	*****	*****	0	NaN
Lofexidine hydrochloride	2,263	2,155	100.0%	89	100.0%	*****	*****	*****	*****	0	NaN
Female	1,105	1,057	49.0%	*****	*****	*****	*****	*****	*****	0	NaN
Male	1,158	1,098	51.0%	*****	*****	*****	*****	0	0.0%	0	NaN
Erenumab-aooe	596,426	326,159	100.0%	163,134	100.0%	90,142	100.0%	12,476	100.0%	4,515	100.0%
Female	511,814	280,181	85.9%	140,104	85.9%	77,107	85.5%	10,599	85.0%	3,823	84.7%
Male	84,612	45,978	14.1%	23,030	14.1%	13,035	14.5%	1,877	15.0%	692	15.3%
Sodium zirconium cyclosilicate	186,726	123,449	100.0%	46,485	100.0%	15,046	100.0%	1,449	100.0%	297	100.0%
Female	77,506	52,426	42.5%	18,528	39.9%	5,910	39.3%	525	36.2%	117	39.4%
Male	109,220	71,023	57.5%	27,957	60.1%	9,136	60.7%	924	63.8%	180	60.6%
Avatrombopag	5,700	3,711	100.0%	1,270	100.0%	623	100.0%	83	100.0%	13	100.0%
Female	2,881	1,889	50.9%	641	50.5%	303	48.6%	*****	*****	*****	*****
Male	2,819	1,822	49.1%	629	49.5%	320	51.4%	*****	*****	*****	*****
Pegvaliase-pqpz	4,121	2,837	100.0%	846	100.0%	354	100.0%	61	100.0%	23	100.0%
Female	1,994	1,320	46.5%	435	51.4%	199	56.2%	*****	*****	*****	*****
Male	2,127	1,517	53.5%	411	48.6%	155	43.8%	*****	*****	*****	*****

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Baricitinib	14,880	8,660	100.0%	3,805	100.0%	2,117	100.0%	234	100.0%	64	100.0%
Female	11,118	6,216	71.8%	3,028	79.6%	1,646	77.8%	180	76.9%	48	75.0%
Male	3,762	2,444	28.2%	777	20.4%	471	22.2%	54	23.1%	16	25.0%
Moxidectin	-	-	-	-	-	-	-	-	-	-	-
Female	-	-	-	-	-	-	-	-	-	-	-
Male	-	-	-	-	-	-	-	-	-	-	-
Cannabidiol	68,418	34,600	100.0%	18,336	100.0%	11,055	100.0%	2,808	100.0%	1,619	100.0%
Female	30,073	15,279	44.2%	8,099	44.2%	4,739	42.9%	1,230	43.8%	726	44.8%
Male	38,345	19,321	55.8%	10,237	55.8%	6,316	57.1%	1,578	56.2%	893	55.2%
Plazomicin	620	620	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	401	401	64.7%	0	NaN	0	NaN	0	NaN	0	NaN
Male	219	219	35.3%	0	NaN	0	NaN	0	NaN	0	NaN
Binimetinib	7,805	4,777	100.0%	1,994	100.0%	915	100.0%	99	100.0%	20	100.0%
Female	3,610	2,224	46.6%	920	46.1%	407	44.5%	*****	*****	*****	*****
Male	4,195	2,553	53.4%	1,074	53.9%	508	55.5%	*****	*****	*****	*****
Encorafenib	8,905	5,294	100.0%	2,346	100.0%	1,128	100.0%	117	100.0%	20	100.0%
Female	4,306	2,552	48.2%	1,129	48.1%	557	49.4%	*****	*****	*****	*****
Male	4,599	2,742	51.8%	1,217	51.9%	571	50.6%	*****	*****	*****	*****
Tecovirimat	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Female	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Ivosidenib	3,853	1,927	100.0%	1,141	100.0%	697	100.0%	69	100.0%	19	100.0%
Female	2,155	1,114	57.8%	599	52.5%	396	56.8%	*****	*****	*****	*****
Male	1,698	813	42.2%	542	47.5%	301	43.2%	*****	*****	*****	*****

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Tafenoquine	269	211	100.0%	47	100.0%	*****	*****	*****	*****	*****	*****
Female	168	133	63.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
Male	101	78	37.0%	*****	*****	*****	*****	*****	*****	*****	*****
Elagolix sodium	57,556	36,587	100.0%	14,194	100.0%	6,229	100.0%	477	100.0%	69	100.0%
Female	57,476	36,532	99.8%	*****	*****	*****	*****	*****	*****	69	100.0%
Male	80	55	0.2%	*****	*****	*****	*****	*****	*****	0	0.0%
Fish oil triglycerides	5,508	5,396	100.0%	70	100.0%	*****	*****	*****	*****	*****	*****
Female	2,961	2,906	53.9%	34	48.6%	*****	*****	*****	*****	*****	*****
Male	2,547	2,490	46.1%	36	51.4%	*****	*****	*****	*****	*****	*****
Lusutrombopag	159	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	99	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	60	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Lutetium Lu 177 dotatate	13,437	1	1	1	1	2	1.0	0.0
Female	6,598	1	1	1	1	2	1.0	0.0
Male	6,839	1	1	1	1	2	1.0	0.0
Bictegravir embicitabine tenofovir alafenamide	888,097	1	30	30	90	2,409	89.2	154.4
Female	234,282	1	30	30	90	2,311	84.8	142.6
Male	653,815	1	30	30	90	2,409	90.7	158.3
Tezacaftor and ivacaftor	12,169	1	28	28	56	1,428	65.9	89.5
Female	6,128	1	28	28	56	1,428	64.6	86.7
Male	6,041	1	28	28	56	1,282	67.2	92.2
Apalutamide	41,977	1	30	30	90	2,042	85.9	124.4
Female	*****	41	41	92	143	143	92.0	72.1
Male	*****	1	30	30	90	2,042	85.9	124.4
Ibalizumab-uiyk	4,526	1	1	1	1	2,202	21.4	92.5
Female	1,420	1	1	1	1	602	11.1	46.1
Male	3,106	1	1	1	1	2,202	26.0	106.9
Tildrakizumab	64,318	1	1	1	1	1,092	5.6	30.7
Female	32,839	1	1	1	1	924	5.6	29.7
Male	31,479	1	1	1	1	1,092	5.5	31.8
Burosumab-twza	19,774	1	1	1	1	1,809	15.4	77.7
Female	11,949	1	1	1	1	1,809	17.0	81.4
Male	7,825	1	1	1	1	1,779	13.0	71.5
Fostamatinib	2,797	1	30	30	90	1,890	77.1	112.2
Female	1,763	1	30	30	90	1,344	76.4	109.9
Male	1,034	1	30	30	90	1,890	78.3	116.1

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Fosnetupitant and palonosetron	158,078	1	1	1	1	525	1.5	6.3
Female	89,292	1	1	1	1	525	1.5	6.4
Male	68,786	1	1	1	1	448	1.5	6.2
Lofexidine hydrochloride	2,263	1	8	12	15	644	14.8	23.5
Female	1,105	1	8	11	15	644	14.7	27.0
Male	1,158	1	8	12	15	348	14.9	19.5
Erenumab-aooe	596,426	1	30	30	86	2,232	80.4	125.6
Female	511,814	1	30	30	86	2,232	80.1	125.1
Male	84,612	1	30	30	90	2,097	82.2	128.9
Sodium zirconium cyclosilicate	186,726	1	28	30	60	1,896	51.5	72.8
Female	77,506	1	22	30	60	1,896	49.1	70.4
Male	109,220	1	28	30	60	1,617	53.2	74.4
Avatrombopag	5,700	1	30	30	60	1,624	57.1	87.6
Female	2,881	1	30	30	60	1,624	56.3	89.5
Male	2,819	1	30	30	60	1,140	57.9	85.5
Pegvaliase-pqpz	4,121	1	30	30	60	1,638	60.9	108.1
Female	1,994	1	30	30	60	1,638	62.9	107.1
Male	2,127	1	30	30	56	1,458	59.0	109.1
Baricitinib	14,880	1	30	30	90	1,566	70.6	101.7
Female	11,118	1	30	30	90	1,566	73.7	102.8
Male	3,762	1	30	30	60	1,421	61.6	97.9
Moxidectin	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days					
		Minimum	Q1	Median	Q3	Maximum	Standard Deviation
Cannabidiol	68,418	1	30	30	90	2,092	107.2
Female	30,073	1	30	30	90	2,092	107.1
Male	38,345	1	30	30	90	2,076	107.3
Plazomicin	620	1	1	1	1	12	1.5
Female	401	1	1	1	1	10	1.5
Male	219	1	1	1	1	12	1.4
Binimetinib	7,805	1	30	30	60	1,860	64.6
Female	3,610	1	30	30	60	1,860	65.0
Male	4,195	1	30	30	60	1,347	64.3
Encorafenib	8,905	1	30	30	60	1,860	65.5
Female	4,306	1	30	30	60	1,860	66.4
Male	4,599	1	30	30	60	1,109	64.6
Tecovirimat	*****	14	14	14	14	14	14.0
Female	0	NaN	NaN	NaN	NaN	NaN	NaN
Male	*****	14	14	14	14	14	14.0
Ivosidenib	3,853	1	30	30	90	1,440	79.8
Female	2,155	2	30	30	90	1,170	77.0
Male	1,698	1	30	46	90	1,440	83.4
Tafenoquine	269	1	1	14	30	835	30.0
Female	168	1	1	6	30	196	22.5
Male	101	1	2	21	30	835	42.5
Elagolix sodium	57,556	1	28	28	56	1,513	56.9
Female	57,476	1	28	28	56	1,513	56.9
Male	80	16	28	28	56	392	55.4

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Fish oil triglycerides	5,508	1	1	1	1	975	3.8	23.8
Female	2,961	1	1	1	1	975	3.6	23.8
Male	2,547	1	1	1	1	737	4.1	23.9
Lusutrombopag	159	7	7	7	7	37	9.2	5.2
Female	99	7	7	7	14	28	9.9	5.2
Male	60	7	7	7	7	37	8.0	4.9

*NaN: Not a number

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Lutetium Lu 177 dotatate	13,437	13,437	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	228	228	1.7%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	3,105	3,105	23.1%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	10,083	10,083	75.0%	0	NaN	0	NaN	0	NaN	0	NaN
Bictegravir embitcitabine tenofovir alafenamide	888,097	490,153	100.0%	232,035	100.0%	130,342	100.0%	24,175	100.0%	11,392	100.0%
0-17 years	4,553	2,645	0.5%	1,144	0.5%	638	0.5%	102	0.4%	24	0.2%
18-24 years	42,716	26,360	5.4%	10,754	4.6%	4,746	3.6%	679	2.8%	177	1.6%
25-40 years	264,447	158,155	32.3%	67,059	28.9%	32,363	24.8%	5,142	21.3%	1,728	15.2%
41-64 years	473,177	252,574	51.5%	125,205	54.0%	73,647	56.5%	14,523	60.1%	7,228	63.4%
≥ 65 years	103,204	50,419	10.3%	27,873	12.0%	18,948	14.5%	3,729	15.4%	2,235	19.6%
Tezacaftor and ivacaftor	12,169	7,236	100.0%	3,053	100.0%	1,680	100.0%	171	100.0%	29	100.0%
0-17 years	4,363	2,528	34.9%	1,123	36.8%	631	37.6%	*****	*****	*****	*****
18-24 years	2,274	1,449	20.0%	538	17.6%	265	15.8%	*****	*****	*****	*****
25-40 years	4,150	2,554	35.3%	1,047	34.3%	492	29.3%	*****	*****	*****	*****
41-64 years	1,229	651	9.0%	309	10.1%	*****	*****	*****	*****	*****	*****
≥ 65 years	153	54	0.7%	36	1.2%	*****	*****	*****	*****	0	0.0%
Apalutamide	41,977	21,985	100.0%	11,251	100.0%	7,387	100.0%	1,070	100.0%	284	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	13	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	4,439	*****	*****	*****	*****	*****	*****	103	9.6%	31	10.9%
≥ 65 years	37,525	19,572	89.0%	10,052	89.3%	6,681	90.4%	967	90.4%	253	89.1%
Ibalizumab-uiyk	4,526	4,074	100.0%	197	100.0%	208	100.0%	31	100.0%	16	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	93	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	738	666	16.3%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	3,002	2,682	65.8%	146	74.1%	141	67.8%	*****	*****	*****	*****
≥ 65 years	693	*****	*****	19	9.6%	28	13.5%	*****	*****	*****	*****
Tildrakizumab	64,318	62,033	100.0%	1,605	100.0%	603	100.0%	61	100.0%	16	100.0%
0-17 years	12	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	229	*****	*****	*****	*****	21	3.5%	*****	*****	0	0.0%
25-40 years	1,411	1,023	1.6%	275	17.1%	*****	*****	*****	*****	0	0.0%
41-64 years	4,676	3,680	5.9%	713	44.4%	251	41.6%	*****	*****	*****	*****
≥ 65 years	57,990	57,162	92.1%	569	35.5%	221	36.7%	*****	*****	*****	*****
Burosumab-twza	19,774	18,396	100.0%	721	100.0%	508	100.0%	95	100.0%	54	100.0%
0-17 years	11,050	10,054	54.7%	515	71.4%	378	74.4%	73	76.8%	30	55.6%
18-24 years	937	877	4.8%	37	5.1%	*****	*****	*****	*****	*****	*****
25-40 years	2,643	2,539	13.8%	53	7.4%	*****	*****	*****	*****	*****	*****
41-64 years	3,188	3,038	16.5%	79	11.0%	54	10.6%	*****	*****	*****	*****
≥ 65 years	1,956	1,888	10.3%	37	5.1%	*****	*****	*****	*****	*****	*****
Fostamatinib	2,797	1,532	100.0%	772	100.0%	426	100.0%	52	100.0%	15	100.0%
0-17 years	19	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	121	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	393	262	17.1%	74	9.6%	*****	*****	*****	*****	*****	*****

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	1,048	574	37.5%	294	38.1%	160	37.6%	*****	*****	*****	*****
≥ 65 years	1,216	611	39.9%	362	46.9%	201	47.2%	*****	*****	*****	*****
Fosnetupitant and palonosetron	158,078	157,379	100.0%	550	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	3,612	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	32,451	32,383	20.6%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	121,571	120,948	76.9%	486	88.4%	*****	*****	*****	*****	0	NaN
Lofexidine hydrochloride	2,263	2,155	100.0%	89	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	908	879	40.8%	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	998	942	43.7%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	236	218	10.1%	*****	*****	*****	*****	0	0.0%	0	NaN
Erenumab-aooe	596,426	326,159	100.0%	163,134	100.0%	90,142	100.0%	12,476	100.0%	4,515	100.0%
0-17 years	3,237	1,860	0.6%	817	0.5%	466	0.5%	76	0.6%	18	0.4%
18-24 years	29,077	16,993	5.2%	7,835	4.8%	3,744	4.2%	397	3.2%	108	2.4%
25-40 years	149,788	85,255	26.1%	40,322	24.7%	20,768	23.0%	2,583	20.7%	860	19.0%
41-64 years	312,121	170,179	52.2%	84,797	52.0%	47,644	52.9%	6,899	55.3%	2,602	57.6%
≥ 65 years	102,203	51,872	15.9%	29,363	18.0%	17,520	19.4%	2,521	20.2%	927	20.5%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sodium zirconium cyclosilicate	186,726	123,449	100.0%	46,485	100.0%	15,046	100.0%	1,449	100.0%	297	100.0%
0-17 years	84	61	0.0%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	514	344	0.3%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	7,853	5,160	4.2%	2,001	4.3%	631	4.2%	*****	*****	*****	*****
41-64 years	54,807	36,434	29.5%	13,412	28.9%	4,433	29.5%	*****	*****	*****	*****
≥ 65 years	123,468	81,450	66.0%	30,931	66.5%	9,933	66.0%	952	65.7%	202	68.0%
Avatrombopag	5,700	3,711	100.0%	1,270	100.0%	623	100.0%	83	100.0%	13	100.0%
0-17 years	22	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	263	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	508	328	8.8%	112	8.8%	*****	*****	*****	*****	*****	*****
41-64 years	2,114	1,458	39.3%	427	33.6%	193	31.0%	*****	*****	*****	*****
≥ 65 years	2,793	1,727	46.5%	671	52.8%	344	55.2%	*****	*****	*****	*****
Pegvaliase-pqpz	4,121	2,837	100.0%	846	100.0%	354	100.0%	61	100.0%	23	100.0%
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	1,101	778	27.4%	237	28.0%	70	19.8%	*****	*****	*****	*****
25-40 years	1,681	1,184	41.7%	330	39.0%	133	37.6%	*****	*****	*****	*****
41-64 years	1,097	723	25.5%	230	27.2%	121	34.2%	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
Baricitinib	14,880	8,660	100.0%	3,805	100.0%	2,117	100.0%	234	100.0%	64	100.0%
0-17 years	329	186	2.1%	73	1.9%	*****	*****	*****	*****	*****	*****
18-24 years	881	537	6.2%	230	6.0%	*****	*****	*****	*****	0	0.0%
25-40 years	2,340	1,425	16.5%	605	15.9%	277	13.1%	*****	*****	*****	*****
41-64 years	7,555	4,358	50.3%	1,930	50.7%	1,126	53.2%	*****	*****	*****	*****

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	3,775	2,154	24.9%	967	25.4%	545	25.7%	84	35.9%	25	39.1%
Moxidectin		-	-	-	-	-	-	-	-	-	-
0-17 years		-	-	-	-	-	-	-	-	-	-
18-24 years		-	-	-	-	-	-	-	-	-	-
25-40 years		-	-	-	-	-	-	-	-	-	-
41-64 years		-	-	-	-	-	-	-	-	-	-
≥ 65 years		-	-	-	-	-	-	-	-	-	-
Cannabidiol	68,418	34,600	100.0%	18,336	100.0%	11,055	100.0%	2,808	100.0%	1,619	100.0%
0-17 years	32,905	16,456	47.6%	8,849	48.3%	5,366	48.5%	1,467	52.2%	767	47.4%
18-24 years	11,246	5,771	16.7%	2,914	15.9%	1,872	16.9%	463	16.5%	226	14.0%
25-40 years	15,520	8,033	23.2%	4,077	22.2%	2,468	22.3%	564	20.1%	378	23.3%
41-64 years	8,167	4,019	11.6%	2,348	12.8%	1,274	11.5%	291	10.4%	235	14.5%
≥ 65 years	580	321	0.9%	148	0.8%	75	0.7%	23	0.8%	13	0.8%
Plazomicin	620	620	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	59	59	9.5%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	25	25	4.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	536	536	86.5%	0	NaN	0	NaN	0	NaN	0	NaN
Binimetinib	7,805	4,777	100.0%	1,994	100.0%	915	100.0%	99	100.0%	20	100.0%
0-17 years	48	30	0.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	68	41	0.9%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	731	458	9.6%	193	9.7%	*****	*****	*****	*****	*****	*****
41-64 years	2,773	1,750	36.6%	652	32.7%	331	36.2%	*****	*****	*****	*****

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	4,185	2,498	52.3%	1,116	56.0%	506	55.3%	*****	*****	*****	*****
Encorafenib	8,905	5,294	100.0%	2,346	100.0%	1,128	100.0%	117	100.0%	20	100.0%
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	747	455	8.6%	200	8.5%	*****	*****	*****	*****	*****	*****
41-64 years	3,036	1,852	35.0%	769	32.8%	369	32.7%	*****	*****	*****	*****
≥ 65 years	5,058	2,950	55.7%	1,357	57.8%	675	59.8%	*****	*****	*****	*****
Tecovirimat	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Ivosidenib	3,853	1,927	100.0%	1,141	100.0%	697	100.0%	69	100.0%	19	100.0%
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
25-40 years	346	158	8.2%	113	9.9%	*****	*****	*****	*****	*****	*****
41-64 years	833	450	23.4%	231	20.2%	127	18.2%	*****	*****	*****	*****
≥ 65 years	2,600	1,277	66.3%	773	67.7%	497	71.3%	*****	*****	*****	*****
Tafenoquine	269	211	100.0%	47	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	15	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
18-24 years	11	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	98	82	38.9%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	127	96	45.5%	*****	*****	*****	*****	0	0.0%	*****	*****

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	18	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Elagolix sodium	57,556	36,587	100.0%	14,194	100.0%	6,229	100.0%	477	100.0%	69	100.0%
0-17 years	*****	609	1.7%	245	1.7%	103	1.7%	*****	*****	*****	*****
18-24 years	9,686	6,282	17.2%	2,353	16.6%	970	15.6%	*****	*****	*****	*****
25-40 years	33,703	21,613	59.1%	8,191	57.7%	3,606	57.9%	257	53.9%	36	52.2%
41-64 years	13,190	8,082	22.1%	3,404	24.0%	1,548	24.9%	140	29.4%	16	23.2%
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
Fish oil triglycerides	5,508	5,396	100.0%	70	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	4,717	4,612	85.5%	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	408	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	171	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	162	162	3.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	50	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
Lusutrombopag	159	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	21	21	13.3%	0	0.0%	0	NaN	0	NaN	0	NaN

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lutetium Lu 177 dotatate	13,437	1	1	1	1	2	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	228	1	1	1	1	1	1.0	0.0
41-64 years	3,105	1	1	1	1	2	1.0	0.0
≥ 65 years	10,083	1	1	1	1	2	1.0	0.0
Bictegravir embitcitabine tenofovir alafenamide	888,097	1	30	30	90	2,409	89.2	154.4
0-17 years	4,553	1	30	30	65	1,779	75.3	113.3
18-24 years	42,716	1	30	30	60	2,167	66.8	98.8
25-40 years	264,447	1	30	30	60	2,369	73.4	116.9
41-64 years	473,177	1	30	30	90	2,409	95.4	165.5
≥ 65 years	103,204	1	30	46	90	2,311	110.9	196.0
Tezacaftor and ivacaftor	12,169	1	28	28	56	1,428	65.9	89.5
0-17 years	4,363	1	28	28	60	1,282	68.6	92.8
18-24 years	2,274	1	28	28	56	1,327	57.9	78.6
25-40 years	4,150	1	28	28	56	1,428	60.8	81.1
41-64 years	1,229	3	28	28	84	1,107	80.8	109.2
≥ 65 years	153	11	28	56	168	682	126.1	135.4
Apalutamide	41,977	1	30	30	90	2,042	85.9	124.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	13	19	30	30	60	120	45.4	27.1
41-64 years	4,439	1	30	30	90	1,441	81.7	121.2
≥ 65 years	37,525	1	30	30	90	2,042	86.4	124.8

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Ibalizumab-uiyk	4,526	1	1	1	1	2,202	21.4	92.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	93	1	1	1	1	406	8.0	43.7
25-40 years	738	1	1	1	1	588	17.1	55.7
41-64 years	3,002	1	1	1	1	2,202	23.1	101.3
≥ 65 years	693	1	1	1	1	1,351	20.1	88.4
Tildrakizumab	64,318	1	1	1	1	1,092	5.6	30.7
0-17 years	12	1	16	84	126	252	89.3	90.3
18-24 years	229	1	1	1	84	420	35.2	61.2
25-40 years	1,411	1	1	1	34	534	33.3	64.4
41-64 years	4,676	1	1	1	28	952	27.9	68.7
≥ 65 years	57,990	1	1	1	1	1,092	3.0	21.9
Burosumab-twza	19,774	1	1	1	1	1,809	15.4	77.7
0-17 years	11,050	1	1	1	1	1,809	19.0	78.1
18-24 years	937	1	1	1	1	1,729	14.2	82.4
25-40 years	2,643	1	1	1	1	1,779	9.6	71.1
41-64 years	3,188	1	1	1	1	1,729	12.4	87.9
≥ 65 years	1,956	1	1	1	1	1,515	7.9	61.0
Fostamatinib	2,797	1	30	30	90	1,890	77.1	112.2
0-17 years	19	29	30	30	90	300	72.4	78.5
18-24 years	121	11	30	30	60	505	55.5	63.0
25-40 years	393	1	30	30	60	861	60.7	81.8
41-64 years	1,048	2	30	30	69	1,890	74.4	107.2
≥ 65 years	1,216	1	30	30	90	1,344	87.0	127.2

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Fosnetupitant and palonosetron	158,078	1	1	1	1	525	1.5	6.3
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	3,612	1	1	1	1	112	1.2	3.9
41-64 years	32,451	1	1	1	1	168	1.2	3.6
≥ 65 years	121,571	1	1	1	1	525	1.6	6.9
Lofexidine hydrochloride	2,263	1	8	12	15	644	14.8	23.5
0-17 years	*****	14	14	14	14	70	23.3	22.9
18-24 years	*****	1	7	9	14	60	11.9	8.6
25-40 years	908	1	8	12	14	375	13.6	17.5
41-64 years	998	1	8	12	15	644	15.2	26.3
≥ 65 years	236	2	9	12	16	348	19.2	33.5
Erenumab-aooe	596,426	1	30	30	86	2,232	80.4	125.6
0-17 years	3,237	1	28	30	84	1,470	76.3	116.3
18-24 years	29,077	1	28	30	60	1,732	67.8	97.9
25-40 years	149,788	1	30	30	84	2,232	73.6	112.4
41-64 years	312,121	1	30	30	88	2,201	81.9	129.5
≥ 65 years	102,203	1	30	30	90	2,097	89.2	138.1
Sodium zirconium	186,726	1	28	30	60	1,896	51.5	72.8
0-17 years	84	2	30	30	49	533	56.1	81.0
18-24 years	514	1	30	30	60	420	48.2	49.1
25-40 years	7,853	1	29	30	60	1,245	51.7	69.3
41-64 years	54,807	1	28	30	60	1,617	51.4	72.8
≥ 65 years	123,468	1	26	30	60	1,896	51.5	73.1

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Avatrombopag	5,700	1	30	30	60	1,624	57.1	87.6
0-17 years	22	15	30	30	105	310	74.1	77.9
18-24 years	263	3	30	30	60	455	47.4	54.3
25-40 years	508	1	30	30	60	914	58.4	80.6
41-64 years	2,114	1	15	30	60	1,115	51.6	81.9
≥ 65 years	2,793	1	30	30	60	1,624	61.8	94.9
Pegvaliase-pqpz	4,121	1	30	30	60	1,638	60.9	108.1
0-17 years	*****	7	30	30	60	868	73.0	115.0
18-24 years	1,101	1	30	30	56	1,458	52.9	87.5
25-40 years	1,681	1	30	30	56	1,403	59.8	108.9
41-64 years	1,097	1	30	30	60	1,638	67.4	121.8
≥ 65 years	*****	7	30	60	150	480	142.1	188.0
Baricitinib	14,880	1	30	30	90	1,566	70.6	101.7
0-17 years	329	1	30	30	90	1,205	82.9	127.4
18-24 years	881	1	30	30	60	667	61.0	67.5
25-40 years	2,340	1	30	30	60	1,566	63.4	82.9
41-64 years	7,555	1	30	30	90	1,350	71.7	100.4
≥ 65 years	3,775	1	30	30	90	1,440	74.0	117.4
Moxidectin	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Cannabidiol	68,418	1	30	30	90	2,092	107.2	191.7
0-17 years	32,905	1	30	30	90	2,092	107.5	180.6
18-24 years	11,246	1	30	30	90	2,012	103.6	175.5
25-40 years	15,520	1	30	30	90	1,999	106.9	205.0
41-64 years	8,167	1	30	31	90	1,970	112.4	227.4
≥ 65 years	580	2	30	30	82	1,854	97.7	187.1
Plazomicin	620	1	1	1	1	12	1.5	1.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	59	1	1	1	1	5	1.1	0.5
41-64 years	25	1	1	3	7	12	3.8	3.1
≥ 65 years	536	1	1	1	1	10	1.4	1.4
Binimetinib	7,805	1	30	30	60	1,860	64.6	88.0
0-17 years	48	14	30	30	60	280	53.8	52.0
18-24 years	68	7	30	30	60	559	61.7	85.0
25-40 years	731	2	30	30	60	967	61.2	83.9
41-64 years	2,773	1	30	30	60	1,860	64.3	94.5
≥ 65 years	4,185	1	30	30	60	1,120	65.6	84.5
Encorafenib	8,905	1	30	30	60	1,860	65.5	86.3
0-17 years	*****	30	30	31	69	270	65.9	74.7
18-24 years	*****	7	30	30	60	557	60.2	78.6
25-40 years	747	2	30	30	60	1,109	63.5	91.1
41-64 years	3,036	1	30	30	60	1,860	64.8	91.7
≥ 65 years	5,058	1	30	30	60	1,110	66.2	82.2

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Tecovirimat	*****	14	14	14	14	14	14.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	14	14	14	14	14	14.0	NaN
41-64 years	*****	14	14	14	14	14	14.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Ivosidenib	3,853	1	30	30	90	1,440	79.8	107.3
0-17 years	*****	28	28	36	54	54	39.3	13.3
18-24 years	*****	1	30	30	60	750	62.9	93.0
25-40 years	346	4	30	43	90	956	80.0	97.0
41-64 years	833	2	30	30	90	1,200	79.8	117.9
≥ 65 years	2,600	2	30	40	90	1,440	80.4	105.5
Tafenoquine	269	1	1	14	30	835	30.0	73.5
0-17 years	15	1	1	7	36	404	43.0	102.2
18-24 years	11	1	1	2	31	76	18.7	23.9
25-40 years	98	1	1	2	30	610	24.7	70.1
41-64 years	127	1	1	21	30	835	34.6	79.7
≥ 65 years	18	1	3	28	28	63	23.2	20.8
Elagolix sodium	57,556	1	28	28	56	1,513	56.9	71.1
0-17 years	*****	1	28	28	56	1,094	61.8	97.3
18-24 years	9,686	1	28	28	56	1,174	54.8	66.9
25-40 years	33,703	1	28	28	56	1,513	56.0	69.7
41-64 years	13,190	1	28	28	56	1,096	60.3	75.2
≥ 65 years	*****	28	56	112	112	420	145.6	157.6

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Fish oil triglycerides	5,508	1	1	1	1	975	3.8	23.8
0-17 years	4,717	1	1	1	1	975	4.1	25.3
18-24 years	408	1	1	1	1	187	2.8	14.3
25-40 years	171	1	1	1	1	31	3.0	4.8
41-64 years	162	1	1	1	1	5	1.1	0.6
≥ 65 years	50	1	1	1	1	96	3.5	13.5
Lusutrombopag	159	7	7	7	7	37	9.2	5.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	7	7	7	7	30	9.3	7.3
41-64 years	128	7	7	7	7	37	9.4	5.3
≥ 65 years	*****	7	7	7	7	14	7.8	2.2

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Lutetium Lu 177 dotatate</i>	13,437	2	55	55	61	2,095	78.2	134.2
<i>Bictegravir embitcitabine tenofovir alafenamide</i>	888,097	1	3	8	21	2,231	27.9	81.5
<i>Tezacaftor and ivacaftor</i>	12,169	1	3	7	18	1,596	21.2	60.3
<i>Apalutamide</i>	41,977	1	3	6	18	1,962	22.8	72.7
<i>Ibalizumab-uiyk</i>	4,526	1	13	13	13	1,117	16.3	40.7
<i>Tildrakizumab</i>	64,318	1	83	83	90	1,378	83.6	50.1
<i>Burosumab-twza</i>	19,774	1	13	27	28	1,335	26.8	36.9
<i>Fostamatinib</i>	2,797	1	3	6	16	872	21.7	65.2
<i>Fosnetupitant and palonosetron</i>	158,078	1	13	19	20	1,658	21.8	47.5
<i>Lofexidine hydrochloride</i>	2,263	1	10	28	95	1,529	87.8	155.4
<i>Erenumab-aooe</i>	596,426	1	3	7	21	2,186	27.4	81.8
<i>Sodium zirconium cyclosilicate</i>	186,726	1	5	17	50	1,815	54.3	112.9
<i>Avatrombopag</i>	5,700	1	4	12	35	1,394	46.6	118.8
<i>Pegvaliase-pqpz</i>	4,121	1	4	9	19	1,849	20.2	60.4
<i>Baricitinib</i>	14,880	1	3	7	18	1,538	22.6	65.5
<i>Moxidectin</i>	0	-	-	-	-	-	-	-
<i>Cannabidiol</i>	68,418	1	3	7	18	1,882	25.0	71.0
<i>Plazomicin</i>	620	1	4	6	7	1,100	30.1	103.8
<i>Binimetinib</i>	7,805	1	3	8	23	1,467	26.2	71.8
<i>Encorafenib</i>	8,905	1	3	8	20	1,467	24.7	69.8
<i>Tecovirimat</i>	*****	15	15	36	56	56	35.5	29.0
<i>Ivosidenib</i>	3,853	1	2	5	15	1,359	22.0	64.3
<i>Tafenoquine</i>	269	1	10	27	56	1,629	65.3	145.5
<i>Elagolix sodium</i>	57,556	1	3	7	20	1,877	27.8	84.4
<i>Fish oil triglycerides</i>	5,508	1	3	6	6	573	7.7	21.3

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Lutetium Lu 177 dotatate	13,437	2	55	55	61	2,095	78.2	134.2
Female	6,598	4	55	55	61	1,898	79.0	136.5
Male	6,839	2	55	55	62	2,095	77.5	131.9
Bictegravir embitcitabine tenofovir alafenamide	888,097	1	3	8	21	2,231	27.9	81.5
Female	234,282	1	3	8	23	2,089	28.6	79.0
Male	653,815	1	3	8	21	2,231	27.6	82.4
Tezacaftor and ivacaftor	12,169	1	3	7	18	1,596	21.2	60.3
Female	6,128	1	3	7	19	1,596	23.0	68.5
Male	6,041	1	3	7	17	1,539	19.4	50.5
Apalutamide	41,977	1	3	6	18	1,962	22.8	72.7
Female	*****	1	1	5	9	9	5.0	5.7
Male	*****	1	3	6	18	1,962	22.8	72.7
Ibalizumab-uiyk	4,526	1	13	13	13	1,117	16.3	40.7
Female	1,420	1	13	13	13	898	17.8	45.8
Male	3,106	1	12	13	13	1,117	15.6	38.2
Tildrakizumab	64,318	1	83	83	90	1,378	83.6	50.1
Female	32,839	1	83	83	90	1,378	83.3	52.3
Male	31,479	1	83	83	90	1,299	84.0	47.6
Burosumab-twza	19,774	1	13	27	28	1,335	26.8	36.9
Female	11,949	1	14	27	28	1,335	27.3	39.5
Male	7,825	1	13	27	28	1,306	25.9	32.5
Fostamatinib	2,797	1	3	6	16	872	21.7	65.2
Female	1,763	1	3	6	16	836	19.7	57.7
Male	1,034	1	3	7	17	872	25.0	76.2

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Fosnetupitant and palonosetron	158,078	1	13	19	20	1,658	21.8	47.5
Female	89,292	1	13	20	20	1,658	22.5	49.9
Male	68,786	1	13	13	20	1,381	20.9	44.2
Lofexidine hydrochloride	2,263	1	10	28	95	1,529	87.8	155.4
Female	1,105	1	10	28	93	1,504	86.8	158.1
Male	1,158	1	11	27	99	1,529	88.7	152.9
Erenumab-aooe	596,426	1	3	7	21	2,186	27.4	81.8
Female	511,814	1	3	7	21	2,179	27.6	82.2
Male	84,612	1	3	7	21	2,186	26.6	79.5
Sodium zirconium cyclosilicate	186,726	1	5	17	50	1,815	54.3	112.9
Female	77,506	1	5	17	51	1,815	55.4	114.1
Male	109,220	1	5	16	49	1,691	53.6	112.1
Avatrombopag	5,700	1	4	12	35	1,394	46.6	118.8
Female	2,881	1	4	13	37	1,394	49.0	124.2
Male	2,819	1	4	10	32	1,359	44.1	113.0
Pegvaliase-pqpz	4,121	1	4	9	19	1,849	20.2	60.4
Female	1,994	1	4	8	19	981	19.5	51.2
Male	2,127	1	4	9	19	1,849	20.8	67.9
Baricitinib	14,880	1	3	7	18	1,538	22.6	65.5
Female	11,118	1	3	7	19	1,538	23.3	67.2
Male	3,762	1	3	7	16	1,478	20.4	60.3
Moxidectin	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Cannabidiol	68,418	1	3	7	18	1,882	25.0	71.0
Female	30,073	1	3	7	18	1,699	25.4	71.5
Male	38,345	1	3	7	18	1,882	24.8	70.7
Plazomicin	620	1	4	6	7	1,100	30.1	103.8
Female	401	1	3	6	10	1,019	28.6	90.0
Male	219	1	5	6	6	1,100	33.0	125.4
Binimetinib	7,805	1	3	8	23	1,467	26.2	71.8
Female	3,610	1	3	9	24	1,401	26.6	69.2
Male	4,195	1	3	8	21	1,467	25.8	73.9

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Encorafenib	8,905	1	3	8	20	1,467	24.7	69.8
Female	4,306	1	3	8	21	1,401	24.6	68.0
Male	4,599	1	3	8	20	1,467	24.9	71.4
Tecovirimat	*****	15	15	36	56	56	35.5	29.0
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	*****	15	15	36	56	56	35.5	29.0
Ivosidenib	3,853	1	2	5	15	1,359	22.0	64.3
Female	2,155	1	2	5	15	1,277	22.0	61.9
Male	1,698	1	2	5	15	1,359	21.9	67.2
Tafenoquine	269	1	10	27	56	1,629	65.3	145.5
Female	168	1	13	31	58	1,629	60.9	142.1
Male	101	1	6	20	48	798	72.6	151.4
Elagolix sodium	57,556	1	3	7	20	1,877	27.8	84.4
Female	57,476	1	3	7	20	1,877	27.8	84.4
Male	80	1	4	8	21	578	34.5	97.8
Fish oil triglycerides	5,508	1	3	6	6	573	7.7	21.3
Female	2,961	1	3	6	6	281	7.6	16.6
Male	2,547	1	3	6	6	573	7.8	25.8
Lusutrombopag	159	1	16	59	160	1,186	131.6	199.8
Female	99	1	9	36	116	1,186	116.9	207.0
Male	60	1	43	79	182	770	155.8	186.4

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Lutetium Lu 177 dotatate	13,437	2	55	55	61	2,095	78.2	134.2
0-17 years	*****	55	55	55	55	55	55.0	0.0
18-24 years	*****	54	55	55	66	153	65.9	25.3
25-40 years	228	50	55	55	62	658	65.8	47.0
41-64 years	3,105	4	55	55	61	2,095	75.7	121.9
≥ 65 years	10,083	2	55	55	61	2,070	79.3	139.2
Bictegravir embitcitabine tenofovir alafenamide	888,097	1	3	8	21	2,231	27.9	81.5
0-17 years	4,553	1	3	8	23	1,698	26.8	71.6
18-24 years	42,716	1	4	10	27	1,778	34.0	83.9
25-40 years	264,447	1	4	10	26	2,162	32.4	85.9
41-64 years	473,177	1	3	7	20	2,231	26.4	80.6
≥ 65 years	103,204	1	2	5	15	2,080	20.5	72.1
Tezacaftor and ivacaftor	12,169	1	3	7	18	1,596	21.2	60.3
0-17 years	4,363	1	3	7	16	721	18.3	39.4
18-24 years	2,274	1	3	8	21	1,519	23.0	55.3
25-40 years	4,150	1	3	7	18	1,558	22.5	67.9
41-64 years	1,229	1	3	6	15	1,596	23.0	90.8
≥ 65 years	153	1	2	6	15	763	31.7	88.3
Apalutamide	41,977	1	3	6	18	1,962	22.8	72.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	13	1	1	4	11	42	10.8	13.8
41-64 years	4,439	1	3	6	16	1,243	19.5	56.5
≥ 65 years	37,525	1	3	6	19	1,962	23.2	74.4
Ibalizumab-uiyk	4,526	1	13	13	13	1,117	16.3	40.7

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	93	3	13	13	14	111	18.3	17.4
25-40 years	738	1	13	13	14	898	20.3	59.4
41-64 years	3,002	1	13	13	13	1,117	16.0	39.8
≥ 65 years	693	1	13	13	13	263	13.0	11.9
Tildrakizumab	64,318	1	83	83	90	1,378	83.6	50.1
0-17 years	12	2	9	28	57	206	47.2	59.8
18-24 years	229	1	39	83	91	645	76.6	59.3
25-40 years	1,411	1	28	83	91	1,298	79.1	84.6
41-64 years	4,676	1	34	83	91	952	78.2	68.0
≥ 65 years	57,990	1	83	83	90	1,378	84.2	47.1
Burosumab-twza	19,774	1	13	27	28	1,335	26.8	36.9
0-17 years	11,050	1	13	24	28	1,335	24.0	35.2
18-24 years	937	1	25	27	31	821	34.3	54.3
25-40 years	2,643	1	27	27	30	1,083	31.1	36.3
41-64 years	3,188	1	26	27	29	1,248	29.6	43.3
≥ 65 years	1,956	1	27	27	28	433	28.5	20.7
Fostamatinib	2,797	1	3	6	16	872	21.7	65.2
0-17 years	19	1	2	3	6	69	10.1	17.9
18-24 years	121	1	4	9	23	449	24.3	49.6
25-40 years	393	1	4	8	19	689	28.0	71.7
41-64 years	1,048	1	3	6	14	872	20.3	63.1
≥ 65 years	1,216	1	3	6	16	836	20.8	66.6
Fosnetupitant and palonosetron	158,078	1	13	19	20	1,658	21.8	47.5
0-17 years	*****	2	11	20	20	20	15.5	9.0

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	*****	2	13	13	20	121	17.0	10.9
25-40 years	3,612	1	13	17	20	825	19.8	32.6
41-64 years	32,451	1	13	14	20	1,434	20.5	41.1
≥ 65 years	121,571	1	13	19	20	1,658	22.3	49.5
Lofexidine hydrochloride	2,263	1	10	28	95	1,529	87.8	155.4
0-17 years	*****	20	31	47	59	114	52.8	33.7
18-24 years	*****	1	12	50	151	1,529	115.6	185.1
25-40 years	908	1	10	27	92	1,275	85.8	149.9
41-64 years	998	1	10	27	92	1,504	86.1	154.7
≥ 65 years	236	1	12	24	83	1,070	89.6	164.7
Erenumab-aooe	596,426	1	3	7	21	2,186	27.4	81.8
0-17 years	3,237	1	3	7	19	1,230	22.7	60.5
18-24 years	29,077	1	3	7	20	1,786	26.0	75.9
25-40 years	149,788	1	3	7	21	1,978	26.8	78.9
41-64 years	312,121	1	3	7	22	2,186	28.0	83.1
≥ 65 years	102,203	1	3	6	20	1,990	27.2	84.1
Sodium zirconium	186,726	1	5	17	50	1,815	54.3	112.9
0-17 years	84	1	6	15	50	814	49.5	104.8
18-24 years	514	1	6	21	81	1,446	72.0	126.1
25-40 years	7,853	1	6	22	71	1,744	73.6	142.4
41-64 years	54,807	1	5	17	53	1,683	58.6	120.0
≥ 65 years	123,468	1	5	16	47	1,815	51.1	107.2
Avatrombopag	5,700	1	4	12	35	1,394	46.6	118.8
0-17 years	22	1	3	7	26	256	24.7	54.0
18-24 years	263	1	5	15	36	929	33.6	71.3
25-40 years	508	1	4	13	33	1,271	41.2	97.0

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	2,114	1	4	12	40	1,394	55.7	137.1
≥ 65 years	2,793	1	4	11	32	1,361	42.0	110.7
Pegvaliase-pqpz	4,121	1	4	9	19	1,849	20.2	60.4
0-17 years	*****	1	4	8	17	161	14.1	18.7
18-24 years	1,101	1	4	8	19	1,024	22.8	65.2
25-40 years	1,681	1	4	9	19	1,849	20.9	65.7
41-64 years	1,097	1	4	8	18	1,140	17.8	52.4
≥ 65 years	*****	1	2	3	15	45	10.6	14.9
Baricitinib	14,880	1	3	7	18	1,538	22.6	65.5
0-17 years	329	1	3	6	16	518	21.0	49.0
18-24 years	881	1	4	9	21	850	21.9	47.1
25-40 years	2,340	1	3	8	19	1,478	22.6	64.9
41-64 years	7,555	1	3	7	18	1,361	20.8	58.6
≥ 65 years	3,775	1	3	7	18	1,538	26.4	81.8
Moxidectin	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Cannabidiol	68,418	1	3	7	18	1,882	25.0	71.0
0-17 years	32,905	1	3	7	20	1,882	28.1	72.4
18-24 years	11,246	1	3	7	18	1,731	27.2	77.8
25-40 years	15,520	1	3	6	16	1,699	21.5	71.3
41-64 years	8,167	1	2	6	14	1,667	17.0	54.3
≥ 65 years	580	1	3	7	16	515	16.4	36.1

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Plazomicin	620	1	4	6	7	1,100	30.1	103.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	59	5	6	6	6	698	21.7	93.6
41-64 years	25	1	1	2	146	1,100	156.2	327.6
≥ 65 years	536	1	4	6	8	729	25.2	77.1
Binimetinib	7,805	1	3	8	23	1,467	26.2	71.8
0-17 years	48	1	4	12	42	712	40.1	104.3
18-24 years	68	1	4	16	34	531	34.0	70.4
25-40 years	731	1	4	8	23	1,401	28.3	84.2
41-64 years	2,773	1	3	8	20	1,467	24.5	68.8
≥ 65 years	4,185	1	3	8	24	1,293	26.6	71.0
Encorafenib	8,905	1	3	8	20	1,467	24.7	69.8
0-17 years	*****	1	5	10	37	741	90.8	229.3
18-24 years	*****	1	4	13	29	531	35.2	81.1
25-40 years	747	1	4	8	20	1,401	27.1	83.1
41-64 years	3,036	1	3	7	19	1,467	23.3	65.3
≥ 65 years	5,058	1	3	8	21	1,293	25.0	69.5
Tecovirimat	*****	15	15	36	56	56	35.5	29.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	15	15	15	15	15	15.0	NaN
41-64 years	*****	56	56	56	56	56	56.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Ivosidenib	3,853	1	2	5	15	1,359	22.0	64.3
0-17 years	*****	2	2	2	7	7	3.7	2.9

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	*****	1	3	6	18	46	10.5	10.9
25-40 years	346	1	2	5	11	377	14.3	31.9
41-64 years	833	1	2	5	14	764	17.8	47.6
≥ 65 years	2,600	1	2	5	16	1,359	24.7	72.3
Tafenoquine	269	1	10	27	56	1,629	65.3	145.5
0-17 years	15	12	26	47	123	527	102.9	136.1
18-24 years	11	7	13	31	77	352	68.0	98.0
25-40 years	98	1	7	25	40	727	47.0	88.5
41-64 years	127	1	8	26	59	1,629	75.6	187.2
≥ 65 years	18	8	18	30	86	197	59.3	65.2
Elagolix sodium	57,556	1	3	7	20	1,877	27.8	84.4
0-17 years	*****	1	3	7	21	918	25.1	66.3
18-24 years	9,686	1	3	8	23	1,877	29.4	83.3
25-40 years	33,703	1	3	7	20	1,847	27.9	86.4
41-64 years	13,190	1	3	7	19	1,569	26.4	81.2
≥ 65 years	*****	1	3	8	9	186	41.4	80.9
Fish oil triglycerides	5,508	1	3	6	6	573	7.7	21.3
0-17 years	4,717	1	3	6	6	573	7.2	20.7
18-24 years	408	1	4	6	6	195	7.3	12.5
25-40 years	171	1	6	6	9	275	22.2	44.7
41-64 years	162	1	6	6	6	137	6.9	11.0
≥ 65 years	50	1	2	4	6	139	7.3	19.4
Lusutrombopag	159	1	16	59	160	1,186	131.6	199.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	22	79	135	241	91.3	74.4

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	128	1	15	55	144	1,186	131.1	206.8
≥ 65 years	*****	1	30	58	222	870	153.7	199.8

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Lutetium Lu 177 dotatate	5,284	4	55	55	61	2,095	63.4	47.2
Female	2,606	4	55	55	61	1,140	63.3	35.2
Male	2,678	13	55	55	61	2,095	63.6	56.4
Bictegravir embicitabine tenofovir alafenamide	171,789	1	3	8	25	2,158	39.2	116.3
Female	44,939	1	3	8	26	2,089	40.2	113.9
Male	126,850	1	3	8	24	2,158	38.8	117.2
Tezacaftor and ivacaftor	2,882	1	3	7	21	1,596	28.3	71.9
Female	1,447	1	3	7	22	1,596	29.9	78.6
Male	1,435	1	3	7	21	1,182	26.7	64.3
Apalutamide	10,617	1	2	6	18	1,962	27.5	95.0
Female	*****	1	1	5	9	9	5.0	5.7
Male	*****	1	2	6	18	1,962	27.5	95.0
Ibalizumab-uiyk	304	1	5	12	13	409	15.5	34.5
Female	77	1	6	13	13	111	14.7	18.4
Male	227	1	4	12	13	409	15.8	38.5
Tildrakizumab	11,421	1	27	28	65	1,298	49.4	57.1
Female	6,077	1	27	28	55	1,298	48.6	56.8
Male	5,344	1	27	28	77	972	50.3	57.3
Burosumab-twza	1,176	1	9	26	29	1,335	32.0	83.1
Female	752	1	8	26	29	1,335	32.6	88.4
Male	424	1	12	26	29	1,306	30.9	72.7
Fostamatinib	776	1	3	7	18	872	29.0	88.2
Female	449	1	3	8	19	836	30.3	90.8
Male	327	1	3	6	17	872	27.3	84.5

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Fosnetupitant and palonosetron	30,109	1	13	20	20	1,414	20.1	31.4
Female	17,277	1	13	20	20	1,414	20.9	35.2
Male	12,832	1	13	20	20	894	19.0	25.4
Lofexidine hydrochloride	1,203	1	11	37	125	1,529	106.0	174.3
Female	592	1	11	38	117	1,504	104.0	177.7
Male	611	1	11	35	144	1,529	107.9	171.1
Erenumab-aooe	136,234	1	3	8	25	2,186	34.8	102.6
Female	116,730	1	3	8	25	2,103	34.7	102.0
Male	19,504	1	3	8	25	2,186	35.4	106.4
Sodium zirconium	57,875	1	6	22	76	1,815	79.2	152.6
Female	24,259	1	6	23	79	1,815	81.0	154.6
Male	33,616	1	6	22	74	1,691	77.8	151.1
Avatrombopag	1,694	1	5	15	55	1,394	74.5	170.6
Female	873	1	5	16	57	1,394	77.3	179.1
Male	821	1	5	14	52	1,359	71.5	161.1
Pegvaliase-pqpz	577	1	4	8	19	985	23.2	70.7
Female	306	1	4	8	20	981	25.5	68.5
Male	271	1	3	7	17	985	20.7	73.2
Baricitinib	4,953	1	3	7	18	1,342	24.4	71.3
Female	3,387	1	3	8	20	1,342	25.9	73.3
Male	1,566	1	3	6	15	1,046	21.1	66.6
Moxidectin	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Cannabidiol	16,339	1	3	8	23	1,882	37.7	102.0
Female	7,258	1	3	8	24	1,699	38.4	103.3
Male	9,081	1	3	8	23	1,882	37.2	100.9
Plazomicin	108	1	1	5	29	1,100	69.4	177.8
Female	75	1	1	6	35	1,019	60.5	147.4
Male	33	1	2	3	20	1,100	89.8	234.2
Binimetinib	2,155	1	3	9	25	1,467	30.3	86.0
Female	956	1	4	10	27	1,401	33.4	93.0
Male	1,199	1	3	9	24	1,467	27.8	79.9
Encorafenib	2,632	1	3	9	23	1,467	28.3	82.8
Female	1,255	1	4	9	25	1,401	29.9	84.7
Male	1,377	1	3	8	21	1,467	26.8	81.0
Tecovirimat	*****	15	15	36	56	56	35.5	29.0
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	*****	15	15	36	56	56	35.5	29.0
Ivosidenib	1,320	1	3	6	18	1,277	24.1	69.6
Female	685	1	3	6	18	1,277	26.0	79.8
Male	635	1	3	6	18	789	22.0	56.7
Tafenoquine	114	1	9	27	69	703	62.6	111.8
Female	73	1	9	32	59	563	53.0	88.7
Male	41	1	7	25	79	703	79.7	143.8
Elagolix sodium	18,968	1	3	8	22	1,877	32.9	100.1
Female	18,942	1	3	8	22	1,877	33.0	100.2
Male	26	1	3	7	19	58	12.3	14.3

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Fish oil triglycerides	199	1	3	6	12	281	19.5	40.0
Female	114	1	4	6	19	281	25.6	48.2
Male	85	1	3	6	7	157	11.2	22.9
Lusutrombopag	81	1	29	78	182	1,186	164.8	235.8
Female	40	5	27	81	184	1,186	175.5	274.0
Male	41	1	34	77	182	770	154.4	194.4

*NaN: Not a number

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Total Number of	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Lutetium Lu 177 dotatate</i>	5,284	4	55	55	61	2,095	63.4	47.2
<i>Bictegravir embicitabine tenofovir alafenamide</i>	171,789	1	3	8	25	2,158	39.2	116.3
<i>Tezacaftor and ivacaftor</i>	2,882	1	3	7	21	1,596	28.3	71.9
<i>Apalutamide</i>	10,617	1	2	6	18	1,962	27.5	95.0
<i>Ibalizumab-uiyk</i>	304	1	5	12	13	409	15.5	34.5
<i>Tildrakizumab</i>	11,421	1	27	28	65	1,298	49.4	57.1
<i>Burosumab-twza</i>	1,176	1	9	26	29	1,335	32.0	83.1
<i>Fostamatinib</i>	776	1	3	7	18	872	29.0	88.2
<i>Fosnetupitant and palonosetron</i>	30,109	1	13	20	20	1,414	20.1	31.4
<i>Lofexidine hydrochloride</i>	1,203	1	11	37	125	1,529	106.0	174.3
<i>Erenumab-aooe</i>	136,234	1	3	8	25	2,186	34.8	102.6
<i>Sodium zirconium cyclosilicate</i>	57,875	1	6	22	76	1,815	79.2	152.6
<i>Avatrombopag</i>	1,694	1	5	15	55	1,394	74.5	170.6
<i>Pegvaliase-pqpz</i>	577	1	4	8	19	985	23.2	70.7
<i>Baricitinib</i>	4,953	1	3	7	18	1,342	24.4	71.3
<i>Moxidectin</i>	0	-	-	-	-	-	-	-
<i>Cannabidiol</i>	16,339	1	3	8	23	1,882	37.7	102.0
<i>Plazomicin</i>	108	1	1	5	29	1,100	69.4	177.8
<i>Binimetinib</i>	2,155	1	3	9	25	1,467	30.3	86.0
<i>Encorafenib</i>	2,632	1	3	9	23	1,467	28.3	82.8
<i>Tecovirimat</i>	*****	15	15	36	56	56	35.5	29.0
<i>Ivosidenib</i>	1,320	1	3	6	18	1,277	24.1	69.6
<i>Tafenoquine</i>	114	1	9	27	69	703	62.6	111.8
<i>Elagolix sodium</i>	18,968	1	3	8	22	1,877	32.9	100.1
<i>Fish oil triglycerides</i>	199	1	3	6	12	281	19.5	40.0
<i>Lusutrombopag</i>	*****	1	29	78	182	1,186	164.8	235.8

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024 , by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Lutetium Lu 177 dotatate	5,284	4	55	55	61	2,095	63.4	47.2
0-17 years	*****	55	55	55	55	55	55.0	0.0
18-24 years	*****	55	55	55	66	153	70.6	36.6
25-40 years	*****	50	55	55	60	190	61.3	18.0
41-64 years	1,271	4	55	55	62	2,095	66.0	72.3
≥ 65 years	3,909	13	55	55	60	1,140	62.6	36.0
Bictegravir embicitabine tenofovir alafenamide	171,789	1	3	8	25	2,158	39.2	116.3
0-17 years	977	1	3	7	23	1,455	33.8	93.8
18-24 years	9,048	1	3	10	32	1,599	46.2	113.5
25-40 years	54,422	1	4	10	30	2,158	44.7	118.6
41-64 years	88,553	1	3	7	23	2,131	37.4	117.6
≥ 65 years	18,789	1	2	6	17	2,080	28.5	104.3
Tezacaftor and ivacaftor	2,882	1	3	7	21	1,596	28.3	71.9
0-17 years	1,076	1	3	7	21	721	26.6	58.5
18-24 years	566	1	4	9	29	439	29.8	55.9
25-40 years	942	1	3	7	18	1,182	28.4	77.6
41-64 years	257	1	3	6	14	1,596	28.3	114.0
≥ 65 years	41	1	5	9	31	584	49.4	100.6
Apalutamide	10,617	1	2	6	18	1,962	27.5	95.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	4	7	7	4.0	3.0
41-64 years	*****	1	2	5	15	949	22.2	66.6
≥ 65 years	9,471	1	2	6	19	1,962	28.1	97.9

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024 , by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Ibalizumab-uiyk	304	1	5	12	13	409	15.5	34.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	7	12	13	13	111	31.2	44.7
25-40 years	56	1	5	13	13	43	11.6	8.8
41-64 years	205	1	5	13	14	409	17.7	41.0
≥ 65 years	*****	1	4	7	12	21	7.6	5.3
Tildrakizumab	11,421	1	27	28	65	1,298	49.4	57.1
0-17 years	*****	12	12	27	36	36	25.0	12.1
18-24 years	*****	2	26	42	83	645	66.4	89.7
25-40 years	408	1	24	33	83	1,298	65.6	109.2
41-64 years	1,207	1	27	31	83	810	60.0	77.2
≥ 65 years	9,741	1	27	28	47	1,140	47.3	50.0
Burosumab-twza	1,176	1	9	26	29	1,335	32.0	83.1
0-17 years	663	1	7	19	28	1,335	28.3	79.8
18-24 years	82	1	16	27	31	776	46.0	101.8
25-40 years	159	1	25	27	31	333	32.4	39.2
41-64 years	176	1	13	27	30	1,248	39.9	124.3
≥ 65 years	96	1	27	27	29	180	30.0	27.2
Fostamatinib	776	1	3	7	18	872	29.0	88.2
0-17 years	*****	2	4	6	38	69	20.5	32.4
18-24 years	*****	1	7	13	38	449	46.5	91.3
25-40 years	122	1	5	10	24	689	42.0	105.9
41-64 years	268	1	3	7	15	872	23.4	72.8
≥ 65 years	356	1	3	7	18	836	27.7	92.0

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024 , by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Fosnetupitant and palonosetron	30,109	1	13	20	20	1,414	20.1	31.4
0-17 years	*****	2	2	11	20	20	11.0	12.7
18-24 years	*****	2	13	17	20	64	18.6	10.2
25-40 years	833	1	13	20	20	265	18.5	16.4
41-64 years	6,593	1	13	20	20	1,414	20.0	33.0
≥ 65 years	22,588	1	13	20	20	1,161	20.2	31.4
Lofexidine hydrochloride	1,203	1	11	37	125	1,529	106.0	174.3
0-17 years	*****	58	58	58	58	58	58.0	NaN
18-24 years	*****	1	17	60	187	1,529	134.8	214.4
25-40 years	501	1	10	31	119	1,275	99.6	164.6
41-64 years	522	1	13	37	121	1,504	107.2	178.9
≥ 65 years	103	1	10	39	128	789	109.7	164.9
Erenumab-aooe	136,234	1	3	8	25	2,186	34.8	102.6
0-17 years	847	1	3	7	20	1,230	26.7	73.7
18-24 years	7,346	1	3	8	23	1,600	29.8	84.1
25-40 years	35,891	1	3	8	24	1,978	32.9	96.4
41-64 years	69,756	1	3	8	26	2,186	35.7	105.2
≥ 65 years	22,394	1	3	8	26	1,990	37.0	110.2
Sodium zirconium	57,875	1	6	22	76	1,815	79.2	152.6
0-17 years	29	1	7	17	57	814	63.1	151.2
18-24 years	199	1	9	29	104	1,446	90.1	156.3
25-40 years	2,764	1	8	30	111	1,744	104.5	187.1
41-64 years	17,518	1	6	23	82	1,683	84.0	158.3
≥ 65 years	37,365	1	6	22	71	1,815	75.0	146.6

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024 , by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Avatrombopag	1,694	1	5	15	55	1,394	74.5	170.6
0-17 years	*****	1	2	3	13	33	8.6	12.0
18-24 years	*****	1	5	17	44	325	41.7	67.7
25-40 years	160	1	5	15	41	700	53.1	106.5
41-64 years	645	1	5	19	76	1,394	91.8	198.6
≥ 65 years	817	1	4	13	48	1,361	68.2	161.8
Pegvaliase-pqpz	577	1	4	8	19	985	23.2	70.7
0-17 years	*****	1	4	8	20	73	14.6	16.0
18-24 years	153	1	3	7	20	374	21.8	42.9
25-40 years	240	1	4	10	19	985	31.1	102.1
41-64 years	141	1	4	7	16	200	14.2	22.4
≥ 65 years	*****	2	2	12	22	22	12.0	14.1
Baricitinib	4,953	1	3	7	18	1,342	24.4	71.3
0-17 years	90	1	2	5	15	368	26.2	60.4
18-24 years	278	1	4	9	22	314	22.6	40.1
25-40 years	763	1	3	8	21	1,342	27.8	81.7
41-64 years	2,314	1	3	7	19	972	21.3	57.5
≥ 65 years	1,508	1	3	7	16	1,046	27.6	87.8
Moxidectin	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024 , by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Cannabidiol	16,339	1	3	8	23	1,882	37.7	102.0
0-17 years	8,607	1	3	8	26	1,882	41.2	101.9
18-24 years	2,825	1	3	7	24	1,731	42.3	111.2
25-40 years	3,307	1	3	7	19	1,699	30.2	98.6
41-64 years	1,486	1	3	7	18	1,667	27.2	93.3
≥ 65 years	114	1	3	8	20	318	22.7	44.0
Plazomicin	108	1	1	5	29	1,100	69.4	177.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	20	20	117	214	214	117.0	137.2
41-64 years	*****	1	2	5	79	1,100	156.1	357.2
≥ 65 years	90	1	1	5	22	729	53.0	121.0
Binimetinib	2,155	1	3	9	25	1,467	30.3	86.0
0-17 years	19	1	2	5	21	98	20.2	28.5
18-24 years	24	1	3	10	39	531	42.0	107.2
25-40 years	207	1	3	8	23	1,401	36.6	125.4
41-64 years	755	1	3	9	23	1,467	26.2	76.3
≥ 65 years	1,150	1	4	10	26	1,036	31.7	83.4
Encorafenib	2,632	1	3	9	23	1,467	28.3	82.8
0-17 years	*****	4	4	37	62	62	34.3	29.1
18-24 years	*****	1	2	5	37	531	54.9	133.6
25-40 years	221	1	4	8	19	1,401	34.5	121.4
41-64 years	881	1	3	8	21	1,467	24.0	71.9
≥ 65 years	1,509	1	3	9	25	1,036	29.5	81.0

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024 , by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Tecovirimat	*****	15	15	36	56	56	35.5	29.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	15	15	15	15	15	15.0	NaN
41-64 years	*****	56	56	56	56	56	56.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Ivosidenib	1,320	1	3	6	18	1,277	24.1	69.6
0-17 years	*****	2	2	5	7	7	4.5	3.5
18-24 years	*****	1	3	6	17	46	11.3	12.4
25-40 years	129	1	2	5	24	221	17.8	30.4
41-64 years	304	1	3	6	17	306	18.9	39.2
≥ 65 years	871	1	3	6	18	1,277	27.1	81.6
Tafenoquine	114	1	9	27	69	703	62.6	111.8
0-17 years	*****	12	22	47	123	527	116.6	184.7
18-24 years	*****	7	10	30	75	77	38.0	32.6
25-40 years	38	1	6	21	36	257	36.5	53.4
41-64 years	55	1	12	28	69	703	73.5	135.8
≥ 65 years	*****	8	10	79	142	197	83.3	77.8
Elagolix sodium	18,968	1	3	8	22	1,877	32.9	100.1
0-17 years	*****	1	3	7	21	918	27.9	82.8
18-24 years	3,185	1	3	8	24	1,877	35.5	108.4
25-40 years	11,227	1	3	7	22	1,779	33.3	102.0
41-64 years	4,278	1	3	8	21	1,517	30.4	89.1
≥ 65 years	*****	1	1	5	8	8	4.5	4.9

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024 , by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Fish oil triglycerides	199	1	3	6	12	281	19.5	40.0
0-17 years	148	1	3	6	7	281	12.0	30.3
18-24 years	*****	1	4	7	13	78	15.1	23.7
25-40 years	28	1	12	40	83	247	61.3	61.8
41-64 years	*****	1	3	7	11	137	23.1	43.9
≥ 65 years	*****	3	4	4	5	5	4.0	0.8
Lusutrombopag	81	1	29	78	182	1,186	164.8	235.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	13	52	108	135	60.3	59.9
41-64 years	59	5	26	84	182	1,186	172.7	250.3
≥ 65 years	*****	1	32	61	222	870	162.0	210.9

*NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024^{1,2}

	Censoring Reason								
	End of Exposure Episode ³			Occurrence of User-Defined Censoring Criteria ⁴		Disenrollment ⁵		End of Data ⁶	
	Total Number of Episodes	Number of Episodes	Percent of Total	Number of Episodes	Percent of Total	Number of Episodes	Percent of Total	Number of Episodes	Percent of Total
<i>Lutetium Lu 177 dotatate</i>	19,800	19,800	100.0%	0	0.0%	*****	*****	*****	*****
<i>Bictegravir embitcitabine</i> <i>tenofovir alafenamide</i>	1,133,058	1,128,829	99.6%	0	0.0%	171,495	15.1%	100,109	8.8%
<i>Tezacaftor and ivacaftor</i>	16,189	16,161	99.8%	0	0.0%	718	4.4%	146	0.9%
<i>Apalutamide</i>	59,444	58,839	99.0%	0	0.0%	6,078	10.2%	4,308	7.2%
<i>Ibalizumab-uiyk</i>	4,891	4,875	99.7%	0	0.0%	72	1.5%	31	0.6%
<i>Tildrakizumab</i>	77,156	77,138	100.0%	0	0.0%	587	0.8%	328	0.4%
<i>Burosumab-twza</i>	21,148	21,142	100.0%	0	0.0%	536	2.5%	419	2.0%
<i>Fostamatinib</i>	4,331	4,235	97.8%	0	0.0%	409	9.4%	231	5.3%
<i>Fosnetupitant and palonosetron</i>	193,360	193,306	100.0%	0	0.0%	276	0.1%	209	0.1%
<i>Lofexidine hydrochloride</i>	10,404	10,402	100.0%	0	0.0%	186	1.8%	92	0.9%
<i>Erenumab-aooe</i>	800,153	799,268	99.9%	0	0.0%	76,208	9.5%	37,390	4.7%
<i>Sodium zirconium cyclosilicate</i>	321,730	317,371	98.6%	0	0.0%	19,674	6.1%	12,882	4.0%
<i>Avatrombopag</i>	9,712	9,581	98.7%	0	0.0%	895	9.2%	599	6.2%
<i>Pegvaliase-pqpz</i>	4,868	4,867	100.0%	0	0.0%	476	9.8%	249	5.1%
<i>Baricitinib</i>	79,878	79,825	99.9%	0	0.0%	2,402	3.0%	1,292	1.6%
<i>Moxidectin</i>	0	-	-	-	-	-	-	-	-
<i>Cannabidiol</i>	95,858	95,401	99.5%	0	0.0%	15,753	16.4%	12,271	12.8%
<i>Plazomicin</i>	905	*****	*****	0	0.0%	*****	*****	0	0.0%
<i>Binimetinib</i>	11,634	11,296	97.1%	0	0.0%	871	7.5%	497	4.3%
<i>Encorafenib</i>	13,660	13,287	97.3%	0	0.0%	1,090	8.0%	617	4.5%
<i>Tecovirimat</i>	41	41	100.0%	0	0.0%	0	0.0%	0	0.0%

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024^{1,2}

Censoring Reason									
	End of Exposure Episode ³		Occurrence of User-Defined Censoring Criteria ⁴		Disenrollment ⁵		End of Data ⁶		
	Total Number of Episodes	Number of Episodes	Percent of Total	Number of Episodes	Percent of Total	Number of Episodes	Percent of Total	Number of Episodes	Percent of Total
Ivosidenib	6,438	6,107	94.9%	0	0.0%	750	11.6%	530	8.2%
Tafenoquine	635	635	100.0%	0	0.0%	46	7.2%	26	4.1%
Elagolix sodium	95,097	95,089	100.0%	0	0.0%	7,848	8.3%	3,554	3.7%
Fish oil triglycerides	5,794	5,794	100.0%	0	0.0%	40	0.7%	33	0.6%
Lusutrombopag	600	*****	*****	0	0.0%	*****	*****	*****	*****

¹An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

²All reasons for censoring may not be displayed to prevent publication of small cells.

³Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

⁴Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

⁵Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

⁶Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

*******Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.**

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Lutetium Lu 177 dotatate		Bictegravir embicitabine tenofovir		Tezacaftor and ivacaftor		Apalutamide	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event								
Had any cohort-defining claim during the query period	6,808	258,667,194	318,618	258,355,384	4,607	258,669,395	19,666	258,654,336
Claim recorded during specified age range	6,808	0	318,618	0	4,607	0	19,666	0
Episode defining index claim recorded during the query period	6,808	0	318,618	0	4,607	0	19,666	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	6,363	445	244,961	73,657	4,020	587	17,467	2,199
Met inclusion and exclusion criteria	6,363	0	244,961	0	4,020	0	17,467	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	6,363	0	244,961	0	4,020	0	17,467	0
Final cohort								
Number of members	6,363	N/A	244,961	N/A	4,020	N/A	17,467	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Ibalizumab-uiyk		Tildrakizumab		Burosumab-twza		Fostamatinib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event								
Had any cohort-defining claim during the query period	423	258,673,579	13,636	258,660,366	1,505	258,672,497	1,747	258,672,255
Claim recorded during specified age range	423	0	13,636	0	1,505	0	1,747	0
Episode defining index claim recorded during the query period	423	0	13,636	0	1,505	0	1,747	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	365	58	12,838	798	1,374	131	1,534	213
Met inclusion and exclusion criteria	365	0	12,838	0	1,374	0	1,534	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	365	0	12,838	0	1,374	0	1,534	0
Final cohort								
Number of members	365	N/A	12,838	N/A	1,374	N/A	1,534	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Fosnetupitant and		Lofexidine hydrochloride		Erenumab-aooe		Sodium zirconium cyclosilicate	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event								
Had any cohort-defining claim during the query period	39,478	258,634,524	9,779	258,664,223	239,993	258,434,009	152,940	258,521,062
Claim recorded during specified age range	39,478	0	9,779	0	239,993	0	*****	*****
Episode defining index claim recorded during the query period	39,478	0	9,779	0	239,993	0	*****	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	35,282	4,196	8,141	1,638	203,727	36,266	135,004	*****
Met inclusion and exclusion criteria	35,282	0	8,141	0	203,727	0	135,004	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	35,282	0	8,141	0	203,727	0	135,004	0
Final cohort								
Number of members	35,282	N/A	8,141	N/A	203,727	N/A	135,004	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Avatrombopag		Pegvaliase-pqpz		Baricitinib		Moxidectin	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event								
Had any cohort-defining claim during the query period	4,556	258,669,446	935	258,673,067	72,147	258,601,855	0	258,674,002
Claim recorded during specified age range	4,556	0	935	0	72,147	0	0	0
Episode defining index claim recorded during the query period	4,556	0	935	0	72,147	0	0	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	4,012	544	747	188	64,998	7,149	0	0
Met inclusion and exclusion criteria	4,012	0	747	0	64,998	0	0	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	4,012	0	747	0	64,998	0	0	0
Final cohort								
Number of members	4,012	N/A	747	N/A	64,998	N/A	0	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Cannabidiol		Plazomicin		Binimetinib		Encorafenib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event								
Had any cohort-defining claim during the query period	31,193	258,642,809	*****	*****	4,341	258,669,661	5,409	258,668,593
Claim recorded during specified age range	31,193	0	*****	0	4,341	0	5,409	0
Episode defining index claim recorded during the query period	31,193	0	*****	0	4,341	0	5,409	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	27,440	3,753	285	*****	3,829	512	4,755	654
Met inclusion and exclusion criteria	27,440	0	285	0	3,829	0	4,755	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	27,440	0	285	0	3,829	0	4,755	0
Final cohort								
Number of members	27,440	N/A	285	N/A	3,829	N/A	4,755	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Tecovirimat		Ivosidenib		Tafenoquine		Elagolix sodium	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607	258,674,002	92,607
Members with a valid index event								
Had any cohort-defining claim during the query period	*****	*****	2,931	258,671,071	407	258,673,595	43,771	258,630,231
Claim recorded during specified age range	*****	0	2,931	0	407	0	43,771	0
Episode defining index claim recorded during the query period	*****	0	2,931	0	407	0	43,771	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	39	*****	2,585	346	366	41	37,541	6,230
Met inclusion and exclusion criteria	39	0	2,585	0	366	0	37,541	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	39	0	2,585	0	366	0	37,541	0
Final cohort								
Number of members	39	N/A	2,585	N/A	366	N/A	37,541	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

	Fish oil triglycerides		Lusutrombopag	
	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements				
Enrolled at any point during the query period	346,550,804	N/A	346,550,804	N/A
Had required coverage type (medical and/or drug coverage)	258,772,839	87,777,965	258,772,839	87,777,965
Enrolled during specified age range	258,766,609	6,230	258,766,609	6,230
Had requestable medical charts	258,766,609	0	258,766,609	0
Met demographic requirements (sex, race, and Hispanic origin)	258,674,002	92,607	258,674,002	92,607
Members with a valid index event				
Had any cohort-defining claim during the query period	329	258,673,673	470	258,673,532
Claim recorded during specified age range	329	0	470	0
Episode defining index claim recorded during the query period	329	0	470	0
Members with required pre-index history				
Had sufficient pre-index continuous enrollment	286	43	441	29
Met inclusion and exclusion criteria	286	0	441	0
Members with required post-index follow-up				
Had sufficient post-index continuous enrollment	286	0	441	0
Final cohort				
Number of members	286	N/A	441	N/A

N/A: Not Applicable


*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Figure 1a. Patient Entry into Study by Month for Lutetium Lu 177 dotatate in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on January 26, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1b. Patient Entry into Study by Month for Bictegravir embitcitabine tenofovir alafenamide in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024



*The FDA approval date for this drug was on February 7, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Figure 1c. Patient Entry into Study by Month for Tezacaftor and ivacaftor in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on February 12, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1d. Patient Entry into Study by Month for Apalutamide in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on February 14, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>


Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1e. Patient Entry into Study by Month for Ibalizumab-uiyk in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on March 6, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new->

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1f. Patient Entry into Study by Month for Tildrakizumab in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024



*The FDA approval date for this drug was on March 20, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Figure 1g. Patient Entry into Study by Month for Burosumab-twza in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on April 17, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1h. Patient Entry into Study by Month for Fostamatinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on April 17, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new->


Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1i. Patient Entry into Study by Month for Fosnetupitant and palonosetron in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on April 19, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>


Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1j. Patient Entry into Study by Month for Lofexidine hydrochloride in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024




*The FDA approval date for this drug was on May 16, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Figure 1k. Patient Entry into Study by Month for Erenumab-aooe in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024



*The FDA approval date for this drug was on May 17, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Figure 1I. Patient Entry into Study by Month for Sodium zirconium cyclosilicate in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024



*The FDA approval date for this drug was on May 18, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Figure 1m. Patient Entry into Study by Month for Avatrombopag in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on May 21, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>


Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1n. Patient Entry into Study by Month for Pegvaliase-pqpz in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on May 24, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>


Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1o. Patient Entry into Study by Month for Baricitinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024



*The FDA approval date for this drug was on May 31, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>


Figure 1p. Patient Entry into Study by Month for Moxidectin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024



*The FDA approval date for this drug was on June 13, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

There was no use during the query period.

Figure 1q. Patient Entry into Study by Month for Cannabidiol in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024



*The FDA approval date for this drug was on June 25, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Figure 1r. Patient Entry into Study by Month for Plazomicin in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on June 25, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1s. Patient Entry into Study by Month for Binimetinib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on June 27, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1t. Patient Entry into Study by Month for Encorafenib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on June 27, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1u. Patient Entry into Study by Month for Tecovirimat in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on July 13, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1v. Patient Entry into Study by Month for Ivosidenib in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on July 20, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>


Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1w. Patient Entry into Study by Month for Tafenoquine in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on July 20, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1x. Patient Entry into Study by Month for Elagolix sodium in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024



*The FDA approval date for this drug was on July 23, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Figure 1y. Patient Entry into Study by Month for Fish oil triglycerides in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on July 27, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1z. Patient Entry into Study by Month for Lusutrombopag in the Sentinel Distributed Database from January 1, 2018 to December 31, 2024

*The FDA approval date for this drug was on July 31, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (June 16, 2025)

Masked DP ID	DP Start Date	DP End Date ¹
DP01	01/01/2000	01/31/2024
DP02	01/01/2000	01/31/2024
DP03	01/01/2008	08/31/2024
DP04	01/01/2006	10/31/2024
DP05	01/01/2005	07/31/2022
DP06	01/01/2000	04/30/2024
DP07	01/01/2004	03/31/2024
DP08	01/01/2000	04/30/2024
DP09	01/01/2007	10/31/2024
DP10	01/01/2000	04/30/2024
DP11	01/01/2014	12/31/2021
DP12	01/01/2008	12/31/2024
DP13	01/01/2010	06/30/2024

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
Lutetium Lu 177 Dotatate	
lutetium Lu 177 dotatate	Lutathera
Bictegravir Embicitabine Tenofovir Alaf	
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate	Biktarvy
bictegravir sodium/emtricitabine/tenofovir alafenamide fumar	Biktarvy
Tezacaftor Ivacaftor	
tezacaftor/ivacaftor	Symdeko
Apalutamide	
apalutamide	Erleada
Ibalizumab-Uiyk	
ibalizumab-uiyk	Trogarzo
Tildrakizumab	
tildrakizumab-asnm	Ilumya
Burosumab-Twza	
burosumab-twza	Crysvita
Fostamatinib	
fostamatinib disodium	Tavalisse
Fosnetupitant Palonosetron	
fosnetupitant chloride HCl/palonosetron HCl	Akynzeo (fosnetupitant)
Lofexidine Hydrochloride	
lofexidine HCl	Lucemyra
lofexidine HCl	lofexidine
LOFEXIDINE HYDROCHLORIDE	lofexidine hydrochloride
LOFEXIDINE HYDROCHLORIDE	Lofexidine
Erenumab-Aooe	
erenumab-aooe	Aimovig Autoinjector
erenumab-aooe	Aimovig Autoinjector (2 Pack)
erenumab-aooe	AIMOVIG
Sodium Zirconium Cyclosilicate	
sodium zirconium cyclosilicate	Lokelma
Avatrombopag	
avatrombopag maleate	Doptelet (10 tab pack)
avatrombopag maleate	Doptelet (15 tab pack)
avatrombopag maleate	Doptelet (30 tab pack)
Pegvaliase-Pqpz	
pegvaliase-pqpz	Palynziq
Baricitinib	
baricitinib	Olumiant
Moxidectin	
MOXIDECTIN	Moxidectin
Cannabidiol	
cannabidiol (CBD)	Epidiolex
Plazomicin	
plazomicin sulfate	Zemdri
Binimetinib	
binimetinib	Mektovi
Encorafenib	
encorafenib	Braftovi
Tecovirimat	
tecovirimat	Tpoxx (National Stockpile)

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
Ivosidenib	
ivosidenib	Tibsovo
Tafenoquine	
tafenoquine succinate	Krintafel
Elagolix sodium	
elagolix sodium	Orilissa
elagolix sodium/estradiol/norethindrone acetate	Oriahnn
Fish Oil Triglycerides	
fatty acids combo. no.6/fish oil/glycerin/phospholipids, egg	Omegaven
Lusutrombopag	
lusutrombopag	Mulpleta

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), and National Drug Code (NDC) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
Lutetium Lu 177 Dotatate			
A9513	Lutetium Lu 177, dotatate, therapeutic, 1 mCi	Procedure	HCPCS
C9031	Lutetium Lu 177, dotatate, therapeutic, 1 mCi	Procedure	HCPCS
69488000301	lutetium Lu 177 dotatate	Procedure	NDC
69488000370	lutetium Lu 177 dotatate	Procedure	NDC
Bictegravir Embicitabine Tenofovir Alaf			
50090624700	bictegravir sodium/emtricitabine/tenofovir alafenamide fumar	Procedure	NDC
61958250101	bictegravir sodium/emtricitabine/tenofovir alafenamide fumar	Procedure	NDC
61958250102	bictegravir sodium/emtricitabine/tenofovir alafenamide fumar	Procedure	NDC
61958250103	bictegravir sodium/emtricitabine/tenofovir alafenamide fumar	Procedure	NDC
61958250501	bictegravir sodium/emtricitabine/tenofovir alafenamide fumar	Procedure	NDC
61958250601	bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate	Procedure	NDC
70518308003	bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate	Procedure	NDC
Tezacaftor Ivacaftor			
51167011301	tezacaftor/ivacaftor	Procedure	NDC
51167066101	tezacaftor/ivacaftor	Procedure	NDC
Apalutamide			
59676060012	apalutamide	Procedure	NDC
59676060056	apalutamide	Procedure	NDC
59676060099	apalutamide	Procedure	NDC
59676060414	apalutamide	Procedure	NDC
59676060430	apalutamide	Procedure	NDC
Ibalizumab-Uiyk			
J1746	Injection, ibalizumab-uiyk, 10 mg	Procedure	HCPCS
62064012201	ibalizumab-uiyk	Procedure	NDC
62064012202	ibalizumab-uiyk	Procedure	NDC
Tildrakizumab			
J3245	Injection, tildrakizumab, 1 mg	Procedure	HCPCS
47335017701	tildrakizumab-asmn	Procedure	NDC
47335017710	tildrakizumab-asmn	Procedure	NDC
47335017795	tildrakizumab-asmn	Procedure	NDC
47335017796	tildrakizumab-asmn	Procedure	NDC
Burosumab-Twza			
J0584	Injection, burosumab-twza, 1 mg	Procedure	HCPCS
42747010201	burosumab-twza	Procedure	NDC
42747020301	burosumab-twza	Procedure	NDC
42747030401	burosumab-twza	Procedure	NDC
69794010201	burosumab-twza	Procedure	NDC
69794020301	burosumab-twza	Procedure	NDC
69794030401	burosumab-twza	Procedure	NDC
Fostamatinib			
71332000101	fostamatinib disodium	Procedure	NDC
71332000201	fostamatinib disodium	Procedure	NDC
Fosnetupitant Palonosetron			
C9033	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	Procedure	HCPCS
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	Procedure	HCPCS
69639010201	fosnetupitant chloride HCl/palonosetron HCl	Procedure	NDC
69639010501	fosnetupitant chloride HCl/palonosetron HCl	Procedure	NDC

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), and National Drug Code (NDC) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
69639010601	fosnetupitant chloride HCl/palonosetron HCl	Procedure	NDC
Lofexidine Hydrochloride			
27505005036	lofexidine HCl	Procedure	NDC
27505005096	lofexidine HCl	Procedure	NDC
78670005036	lofexidine HCl	Procedure	NDC
78670005096	lofexidine HCl	Procedure	NDC
78670005003	lofexidine HCl	Procedure	NDC
66993034537	lofexidine HCl	Procedure	NDC
66993034576	lofexidine HCl	Procedure	NDC
71921025036	lofexidine HCl	Procedure	NDC
71921025096	lofexidine HCl	Procedure	NDC
27505005003	lofexidine HCl	Procedure	NDC
72205024642	LOFEXIDINE HYDROCHLORIDE	Procedure	NDC
72205024643	LOFEXIDINE HYDROCHLORIDE	Procedure	NDC
14445014636	LOFEXIDINE HYDROCHLORIDE	Procedure	NDC
14445014696	LOFEXIDINE HYDROCHLORIDE	Procedure	NDC
Erenumab-Aoee			
55513084001	erenumab-aoee	Procedure	NDC
55513084002	erenumab-aoee	Procedure	NDC
55513084100	erenumab-aoee	Procedure	NDC
55513084101	erenumab-aoee	Procedure	NDC
55513084102	erenumab-aoee	Procedure	NDC
55513084201	erenumab-aoee	Procedure	NDC
55513084300	erenumab-aoee	Procedure	NDC
55513084301	erenumab-aoee	Procedure	NDC
Sodium Zirconium Cyclosilicate			
00310110501	sodium zirconium cyclosilicate	Procedure	NDC
00310110530	sodium zirconium cyclosilicate	Procedure	NDC
00310110539	sodium zirconium cyclosilicate	Procedure	NDC
00310111001	sodium zirconium cyclosilicate	Procedure	NDC
00310111030	sodium zirconium cyclosilicate	Procedure	NDC
00310111039	sodium zirconium cyclosilicate	Procedure	NDC
00310111091	sodium zirconium cyclosilicate	Procedure	NDC
00310111093	sodium zirconium cyclosilicate	Procedure	NDC
00310111094	sodium zirconium cyclosilicate	Procedure	NDC
00310111098	sodium zirconium cyclosilicate	Procedure	NDC
50090650100	sodium zirconium cyclosilicate	Procedure	NDC
50090650101	sodium zirconium cyclosilicate	Procedure	NDC
50090650200	sodium zirconium cyclosilicate	Procedure	NDC
Avatrombopag			
71369002010	avatrombopag maleate	Procedure	NDC
71369002011	avatrombopag maleate	Procedure	NDC
71369002015	avatrombopag maleate	Procedure	NDC
71369002016	avatrombopag maleate	Procedure	NDC
71369002030	avatrombopag maleate	Procedure	NDC
Pegvaliase-Pqpz			
68135005889	pegvaliase-qpz	Procedure	NDC
68135005890	pegvaliase-qpz	Procedure	NDC

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), and National Drug Code (NDC) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
68135067339	pegvaliase-pqpz	Procedure	NDC
68135067340	pegvaliase-pqpz	Procedure	NDC
68135067345	pegvaliase-pqpz	Procedure	NDC
68135075619	pegvaliase-pqpz	Procedure	NDC
68135075620	pegvaliase-pqpz	Procedure	NDC
Baricitinib			
XW0DXM6	Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW0G7M6	Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6	Procedure	ICD-10-PCS
XW0H7M6	Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6	Procedure	ICD-10-PCS
00002418230	baricitinib	Procedure	NDC
00002418261	baricitinib	Procedure	NDC
00002447930	baricitinib	Procedure	NDC
00002447961	baricitinib	Procedure	NDC
00002473230	baricitinib	Procedure	NDC
00002688530	baricitinib	Procedure	NDC
Moxidectin			
71705005001	MOXIDECTIN	Procedure	NDC
Cannabidiol			
70127010001	cannabidiol (CBD)	Procedure	NDC
70127010006	cannabidiol (CBD)	Procedure	NDC
70127010010	cannabidiol (CBD)	Procedure	NDC
70127010060	cannabidiol (CBD)	Procedure	NDC
Plazomicin			
C9039	Injection, plazomicin, 5 mg	Procedure	HCPCS
J0291	Injection, plazomicin, 5 mg	Procedure	HCPCS
XW033G4	Introduction of Plazomicin Anti-infective into Peripheral Vein, Percutaneo	Procedure	ICD-10-PCS
XW043G4	Introduction of Plazomicin Anti-infective into Central Vein, Percutaneous	Procedure	ICD-10-PCS
69097082037	plazomicin sulfate	Procedure	NDC
69097082096	plazomicin sulfate	Procedure	NDC
71045001001	plazomicin sulfate	Procedure	NDC
71045001002	plazomicin sulfate	Procedure	NDC
80735082037	plazomicin sulfate	Procedure	NDC
80735082096	plazomicin sulfate	Procedure	NDC
Binimetinib			
70255001002	binimetinib	Procedure	NDC
70255001003	binimetinib	Procedure	NDC
Encorafenib			
70255002001	encorafenib	Procedure	NDC
70255002002	encorafenib	Procedure	NDC
70255002501	encorafenib	Procedure	NDC
70255002502	encorafenib	Procedure	NDC
70255002503	encorafenib	Procedure	NDC
70255002504	encorafenib	Procedure	NDC
70255002505	encorafenib	Procedure	NDC
70255002506	encorafenib	Procedure	NDC

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), and National Drug Code (NDC) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
Tecovirimat			
50072001001	tecovirimat	Procedure	NDC
50072001030	tecovirimat	Procedure	NDC
50072020042	tecovirimat	Procedure	NDC
Ivosidenib			
71334010001	ivosidenib	Procedure	NDC
72694061760	ivosidenib	Procedure	NDC
Tafenoquine			
00173088913	tafenoquine succinate	Procedure	NDC
00173088939	tafenoquine succinate	Procedure	NDC
71475025701	tafenoquine succinate	Procedure	NDC
71475025702	tafenoquine succinate	Procedure	NDC
Elagolix Sodium			
00074003801	elagolix sodium	Procedure	NDC
00074003807	elagolix sodium	Procedure	NDC
00074003828	elagolix sodium	Procedure	NDC
00074003901	elagolix sodium	Procedure	NDC
00074003914	elagolix sodium	Procedure	NDC
00074003956	elagolix sodium	Procedure	NDC
00074101714	elagolix sodium/estradiol/norethindrone acetate	Procedure	NDC
00074101756	elagolix sodium/estradiol/norethindrone acetate	Procedure	NDC
Fish Oil Triglycerides			
B4187	Omegaven, 10 g lipids	Procedure	HCPCS
63323020500	fatty acids combo. no.6/fish oil/glycerin/phospholipids, egg	Procedure	NDC
63323020521	fatty acids combo. no.6/fish oil/glycerin/phospholipids, egg	Procedure	NDC
63323020531	fatty acids combo. no.6/fish oil/glycerin/phospholipids, egg	Procedure	NDC
63323020550	fatty acids combo. no.6/fish oil/glycerin/phospholipids, egg	Procedure	NDC
Lusutrombopag			
59630055107	lusutrombopag	Procedure	NDC
59630055177	lusutrombopag	Procedure	NDC

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Acquired Hypothyroidism			
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Alcohol Abuse			
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
T51.0X1A	Toxic effect of ethanol, accidental (unintentional), initial encounter	Procedure	ICD-10-PCS
T51.0X2A	Toxic effect of ethanol, intentional self-harm, initial encounter	Procedure	ICD-10-PCS
T51.0X3A	Toxic effect of ethanol, assault, initial encounter	Procedure	ICD-10-PCS
T51.0X4A	Toxic effect of ethanol, undetermined, initial encounter	Procedure	ICD-10-PCS
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
Alzheimers			
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
Acute Myocardial Infraction			
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I21.B	Myocardial infarction with coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
Anemia			
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.04	Hb-SS disease with dactylitis	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.214	Sickle-cell/Hb-C disease with dactylitis	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia, unspecified, with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia, unspecified, with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.414	Sickle-cell thalassemia, unspecified, with dactylitis	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D57.419	Sickle-cell thalassemia, unspecified, with crisis	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.434	Sickle-cell thalassemia beta zero with dactylitis	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.454	Sickle-cell thalassemia beta plus with dactylitis	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.814	Other sickle-cell disorders with dactylitis	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.30	Hemolytic-uremic syndrome, unspecified	Diagnosis	ICD-10-CM
D59.31	Infection-associated hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.32	Hereditary hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.39	Other hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.02	Shwachman-Diamond syndrome	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
Asthma			
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
Atrial Fibrillation			
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
Benign Prostatic Hyperplasia			
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
Breast Cancer			
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Cardiac Arrest			
I46.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
I46.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
I97.120	Postprocedural cardiac arrest following cardiac surgery	Diagnosis	ICD-10-CM
I97.121	Postprocedural cardiac arrest following other surgery	Diagnosis	ICD-10-CM
I97.710	Intraoperative cardiac arrest during cardiac surgery	Diagnosis	ICD-10-CM
I97.711	Intraoperative cardiac arrest during other surgery	Diagnosis	ICD-10-CM
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
Chronic Kidney Disease			
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sjogren syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.B1	Recurrent and persistent immunoglobulin A nephropathy with glomerular lesion	Diagnosis	ICD-10-CM
N02.B2	Recurrent and persistent immunoglobulin A nephropathy with focal and segmental glomerular lesion	Diagnosis	ICD-10-CM
N02.B3	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranoproliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.B4	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.B5	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.B6	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.B9	Other recurrent and persistent immunoglobulin A nephropathy	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.20	Nephrotic syndrome with diffuse membranous glomerulonephritis, unspecified	Diagnosis	ICD-10-CM
N04.21	Primary membranous nephropathy with nephrotic syndrome	Diagnosis	ICD-10-CM
N04.22	Secondary membranous nephropathy with nephrotic syndrome	Diagnosis	ICD-10-CM
N04.29	Other nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.20	Isolated proteinuria with diffuse membranous glomerulonephritis, unspecified	Diagnosis	ICD-10-CM
N06.21	Primary membranous nephropathy with isolated proteinuria	Diagnosis	ICD-10-CM
N06.22	Secondary membranous nephropathy with isolated proteinuria	Diagnosis	ICD-10-CM
N06.29	Other isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.11	Contrast-induced nephropathy	Diagnosis	ICD-10-CM
N14.19	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Colorectal Cancer			
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Chronic Obstructive Pulmonary Disease			
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with (acute) lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.81	Bronchiolitis obliterans and bronchiolitis obliterans syndrome	Diagnosis	ICD-10-CM
J44.89	Other specified chronic obstructive pulmonary disease	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
Coronary Angioplasty Bypass			
00566	Anesthesia for direct coronary artery bypass grafting; without pump oxygenator	Procedure	CPT-4
00567	Anesthesia for direct coronary artery bypass grafting; with pump oxygenator	Procedure	CPT-4
02104Z3	Bypass Coronary Artery, One Artery from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z3	Bypass Coronary Artery, Two Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124Z3	Bypass Coronary Artery, Three Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134Z3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270346	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027034Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0270356	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027035Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270366	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027036Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270376	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027037Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
02703E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703Z6	Dilation of Coronary Artery, One Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02703ZZ	Dilation of Coronary Artery, One Artery, Percutaneous Approach	Procedure	ICD-10-PCS
0270446	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027044Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270456	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027045Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270466	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027046Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270476	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027047Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
02704G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704Z6	Dilation of Coronary Artery, One Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704ZZ	Dilation of Coronary Artery, One Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271346	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027134Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0271356	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027135Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271366	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027136Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271376	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027137Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
02713TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713Z6	Dilation of Coronary Artery, Two Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02713ZZ	Dilation of Coronary Artery, Two Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
0271446	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027144Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271456	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027145Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271466	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027146Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271476	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027147Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714Z6	Dilation of Coronary Artery, Two Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714ZZ	Dilation of Coronary Artery, Two Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0272346	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027234Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0272356	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027235Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272366	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027236Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272376	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027237Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723Z6	Dilation of Coronary Artery, Three Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02723ZZ	Dilation of Coronary Artery, Three Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
0272446	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027244Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272456	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
027245Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272466	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027246Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272476	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027247Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724Z6	Dilation of Coronary Artery, Three Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724ZZ	Dilation of Coronary Artery, Three Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273346	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027334Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0273356	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027335Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273366	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027336Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0273376	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027337Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733Z6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02733ZZ	Dilation of Coronary Artery, Four or More Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
0273446	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027344Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273456	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027345Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273466	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027346Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273476	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027347Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
02734DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734Z6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734ZZ	Dilation of Coronary Artery, Four or More Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0644T	Transcatheter removal or debulking of intracardiac mass (eg, vegetations, thrombus) via suction (eg, vacuum, aspiration) device, percutaneous approach, with intraoperative reinfusion of aspirated blood, including imaging guidance, when performed	Procedure	CPT-3
33508	Endoscopy, surgical, including video-assisted harvest of vein(s) for coronary artery bypass procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4
33509	Harvest of upper extremity artery, 1 segment, for coronary artery bypass procedure, endoscopic	Procedure	CPT-4
33510	Coronary artery bypass, vein only; single coronary venous graft	Procedure	CPT-4
33511	Coronary artery bypass, vein only; 2 coronary venous grafts	Procedure	CPT-4
33512	Coronary artery bypass, vein only; 3 coronary venous grafts	Procedure	CPT-4
33513	Coronary artery bypass, vein only; 4 coronary venous grafts	Procedure	CPT-4
33514	Coronary artery bypass, vein only; 5 coronary venous grafts	Procedure	CPT-4
33516	Coronary artery bypass, vein only; 6 or more coronary venous grafts	Procedure	CPT-4
33517	Coronary artery bypass, using venous graft(s) and arterial graft(s); single vein graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
33518	Coronary artery bypass, using venous graft(s) and arterial graft(s); 2 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33519	Coronary artery bypass, using venous graft(s) and arterial graft(s); 3 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33520	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Single Graft	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
33521	Coronary artery bypass, using venous graft(s) and arterial graft(s); 4 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33522	Coronary artery bypass, using venous graft(s) and arterial graft(s); 5 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33523	Coronary artery bypass, using venous graft(s) and arterial graft(s); 6 or more venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33525	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Two Coronary Grafts	Procedure	CPT-4
33528	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Three Or More Coronary Grafts	Procedure	CPT-4
33530	Reoperation, coronary artery bypass procedure or valve procedure, more than 1 month after original operation (List separately in addition to code for primary procedure)	Procedure	CPT-4
33533	Coronary artery bypass, using arterial graft(s); single arterial graft	Procedure	CPT-4
33534	Coronary artery bypass, using arterial graft(s); 2 coronary arterial grafts	Procedure	CPT-4
33535	Coronary artery bypass, using arterial graft(s); 3 coronary arterial grafts	Procedure	CPT-4
33536	Coronary artery bypass, using arterial graft(s); 4 or more coronary arterial grafts	Procedure	CPT-4
33572	Coronary endarterectomy, open, any method, of left anterior descending, circumflex, or right coronary artery performed in conjunction with coronary artery bypass graft procedure, each vessel (List separately in addition to primary procedure)	Procedure	CPT-4
35500	Harvest of upper extremity vein, 1 segment, for lower extremity or coronary artery bypass procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4
35600	Harvest of upper extremity artery, 1 segment, for coronary artery bypass procedure, open	Procedure	CPT-4
4110F	Internal mammary artery graft performed for primary, isolated coronary artery bypass graft procedure (CABG)	Procedure	CPT-2
92920	Percutaneous transluminal coronary angioplasty; single major coronary artery or branch	Procedure	CPT-4
92921	Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92924	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92925	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92928	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92929	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
92933	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92934	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92937	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single	Procedure	CPT-4
92938	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each ad	Procedure	CPT-4
92941	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty, including aspirati	Procedure	CPT-4
92943	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	CPT-4
92944	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; each additional coronary artery, co	Procedure	CPT-4
C9600	Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9601	Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9602	Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9603	Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9604	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when perfo	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C9605	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when perfo	Procedure	HCPCS
C9606	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, inclu	Procedure	HCPCS
C9607	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	HCPCS
C9608	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; each additional corona	Procedure	HCPCS
S2205	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), single coronary arterial graft	Procedure	HCPCS
S2206	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), two coronary arterial grafts	Procedure	HCPCS
S2207	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using venous graft only, single coronary venous graft	Procedure	HCPCS
S2208	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using single arterial and venous graft(s), single venous graft	Procedure	HCPCS
S2209	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using two arterial grafts and single venous graft	Procedure	HCPCS
T82.2	Mechanical complication of coronary artery bypass graft and biological heart valve graft	Diagnosis	ICD-10-CM
T82.21	Mechanical complication of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.211	Breakdown (mechanical) of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.211A	Breakdown (mechanical) of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.211D	Breakdown (mechanical) of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.211S	Breakdown (mechanical) of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
T82.212	Displacement of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.212A	Displacement of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.212D	Displacement of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.212S	Displacement of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
T82.213	Leakage of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.213A	Leakage of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.213D	Leakage of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
T82.213S	Leakage of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
T82.218	Other mechanical complication of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.218A	Other mechanical complication of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.218D	Other mechanical complication of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.218S	Other mechanical complication of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM
Dementia			
F01.50	Vascular dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.51	Vascular dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F01.511	Vascular dementia, unspecified severity, with agitation	Diagnosis	ICD-10-CM
F01.518	Vascular dementia, unspecified severity, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.52	Vascular dementia, unspecified severity, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.53	Vascular dementia, unspecified severity, with mood disturbance	Diagnosis	ICD-10-CM
F01.54	Vascular dementia, unspecified severity, with anxiety	Diagnosis	ICD-10-CM
F01.A0	Vascular dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.A11	Vascular dementia, mild, with agitation	Diagnosis	ICD-10-CM
F01.A18	Vascular dementia, mild, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.A2	Vascular dementia, mild, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.A3	Vascular dementia, mild, with mood disturbance	Diagnosis	ICD-10-CM
F01.A4	Vascular dementia, mild, with anxiety	Diagnosis	ICD-10-CM
F01.B0	Vascular dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.B11	Vascular dementia, moderate, with agitation	Diagnosis	ICD-10-CM
F01.B18	Vascular dementia, moderate, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.B2	Vascular dementia, moderate, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.B3	Vascular dementia, moderate, with mood disturbance	Diagnosis	ICD-10-CM
F01.B4	Vascular dementia, moderate, with anxiety	Diagnosis	ICD-10-CM
F01.C0	Vascular dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.C11	Vascular dementia, severe, with agitation	Diagnosis	ICD-10-CM
F01.C18	Vascular dementia, severe, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.C2	Vascular dementia, severe, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.C3	Vascular dementia, severe, with mood disturbance	Diagnosis	ICD-10-CM
F01.C4	Vascular dementia, severe, with anxiety	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F02.811	Dementia in other diseases classified elsewhere, unspecified severity, with agitation	Diagnosis	ICD-10-CM
F02.818	Dementia in other diseases classified elsewhere, unspecified severity, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.82	Dementia in other diseases classified elsewhere, unspecified severity, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.83	Dementia in other diseases classified elsewhere, unspecified severity, with mood disturbance	Diagnosis	ICD-10-CM
F02.84	Dementia in other diseases classified elsewhere, unspecified severity, with anxiety	Diagnosis	ICD-10-CM
F02.A0	Dementia in other diseases classified elsewhere, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.A11	Dementia in other diseases classified elsewhere, mild, with agitation	Diagnosis	ICD-10-CM
F02.A18	Dementia in other diseases classified elsewhere, mild, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.A2	Dementia in other diseases classified elsewhere, mild, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.A3	Dementia in other diseases classified elsewhere, mild, with mood disturbance	Diagnosis	ICD-10-CM
F02.A4	Dementia in other diseases classified elsewhere, mild, with anxiety	Diagnosis	ICD-10-CM
F02.B0	Dementia in other diseases classified elsewhere, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.B11	Dementia in other diseases classified elsewhere, moderate, with agitation	Diagnosis	ICD-10-CM
F02.B18	Dementia in other diseases classified elsewhere, moderate, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.B2	Dementia in other diseases classified elsewhere, moderate, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.B3	Dementia in other diseases classified elsewhere, moderate, with mood disturbance	Diagnosis	ICD-10-CM
F02.B4	Dementia in other diseases classified elsewhere, moderate, with anxiety	Diagnosis	ICD-10-CM
F02.C0	Dementia in other diseases classified elsewhere, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.C11	Dementia in other diseases classified elsewhere, severe, with agitation	Diagnosis	ICD-10-CM
F02.C18	Dementia in other diseases classified elsewhere, severe, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.C2	Dementia in other diseases classified elsewhere, severe, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.C3	Dementia in other diseases classified elsewhere, severe, with mood disturbance	Diagnosis	ICD-10-CM
F02.C4	Dementia in other diseases classified elsewhere, severe, with anxiety	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F03.911	Unspecified dementia, unspecified severity, with agitation	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F03.918	Unspecified dementia, unspecified severity, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.92	Unspecified dementia, unspecified severity, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.93	Unspecified dementia, unspecified severity, with mood disturbance	Diagnosis	ICD-10-CM
F03.94	Unspecified dementia, unspecified severity, with anxiety	Diagnosis	ICD-10-CM
F03.A0	Unspecified dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.A11	Unspecified dementia, mild, with agitation	Diagnosis	ICD-10-CM
F03.A18	Unspecified dementia, mild, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.A2	Unspecified dementia, mild, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.A3	Unspecified dementia, mild, with mood disturbance	Diagnosis	ICD-10-CM
F03.A4	Unspecified dementia, mild, with anxiety	Diagnosis	ICD-10-CM
F03.B0	Unspecified dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.B11	Unspecified dementia, moderate, with agitation	Diagnosis	ICD-10-CM
F03.B18	Unspecified dementia, moderate, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.B2	Unspecified dementia, moderate, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.B3	Unspecified dementia, moderate, with mood disturbance	Diagnosis	ICD-10-CM
F03.B4	Unspecified dementia, moderate, with anxiety	Diagnosis	ICD-10-CM
F03.C0	Unspecified dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.C11	Unspecified dementia, severe, with agitation	Diagnosis	ICD-10-CM
F03.C18	Unspecified dementia, severe, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.C2	Unspecified dementia, severe, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.C3	Unspecified dementia, severe, with mood disturbance	Diagnosis	ICD-10-CM
F03.C4	Unspecified dementia, severe, with anxiety	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal neurocognitive disorder	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G31.83	Neurocognitive disorder with Lewy bodies	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
Depression			
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
Diabetes			
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Drug Abuse			
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Endometrial Cancer			
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Glaucoma			
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
Heart Failure			
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
Hyperlipidemia			
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
Hypertension			
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I1A.0	Resistant hypertension	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
Ischemic Heart Disease			
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.2	Refractory angina pectoris	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.81	Angina pectoris with coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I20.89	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.81	Acute coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I24.89	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.112	Atherosclerotic heart disease of native coronary artery with refractory angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.702	Atherosclerosis of coronary artery bypass graft(s), unspecified, with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.712	Atherosclerosis of autologous vein coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.722	Atherosclerosis of autologous artery coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.732	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.752	Atherosclerosis of native coronary artery of transplanted heart with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.762	Atherosclerosis of bypass graft of coronary artery of transplanted heart with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.792	Atherosclerosis of other coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.85	Chronic coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
Liver Disease CCW			
K70	Alcoholic liver disease	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K70.1	Alcoholic hepatitis	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.4	Alcoholic hepatic failure	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
K71.0	Toxic liver disease with cholestasis	Diagnosis	ICD-10-CM
K71.11	Toxic liver disease with hepatic necrosis, with coma	Diagnosis	ICD-10-CM
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K71.8	Toxic liver disease with other disorders of liver	Diagnosis	ICD-10-CM
K71.9	Toxic liver disease, unspecified	Diagnosis	ICD-10-CM
K72	Hepatic failure, not elsewhere classified	Diagnosis	ICD-10-CM
K72.0	Acute and subacute hepatic failure	Diagnosis	ICD-10-CM
K72.00	Acute and subacute hepatic failure without coma	Diagnosis	ICD-10-CM
K72.01	Acute and subacute hepatic failure with coma	Diagnosis	ICD-10-CM
K72.1	Chronic hepatic failure	Diagnosis	ICD-10-CM
K72.10	Chronic hepatic failure without coma	Diagnosis	ICD-10-CM
K72.11	Chronic hepatic failure with coma	Diagnosis	ICD-10-CM
K72.9	Hepatic failure, unspecified	Diagnosis	ICD-10-CM
K72.90	Hepatic failure, unspecified without coma	Diagnosis	ICD-10-CM
K72.91	Hepatic failure, unspecified with coma	Diagnosis	ICD-10-CM
K74	Fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.00	Hepatic fibrosis, unspecified	Diagnosis	ICD-10-CM
K74.01	Hepatic fibrosis, early fibrosis	Diagnosis	ICD-10-CM
K74.02	Hepatic fibrosis, advanced fibrosis	Diagnosis	ICD-10-CM
K74.1	Hepatic sclerosis	Diagnosis	ICD-10-CM
K74.2	Hepatic fibrosis with hepatic sclerosis	Diagnosis	ICD-10-CM
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.6	Other and unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
K75.0	Abscess of liver	Diagnosis	ICD-10-CM
K75.1	Phlebitis of portal vein	Diagnosis	ICD-10-CM
K75.8	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K75.89	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.9	Inflammatory liver disease, unspecified	Diagnosis	ICD-10-CM
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K76.1	Chronic passive congestion of liver	Diagnosis	ICD-10-CM
K76.2	Central hemorrhagic necrosis of liver	Diagnosis	ICD-10-CM
K76.3	Infarction of liver	Diagnosis	ICD-10-CM
K76.5	Hepatic veno-occlusive disease	Diagnosis	ICD-10-CM
K76.6	Portal hypertension	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
K76.8	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.81	Hepatopulmonary syndrome	Diagnosis	ICD-10-CM
K76.82	Hepatic encephalopathy	Diagnosis	ICD-10-CM
K76.89	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.9	Liver disease, unspecified	Diagnosis	ICD-10-CM
K77	Liver disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
K80.30	Calculus of bile duct with cholangitis, unspecified, without obstruction	Diagnosis	ICD-10-CM
K80.31	Calculus of bile duct with cholangitis, unspecified, with obstruction	Diagnosis	ICD-10-CM
K80.32	Calculus of bile duct with acute cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.33	Calculus of bile duct with acute cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.34	Calculus of bile duct with chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.35	Calculus of bile duct with chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.36	Calculus of bile duct with acute and chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.37	Calculus of bile duct with acute and chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K83.0	Cholangitis	Diagnosis	ICD-10-CM
R16.0	Hepatomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
Z48.23	Encounter for aftercare following liver transplant	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
Liver Disease Extended DX List			
K70	Alcoholic liver disease	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.1	Alcoholic hepatitis	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.4	Alcoholic hepatic failure	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
K71	Toxic liver disease	Diagnosis	ICD-10-CM
K71.0	Toxic liver disease with cholestasis	Diagnosis	ICD-10-CM
K71.1	Toxic liver disease with hepatic necrosis	Diagnosis	ICD-10-CM
K71.10	Toxic liver disease with hepatic necrosis, without coma	Diagnosis	ICD-10-CM
K71.11	Toxic liver disease with hepatic necrosis, with coma	Diagnosis	ICD-10-CM
K71.2	Toxic liver disease with acute hepatitis	Diagnosis	ICD-10-CM
K71.3	Toxic liver disease with chronic persistent hepatitis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K71.4	Toxic liver disease with chronic lobular hepatitis	Diagnosis	ICD-10-CM
K71.5	Toxic liver disease with chronic active hepatitis	Diagnosis	ICD-10-CM
K71.50	Toxic liver disease with chronic active hepatitis without ascites	Diagnosis	ICD-10-CM
K71.51	Toxic liver disease with chronic active hepatitis with ascites	Diagnosis	ICD-10-CM
K71.6	Toxic liver disease with hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K71.8	Toxic liver disease with other disorders of liver	Diagnosis	ICD-10-CM
K71.9	Toxic liver disease, unspecified	Diagnosis	ICD-10-CM
K72	Hepatic failure, not elsewhere classified	Diagnosis	ICD-10-CM
K72.0	Acute and subacute hepatic failure	Diagnosis	ICD-10-CM
K72.00	Acute and subacute hepatic failure without coma	Diagnosis	ICD-10-CM
K72.01	Acute and subacute hepatic failure with coma	Diagnosis	ICD-10-CM
K72.1	Chronic hepatic failure	Diagnosis	ICD-10-CM
K72.10	Chronic hepatic failure without coma	Diagnosis	ICD-10-CM
K72.11	Chronic hepatic failure with coma	Diagnosis	ICD-10-CM
K72.9	Hepatic failure, unspecified	Diagnosis	ICD-10-CM
K72.90	Hepatic failure, unspecified without coma	Diagnosis	ICD-10-CM
K72.91	Hepatic failure, unspecified with coma	Diagnosis	ICD-10-CM
K73	Chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.0	Chronic persistent hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.1	Chronic lobular hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.2	Chronic active hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.8	Other chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.9	Chronic hepatitis, unspecified	Diagnosis	ICD-10-CM
K74	Fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.00	Hepatic fibrosis, unspecified	Diagnosis	ICD-10-CM
K74.01	Hepatic fibrosis, early fibrosis	Diagnosis	ICD-10-CM
K74.02	Hepatic fibrosis, advanced fibrosis	Diagnosis	ICD-10-CM
K74.1	Hepatic sclerosis	Diagnosis	ICD-10-CM
K74.2	Hepatic fibrosis with hepatic sclerosis	Diagnosis	ICD-10-CM
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.6	Other and unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
K75	Other inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.0	Abscess of liver	Diagnosis	ICD-10-CM
K75.1	Phlebitis of portal vein	Diagnosis	ICD-10-CM
K75.2	Nonspecific reactive hepatitis	Diagnosis	ICD-10-CM
K75.3	Granulomatous hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K75.4	Autoimmune hepatitis	Diagnosis	ICD-10-CM
K75.8	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K75.89	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K75.9	Inflammatory liver disease, unspecified	Diagnosis	ICD-10-CM
K76	Other diseases of liver	Diagnosis	ICD-10-CM
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM
K76.1	Chronic passive congestion of liver	Diagnosis	ICD-10-CM
K76.2	Central hemorrhagic necrosis of liver	Diagnosis	ICD-10-CM
K76.3	Infarction of liver	Diagnosis	ICD-10-CM
K76.4	Peliosis hepatis	Diagnosis	ICD-10-CM
K76.5	Hepatic veno-occlusive disease	Diagnosis	ICD-10-CM
K76.6	Portal hypertension	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
K76.8	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.81	Hepatopulmonary syndrome	Diagnosis	ICD-10-CM
K76.82	Hepatic encephalopathy	Diagnosis	ICD-10-CM
K76.89	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.9	Liver disease, unspecified	Diagnosis	ICD-10-CM
K77	Liver disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
K80.30	Calculus of bile duct with cholangitis, unspecified, without obstruction	Diagnosis	ICD-10-CM
K80.31	Calculus of bile duct with cholangitis, unspecified, with obstruction	Diagnosis	ICD-10-CM
K80.32	Calculus of bile duct with acute cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.33	Calculus of bile duct with acute cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.34	Calculus of bile duct with chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.35	Calculus of bile duct with chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.36	Calculus of bile duct with acute and chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.37	Calculus of bile duct with acute and chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K83.0	Cholangitis	Diagnosis	ICD-10-CM
R16.0	Hepatomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
Z48.23	Encounter for aftercare following liver transplant	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
Liver Disease Procedures			
06L20ZZ	Occlusion of Gastric Vein, Open Approach	Procedure	ICD-10-PCS
06L23ZZ	Occlusion of Gastric Vein, Percutaneous Approach	Procedure	ICD-10-PCS
06L24ZZ	Occlusion of Gastric Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
06L30ZZ	Occlusion of Esophageal Vein, Open Approach	Procedure	ICD-10-PCS
06L33ZZ	Occlusion of Esophageal Vein, Percutaneous Approach	Procedure	ICD-10-PCS
06L34ZZ	Occlusion of Esophageal Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9S30Z	Drainage of Greater Omentum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9S3ZZ	Drainage of Greater Omentum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9S40Z	Drainage of Greater Omentum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9S4ZZ	Drainage of Greater Omentum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9T30Z	Drainage of Lesser Omentum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9T3ZZ	Drainage of Lesser Omentum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9T40Z	Drainage of Lesser Omentum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9T4ZZ	Drainage of Lesser Omentum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D9V30Z	Drainage of Mesentery with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9V3ZZ	Drainage of Mesentery, Percutaneous Approach	Procedure	ICD-10-PCS
0D9V40Z	Drainage of Mesentery with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9V4ZZ	Drainage of Mesentery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9W30Z	Drainage of Peritoneum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9W3ZZ	Drainage of Peritoneum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9W40Z	Drainage of Peritoneum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9W4ZZ	Drainage of Peritoneum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DL57DZ	Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DL58DZ	Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0W9F30Z	Drainage of Abdominal Wall with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9F3ZZ	Drainage of Abdominal Wall, Percutaneous Approach	Procedure	ICD-10-PCS
0W9F40Z	Drainage of Abdominal Wall with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9F4ZZ	Drainage of Abdominal Wall, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9G30Z	Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9G3ZZ	Drainage of Peritoneal Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0W9G40Z	Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9G4ZZ	Drainage of Peritoneal Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9J30Z	Drainage of Pelvic Cavity with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9J3ZZ	Drainage of Pelvic Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
Lung Cancer			
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Obesity			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Osteoporosis			
M80.00XA	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0B1A	Age-related osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0B2A	Age-related osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0B9A	Age-related osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.869A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88XA	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AXA	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8B1A	Other osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8B2A	Other osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8B9A	Other osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
Overweight			
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
Prostate			
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
Rheumatoid Arthritis			
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
Smoking			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
Transient Ischemic Attack			
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction due to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM

Appendix E. List of Non- Proprietary and Proprietary Names of Medical Products Used to Define Covariates in this Request

Non- Proprietary	Proprietary Name
Obesity	
benzphetamine HCl	Regimex
benzphetamine HCl	benzphetamine
diethylpropion HCl	diethylpropion
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
liraglutide	liraglutide
lorcaserin HCl	Belviq
lorcaserin HCl	Belviq XR
naltrexone HCl/bupropion HCl	Contrave
orlistat	Alli
orlistat	Xenical
phendimetrazine tartrate	phendimetrazine tartrate
phentermine HCl	Adipex-P
phentermine HCl	Lomaira
phentermine HCl	phentermine
phentermine HCl/topiramate	Qsymia
semaglutide	Ozempic
semaglutide	Wegovy
tirzepatide	Mounjaro
tirzepatide	Zepbound
Smoking	
nicotine	Nicoderm CQ
nicotine	Nicotrol
nicotine	Nicotrol NS
nicotine	nicotine
nicotine bitartrate	Nicotine Tartrate
nicotine polacrilex	Nicorelief
nicotine polacrilex	Nicorette
nicotine polacrilex	Quit 2
nicotine polacrilex	Quit 4
nicotine polacrilex	Stop Smoking Aid
nicotine polacrilex	nicotine (polacrilex)
nicotine polacrilex	nicotine polacrilex (bulk)
varenicline tartrate	Chantix
varenicline tartrate	Chantix Continuing Month Box
varenicline tartrate	Chantix Starting Month Box
varenicline tartrate	Tyrvaya
varenicline tartrate	varenicline tartrate

Appendix F. Specifications Defining Parameters for Baseline Characteristics in this Request

Specifications for Type 5 Request: cder_mpl1r_wp297

An execution execution of the Cohort Identification and Descriptive Analysis (CIDA) tool 14.2.0 was requested to investigate utilization and uptake of New Molecular Entities (NMEs) approved in year 2018 in the Sentinel Distributed Database (SDD).

Query period: January 1, 2018 - December 31, 2024
Coverage requirement: Medical and Drug Coverage
Minimum Pre-Index Enrollment Days: 183 days
Minimum Post-Index Required Days: 0 days
Enrollment Gap: 45 days
Age Groups: 0-17, 18-24, 25-40, 41-64, 65+ years
Sex: M, F
Other Demographic Restrictions: N/A
Stratifications: Age group, Sex, Calendar Month (for Figures only)
Data Restrictions: None
Chart Availability Restriction Indicator: No
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No
Drop Censor Output Indicator: Yes (Indicates if counts of episodes censored by death and query end should be excluded from output to prevent death small cells from being sent to SOC.)

Exposure

Scenario	Index Exposure	Cohort definition	Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
1	Iutetium Lu 177 dotatate	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for Baseline Characteristics in this Request

Specifications for Type 5 Request: cder_mpl1r_wp297										
Scenario	Index Exposure	Cohort definition	Exposure				Exposure Episode Gap	Exposure Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type					
2	bictegravir, embitcitabine, tenofovir alafenamide	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
3	tezacaftor; ivacaftor	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
4	apalutamide	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
5	ibalizumab-uiyk	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	

Appendix F. Specifications Defining Parameters for Baseline Characteristics in this Request

Specifications for Type 5 Request: cder_mpl1r_wp297									
Scenario	Index Exposure	Cohort definition	Exposure						
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
6	tildrakizumab	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
7	burosumab-twza	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
8	fostamatinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
9	fosnetupitant and palonosetron	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for Baseline Characteristics in this Request

Specifications for Type 5 Request: cder_mpl1r_wp297									
Scenario	Index Exposure	Cohort definition	Exposure						
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
10	lofexidine hydrochloride	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
11	erenumab-aooe	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
12	sodium zirconium cyclosilicate	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
13	avatrombopag	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for Baseline Characteristics in this Request

Specifications for Type 5 Request: cder_mpl1r_wp297									
Scenario	Index Exposure	Cohort definition	Exposure						
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
14	pegvaliase-pqpz	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
15	baricitinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
16	moxidectin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
17	cannabidiol	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for Baseline Characteristics in this Request

Specifications for Type 5 Request: cder_mpl1r_wp297									
Scenario	Index Exposure	Cohort definition	Exposure						
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
18	plazomicin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
19	binimetinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
20	encorafenib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
21	tecovirimat	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for Baseline Characteristics in this Request

Specifications for Type 5 Request: cder_mpl1r_wp297									
Scenario	Index Exposure	Cohort definition	Exposure						
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
22	ivosidenib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
23	tafenoquine	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
24	elagolix sodium	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
25	fish oil triglycerides	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for Baseline Characteristics in this Request

Specifications for Type 5 Request: cder_mpl1r_wp297

Exposure									
Scenario	Index Exposure	Cohort definition	Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
26	lusutrombopag	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
International Classification of Diseases, Ninth Revision (ICD-9), International Classification of Diseases, Tenth Revision (ICD-10), Healthcare Common Procedure Coding System (HCPCS), and CPT National Drug Codes (NDCs) are checked against FirstDataBank's FDBMedKnowledge®									

Appendix G. Specifications Defining Parameters in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
<i>Chronic Conditions Data Warehouse</i>									
Acute Myocardial Infarction	1	DX		IPP, IPS	1	-183	-1	N/A	Y
Alzheimer's Disease	2	DX		Any	1	-183	-1	N/A	Y
Non-Alzheimer's Dementia	3	DX		Any	1	-183	-1	N/A	Y
Atrial Fibrillation	4	DX		IPP, IPS	1	-183	-1	N/A	Y
	5	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	6	CC	4 or 5		1			N/A	Y
Diabetes	7	DX		IP*, IS*	1	-183	-1	N/A	Y
	8	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	9	CC	7 or 8		1			N/A	Y
Heart Failure	10	DX		IP*, AV*, ED*, OA*	1	-183	-1	N/A	Y
Hyperlipidemia	11	DX		IP*, IS*	1	-183	-1	N/A	Y
	12	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	13	CC	11 or 12		1			N/A	Y
Hypertension	14	DX		IP*, IS*	1	-183	-1	N/A	Y
	15	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	16	CC	14 or 15		1			N/A	Y
Depression	17	DX		Any	1	-183	-1	N/A	Y
Ischemic Heart Disease	18	DX		Any	1	-183	-1	N/A	Y
Rheumatoid Arthritis/Osteoarthritis	19	DX		Any	2	-183	-1	N/A	Y
Stroke/Transient Ischemic Attack (TIA)	20	DX		IP*	1	-183	-1	N/A	Y
	21	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	22	CC	20 or 21		1			N/A	Y
Breast Cancer	23	DX		IP*, IS*	1	-183	-1	N/A	Y
	24	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	25	CC	23 or 24		1			N/A	Y
Colorectal Cancer	26	DX		IP*, IS*	1	-183	-1	N/A	Y
	27	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	28	CC	26 or 27		1			N/A	Y
Prostate Cancer	29	DX		IP*, IS*	1	-183	-1	N/A	Y
	30	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	31	CC	29 or 30		1			N/A	Y
Lung Cancer	32	DX		IP*, IS*	1	-183	-1	N/A	Y
	33	DX		AV*, ED* OA*	2	-183	-1	N/A	Y

Appendix G. Specifications Defining Parameters in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
Endometrial Cancer	34	CC	32 or 33		1			N/A	Y
	35	DX		IP*, IS*	1	-183	-1	N/A	Y
	36	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
Acquired Hypothyroidism	37	CC	35 or 36		1			N/A	Y
	38	DX		IP*, IS*,	1	-183	-1	N/A	Y
	39	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
Anemia	40	CC	38 or 39		1			N/A	Y
	41	DX		Any	1	-183	-1	N/A	Y
Asthma	42	DX		IP*, IS*,	1	-183	-1	N/A	Y
	43	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	44	CC	42 or 43		1			N/A	Y
Benign Prostatic Hyperplasia	45	DX		IP*, IS*,	1	-183	-1	N/A	Y
	46	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	47	CC	45 or 46		1			N/A	Y
Chronic Kidney Disease	48	DX		IP*, IS*,	1	-183	-1	N/A	Y
	49	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	50	CC	48 or 49		1			N/A	Y
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	51	DX		IP*, IS*,	1	-183	-1	N/A	Y
	52	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	53	CC	51 or 52		1			N/A	Y
Glaucoma	54	DX		AV*, ED*, OA*	1	-183	-1	N/A	Y
Osteoporosis	55	DX		IP*, IS*,	1	-183	-1	N/A	Y
	56	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	57	CC	55 or 56		1			N/A	Y
<i>Other</i>									
Obesity (Diagnosis or Procedure Codes)	58	DX, PX		Any	1	-183	-1	N/A	Y
Obesity (Dispensing Codes)	59	RX		Any	1	-183	-1	N/A	Y
Overweight	60	DX		Any	1	-183	-1	N/A	Y
Smoking (Diagnosis or Procedure Codes)	61	DX, PX		Any	1	-183	-1	N/A	Y
Smoking (Dispensing Codes)	62	RX		Any	1	-183	-1	N/A	Y
Alcohol Abuse or Dependence	63	DX, PX		Any	1	-183	-1	N/A	Y
Drug Abuse or Dependence	64	DX, PX		Any	1	-183	-1	N/A	Y

Appendix G. Specifications Defining Parameters in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
History of Cardiac Arrest	65	DX		Any	1	-183	-1	N/A	Y
History of Coronary Angioplasty or Bypass	66	DX		Any	1	-183	-1	N/A	Y
Liver Disease CCW	67	DX		IP*, IS*	1	-183	-1	N/A	Y
	68	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	69	CC	67 or 68		1			N/A	Y
	70	PX		AV*	1	-183	-1	N/A	Y
	71	DX		AV*	1	-183	-1	N/A	Y
	72	CC	70 and 71		1			N/A	Y
	73	PX		ED*	1	-183	-1	N/A	Y
	74	DX		ED*	1	-183	-1	N/A	Y
	75	CC	73 and 74		1			N/A	Y
	76	PX		OA*	1	-183	-1	N/A	Y
	77	DX		OA*	1	-183	-1	N/A	Y
	78	CC	76 and 77		1			N/A	Y
	79	PX		IS*	1	-183	-1	N/A	Y
	80	DX		IS*	1	-183	-1	N/A	Y
	81	CC	79 and 80		1			N/A	Y
	82	CC	69 or 72 or 75 or 78 or 81		1			N/A	Y
Liver Disease Extended	83	DX		IP*, IS*,	1	-183	-1	N/A	Y
	84	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	85	CC	83 or 84		1			N/A	Y
	86	PX		AV*	1	-183	-1	N/A	Y
	87	DX		AV*	1	-183	-1	N/A	Y
	88	CC	86 and 87		1			N/A	Y
	89	PX		ED*	1	-183	-1	N/A	Y
	90	DX		ED*	1	-183	-1	N/A	Y
	91	CC	89 and 90		1			N/A	Y
	92	PX		OA*	1	-183	-1	N/A	Y
	93	DX		OA*	1	-183	-1	N/A	Y
	94	CC	92 and 93		1			N/A	Y
	95	PX		IS*	1	-183	-1	N/A	Y
	96	DX		IS*	1	-183	-1	N/A	Y

Appendix G. Specifications Defining Parameters in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (<i>only applies to RX codes</i>)	Lookback Period Date Only
	97	CC	95 and 96		1			N/A	Y
	98	CC	85 or 88 or 91 or 94 or 97		1			N/A	Y

The wildcard symbol () can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.

The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Scodary) uses the second diagnosis position.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital.


'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

N: Lookback period should search for evidence of a date or an interval Y: Lookback period should search for evidence of a date only

RX: Drug code DX: Diagnosis code PX: Procedure code CC: Complex covariates (multiple COVARNUM values are used to define a covariate)

N/A: Not applicable

Appendix H. Diagram Detailing the Design of the Request



¹ Includes all valid exposure during the query period; only the first valid episode's incidence is assessed using the washout period.

² 26 scenarios defined on initiation of NMEs approved in 2018 part 1 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME.

³ Baseline characteristics:

Window I: Age, Sex, Race, Hispanic Ethnicity, Year

Window II: Chronic conditions warehouse (CCW), alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, history of coronary angioplasty or bypass, obesity, overweight, and smoking, Liver Disease CCW, Liver Disease Extended

⁴ Censoring: earliest of death, disenrollment, data partner data end date, query end date